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Abstract 
There is considerable interest to design metal-based inorganic compounds due to their 
potential applications in molecular biology, biotechnology and medicine. This subject 
owes much of its success to the spectacular discovery of cisplatin, gadolinium complexes 
in magnetic resonance imaging (MRI) and copper complexes as DNA-foot printing 
reagents and artificial nuclease agents. Metal ions can be introduced into a biological 
system either for therapeutic effect or as diagnostic aids. Alternatively, metal ions can be 
removed fi-om a biological system by judicious use of metal-binding molecules termed as 
ligands (Latin word ligare, meaning that which binds). The redox properties of the metal 
center(s) in complexes are essential to generate reactive oxygen species (ROS) for DNA 
cleavage. 
Ligands are capable of muting the adverse effects of metal ion overload, inhibit selected 
metalloenzymes or facilitate metal ion redistribution. Some important ligands modifying 
effects include modifying reactivity, lipophilicity, stabilizing specific oxidation states and 
contributing to substitution inertness (in case of macrocyclic complexes). Tailored and 
multifunctional ligands for metal-based medicinal agents offer many exciting 
possibilities. Biological systems themselves, provide innumerable examples of designer 
ligands for example, metalloprotein hemoglobin, which act as a molecular shuttle for 
oxygen via reversible binding of O2 to the iron center, as well as manganese superoxide 
dismutase (MnSOD) and catalase are metalloenzymes of the body's antioxidant defence 
system. Other important biological ligand motifs like -NH imidazole, histidine, 
aminoacid with simple hydroxy or amino functions like serine (Ser), threonine (Thr), 
lysine (Lys) or tryptophan (Trp) are also noteworthy. The affinities of individual amino 
acid side chain to certain oxidation states of metals are often characteristic resulting in a 
typical selectivity pattern. Similarly, carbohydrates are naturally occurring chiral 
polyfunctional ligands. Recently, a polysaccharide-iron complex named "Niferex" has 
been synthesized fi-om FeCh and glucose and is currently used for the treatment of iron 
deficiency anaemia. Introduction of substituents into the carbohydrate skeleton may 
influence complex properties like solubility and molecular targeting to a wide variety of 
metal-based drugs. 
Recent advances in ligand design for metal-based drugs have resulted in potent 
antitumour compounds that are active in cisplatin resistant cell lines and also include 
additional features to allow for an increased understanding of the mechanism of action of 
the drug candidates. The mechanistic details and mode of action of these newly 
synthesized metal-based chemotherapeutics are not vivid, hence new modalities could 
offer important responses in efficacy of the drugs. Since DNA is the primary cellular 
receptor of many metal complexes, which exert their antitumour effects through DNA 
binding, thereby interfering in the complicated mechanisms of uncontrolled proliferation. 
The metal complexes which are favoured as effective drug candidates are molecules that 
(i) damage DNA 
Ill 
(ii) block DNA synthesis indirectly through inhibition of nucleic acid precursor 
biosynthesis 
(iii) disrupt hormonal stimulation of cell growth 
(iv) must recognize nucleic acids particularly in sequence specific fashion and then bind 
to DNA in a way that alters their function. 
In view of this rationale, we have synthesized and characterized a variety of complexes 
derived from well-designed ligand motifs with first row transition metal and tin chlorides 
employing de novo synthetic strategy. The interaction studies of these complexes with 
CT DNA have been studied by UV/vis, fluorescence, cyclic voltammetry and viscosity 
measurements. 
Synthesis of new bimetallic water soluble complexes [Ci2H23N407CoCu]Cl25H20, 
[Ci2H23N407CoNi]Cl25H20 and [Ci2H23N407CoMn]Cl25H20 were achieved by the 
reaction of Co(III) complex [Ci2H2iN406Co]5H20, with Cu^ ,^ Ni^ "^  and Mn^ "^  metal ions. 
The complexes were characterized by elemental analysis, IR, UV/vis, EPR, ' H , '^C and 
2D NMR spectroscopy and molar conductance measurements. The interaction of the 
monometallic complex [Ci2H2iN406Co]5H20 and bimetallic complexes 
[Ci2H23N407CoCu]Cl25H20, [Ci2H23N407CoNi]Cl25H20 and [C,2H23N407CoMn] 
CI25H2O with CT DNA have been carried out by UV/vis titration, cyclic voltammetry 
and viscosity measurements. The absorption spectra of complexes exhibited red shift with 
overall "hyperchromic effect" in the presence of CT DNA. The binding affinity of the 
bimetallic complexes to CT DNA is two fold in comparison to the complex 
IV 
[Ci2H2iN406Co]5H20. The intrinsic binding constant value Kb of the complex 
[Ci2H2iN406Co]5H20 was found to be 1.2 x 10^  M"' while the Kb value of complexes 
[Ci2H23N407CoCu]Cl25H20, [C,2H23N407CoNi]Cl25H20 and 
[Ci2H23N407CoMn]Cl25H20 were of the order of 1.4 x 10^  M"', 2.2 x 10^  M"' and 2.1 x 
10^  M"', respectively. The Kb values are close to border between classical intercalation 
and non-classical intercalation that indicates the binding mode may be electrostatic, 
probably with covalent preference in bimetallic complexes. The electrochemical 
behaviour of the complexes [Ci2H2iN406Co]5H20, [Ci2H23N407CoCu]Cl25H20, 
[Ci2H23N407CoNi]Cl25H20 and [Ci2H23N407CoMn]Cl25H20 were studied in H2O and 
displays a quasireversible Co "/Co', Cu'VCu', Ni"/Ni' and Mn'VMn' redox couples. The 
voltammetric studies of the complexes in absence and presence of CT DNA exhibited a 
shift in the formal potential E° and ratio of anodic to cathodic peak currents Ipa/Ipc, 
indicating binding of the complexes to CT DNA.The viscosity of CT DNA decreases 
with increasing concentration of the complex, suggesting that complexes 
[Ci2H23N407CoCu]Cl25H20, [Ci2H23N407CoNi]Cl25H20 and 
[Ci2H23N407CoMn]Cl25H20 bind to CT DNA by electrostatic association with covalent 
preference. 
The homodinuclear [Ci6H3oN805Sn2Cl4], heterotetranuclear [Ci6H38N809Sn2Cu2Clg] and 
[Ci6H38N809Sn2Mn2Cl8] macrocyclic complexes were synthesized and characterized by 
elemental analysis, IR, ^H, '^C and 2D NMR correlation spectroscopy, UV/vis, EPR and 
molar conductance measurements. The interaction studies of [Ci6H3oN805Sn2Cl4], 
[Ci6H38N809Sn2Cu2Cl8] and [Ci6H38N809Sn2Mn2Cl8] with CT DNA were carried out by 
UV/vis titration, fluorescence, cyclic voltammetry and viscosity measurements. The 
complexes exhibited hyperchromism with blue shift of 1-4 nm. The intrinsic binding 
constant Kb for the complexes [Ci6H3oN805Sn2Cl4], [Ci6H38N809Sn2Cu2Cl8] and 
[C|6H38N809Sn2Mn2Cl8] were determined to be 4.0 x 10"* M"', 6.0 x lO'* M"' and 4.1 x lO"* 
M ' , respectively. The Kb values along with the Stem-Volmer constant K revealed that 
the complex [Ci6H38N809Sn2Cu2Cl8] binds more avidly to CT DNA in comparison to 
[Ci6H3oN805Sn2Cl4] and [Ci6H38N809Sn2Mn2Cl8]. These results were further 
authenticated by carrying out interaction studies of [Ci6H3oN805Sn2Cl4], 
[Ci6H38N809Sn2Cu2Cl8] and [Ci6H38N809Sn2Mn2Cl8] with supercoiled pBR322 DNA 
employing gel electrophoresis, noticeably complex [Ci6H38N809Sn2Cu2Cl8] exhibited 
effective DNA binding and cleavage in comparison to [Ci6H3oN805Sn2Cl4] and 
[C,6H38N809Sn2Mn2Cl8]. 
To overcome the dose resistance, toxicity of the drugs, a model study based on 
electrochemotherapy (ECT) was carried out and the results were compared in absence 
and presence of the applied potential. On application of direct potential to the complexes 
[C,6H3oN805Sn2Cl4], [C,6H38N809Sn2Cu2Cl8] and [C,6H3gN809Sn2Mn2Cl8], multifold 
increase in the magnitude of intrinsic binding constant Kb values were observed which 
suggests that the chemotherapeutic activity of the drug in presence of direct potential 
enhanced their easier permeability across the cell membrane and enabled the complexes 
to bind to a specific target DNA at lower concentration of drugs. The electrochemical 
VI 
behavior of complexes [Ci6H38Ng09Sn2Cu2Cl8] and [Ci6H38N809Sn2Mn2Cl8] were 
studied in H2O which displayed a quasireversible Cu"/Cu' and Mn'V Mn' redox couples. 
The shifts in electrochemical parameters ascertain the binding of [Ci6H38N809Sn2Cu2Cl8] 
and [Ci6H38N809Sn2Mn2Cl8] with CT DNA. The decrease in viscosity of CT DNA with 
increasing concentration of [Ci6H3oN805Sn2Cl4], [Ci6H38N809Sn2Cu2Cl8] and 
[Ci6H38N809Sn2Mn2Cl8] fiarther support the binding of macrocyclic complexes with CT 
DNA. The complexes [Ci6H3oN805Sn2Cl4] and [Ci6H38N809Sn2Mn2Clg] exhibit different 
DNA binding modes which were ascertained by UV/vis, fluorescence spectroscopy and 
viscosity measurements. The complexes [Ci6H3oN805Sn2Cl4] and 
[Ci6H38N809Sn2Mn2Cl8] bind to CT DNA through electrostatic interaction, while 
[Ci6H38N809Sn2Cu2Cl8] complex binds to CT DNA through covalent in addition to the 
electrostatic interaction. The results of in vitro binding studies have been corroborated 
with molecular modeling. 
A new series of the glycosylated metal complexes [D-GlcCu(Pz)2], [D-GlcNi(Pz)2], [D-
GlcCo(Pz)2], [D-GlcFe(Pz)2]Cl, [D-GlcCu(hn)2], [D-GlcNi(Im)2] and [D-GlcFe(Im)2]Cl 
were synthesized and characterized by elemental analysis, molar conductance 
measurements and spectroscopic methods. The interaction of [D-GlcCu(Pz)2], [D-
GlcNi(Pz)2], [D-GlcCo(Pz)2], [D-GlcFe(Pz)2]Cl, [D-GlcCu(Im)2], [D-GlcNi(Im)2] and 
[D-GlcFe(Im)2]Cl with CT DNA have been carried out using absorption, emission, 
electrochemical and viscometeric methods. The intrinsic binding constant Kb of [D-
GlcCu(Pz)2], [D-GlcNi(Pz)2], [D-GlcCo(Pz)2], [D-GlcFe(Pz)2]Cl, [D-GlcCu(Im)2], [D-
Vll 
GlcNi(Im)2] and [D-GlcFe(Im)2]Cl were determined as 13.4 x 10^  M"', 4.5 x 10^  M"', 2.1 
X 10^  M'', 4.03 X 10^  M"', 9.4 x 10^  M"', 3.14 x 10^  M"' and 3.3 x 10^ M"', respectively 
suggestive of strong binding of complexes with CT DNA, furthermore higher value of Kb 
for [D-GlcCu(Pz)2] and [D-GlcCu(Im)2] implies that these complexes interact more 
strongly with CT DNA in comparison to other complexes. The quenching constant K 
obtained from emission spectral methods were 1.33, 0.55, 0.33, 0.5, 0.48, 0.44 and 0.4, 
respectively. The hyperchromism observed in the ligand based transitions of complexes 
[D-GlcCu(Pz)2], [D-GlcNi(Pz)2], [D-GlcCo(Pz)2], [D-GlcFe(Pz)2]Cl, [D-GlcCu(Im)2], 
[D-GlcNi(Im)2] and [D-GlcFe(Im)2]Cl on binding to CT DNA suggest a covalent mode 
of binding, which involves the most favored coordination of guanine N7 of DNA to form 
MN3O2 chromophore. Complex [D-GlcCu(Pz)2], hydrotically cleave supercoiled pBR322 
DNA in Tris-HCl buffer in absence of an activating agent. The enhanced cleavage of 
pBR322 DNA was observed in presence of ascorbic acid as a reducing agent, [D-
GlcCu(Pz)2], also displays efficient photonuclease activity through double strand DNA 
breaks when irradiated with 365 nm light through mechanistic pathway involving 
hydroxyl radicals. In addition to the above binding studies, an in vitro "binding model 
study" of complex [D-GlcCu(Pz)2], with protein HSA, L-tyrptophan and their mixtures 
with CT DNA was carried out, which shows that [D-GlcCu(Pz)2] exhibited higher 
binding ability towards CT DNA in comparison to other biomolecules. 
In another set of experiments, new 3,4:9,10-Dibenzo-2,ll-dihydroxy-l,12-bispiperazine 
5,8-dioxododecane metal complexes [C24H36N4O6CU] and [C24H32N404Zn] were 
VIU 
synthesized and characterized by elemental analysis, IR, EPR, NMR, UV/vis, mass 
spectroscopy and molar conductance measurements. The complexes are non ionic in 
nature and possess octahedral geometry around Cu^ "^ / Zn^^ central metal ions. The binding 
studies of [C24H36N4O6CU] and [C24H32N404Zn] with CT DNA were investigated by 
UV/vis, fluorescence, cyclic voltammetry and viscosity measurements. The calculated 
binding constant Kb for [C24H36N4O6CU] and [C24H32N404Zn] obtained from UV/vis 
absorption studies were 7.6 x 10^  M"', 8.08 x 10^  M"', respectively. The intrinsic binding 
constants were also estimated to be 7.0 x 10"* M'' and 7.53 xlO^ M* for [C24H36N4O6CU] 
and [C24H32N404Zn], respectively by using emission titrations. These experimental 
results suggest that complexes are groove binders and interact to CT DNA with different 
affinities. Both the complexes in absence and presence of CT DNA show quasireversible 
wave corresponding to Cu'V Cu' and Zn'VZn' redox couple. The Changes in E1/2, AE, 
Ipa/Ipc ascertain the interaction of [C24H36N4O6CU] and [C24H32N404Zn] with CT DNA. 
Further, increase in viscosity of CT DNA with increasing concentration of complexes 
was observed. In vitro, antimicrobial activity against fungi A. brassicicola, A. niger and 
bacteria E. coli, P. aeruginosa of complexes were carried out, which indicate that 
complex [C24H32N404Zn] is more active against both fungal and bacterial strains as 
shown by % inhibition data. 
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Abstract 
Abstract 
There is considerable interest to design metal-based inorganic compounds due to their 
potential applications in molecular biology, biotechnology and medicine. This subject 
owes much of its success to the spectacular discovery of cisplatin, gadolinium complexes 
in magnetic resonance imaging (MRI) and copper complexes as DNA-foot printing 
reagents and artificial nuclease agents. Metal ions can be introduced into a biological 
system either for therapeutic effect or as diagnostic aids. Alternatively, metal ions can be 
removed from a biological system by judicious use of metal-binding molecules termed as 
ligands (Latin word ligare, meaning that which binds). The redox properties of the metal 
center(s) in complexes are essential to generate reactive oxygen species (ROS) for DNA 
cleavage. 
Ligands are capable of muting the adverse effects of metal ion overload, inhibit selected 
metalloenzymes or facilitate metal ion redistribution. Some important ligands modifying 
effects include modifying reactivity, lipophilicity, stabilizing specific oxidation states and 
contributing to substitution inertness (in case of macrocyclic complexes). Tailored and 
multifunctional ligands for metal-based medicinal agents offer many exciting 
possibilities. Biological systems themselves, provide innumerable examples of designer 
ligands for example, metalloprotein hemoglobin, which act as a molecular shuttle for 
oxygen via reversible binding of O2 to the iron center, as well as manganese superoxide 
dismutase (MnSOD) and catalase are metalloenzymes of the body's antioxidant defence 
system. Other important biological ligand motifs like -NH imidazole, histidine, 
aminoacid with simple hydroxy or amino functions like serine (Ser)., threonine (Thr), 
lysine (Lys) or tryptophan (Trp) are also noteworthy. The affinities of individual amino 
acid side chain to certain oxidation states of metals are often charactenstic resulting in a 
typical selectivity pattern. Similarly, carbohydrates are naturally occurring chiral 
polyfixnctional ligands. Recently, a polysaccharide-iron complex named "Niferex" has 
been synthesized from FeCb and glucose and is currently used for the treatment of iron 
deficiency anaemia. Introduction of substituents into the carbohydrate skeleton may 
influence complex properties like solubility and molecular targeting to a wide variety of 
metal-based drugs. 
Recent advances in ligand design for metal-based drugs have resulted in potent 
antitumour compounds that are active in cisplatin resistant cell lines and also include 
additional features to allow for an increased understanding of the mechanism of action of 
the drug candidates. The mechanistic details and mode of action of these newly 
synthesized metal-based chemotherapeutics are not vivid, hence new modalities could 
offer important responses in efficacy of the drugs. Since DNA is the primary cellular 
receptor of many metal complexes, which exert their antitumour effects through DNA 
binding, thereby interfering in the complicated mechanisms of uncontrolled proliferation. 
The metal complexes which are favoured as effective drug candidates are molecules that 
(i) damage DNA 
m 
(ii) block DNA synthesis indirectly through inhibition of nucleic acid precursor 
biosynthesis 
(iii) disrupt hormonal stimulation of cell growth 
(iv) must recognize nucleic acids particularly in sequence specific fashion and then bind 
to DNA in a way that alters their fiinction. 
In view of this rationale, we have synthesized and characterized a variety of complexes 
derived from well-designed ligand motifs with first row transition metal and tin chlorides 
employing de novo synthetic strategy. The interaction studies of these complexes with 
CT DNA have been studied by UV/vis, fluorescence, cyclic voltammetry and viscosity 
measurements. 
Synthesis of new bimetallic water soluble complexes [Ci2H23N407CoCu]Cl25H20, 
[Ci2H23N407CoNi]Cl25H20 and [Ci2H23N407CoMn]Cl25H20 were achieved by the 
reaction of Co(III) complex [Ci2H2iN406Co]5H20, with Cu^ "^ , Ni^ "^  and Mn^* metal ions. 
The complexes were characterized by elemental analysis, IR, UV/vis, EPR, 'H , '^C and 
2D NMR spectroscopy and molar conductance measurements. The interaction of the 
monometallic complex [Ci2H2iN406Co]5H20 and bimetallic complexes 
[Ci2H23N407CoCu]Cl25H20, [Ci2H23N407CoNi]Cl25H20 and [Ci2H2jN407CoMn] 
CI25H2O with CT DNA have been carried out by UV/vis titration, cyclic voltammetry 
and viscosity measurements. The absorption spectra of complexes exhibited red shift with 
overall "hyperchromic effect" in the presence of CT DNA. The binding affinity of the 
bimetallic complexes to CT DNA is two fold in comparison to the complex 
IV 
[Ci2H2iN406Co]5H20. The intrinsic binding constant value Kb of the complex 
[Ci2H2iN406Co]5H20 was found to be 1.2 x 10^  M'' while the Kb value of complexes 
[Ci2H23N407CoCu]Cl25H20, [Ci2H23N407CoNi]Cl25H20 and 
[Ci2H23N407CoMn]Cl25H20 were of the order of 1.4 x 10^  M'', 2.2 x 10^  M"' and 2.1 x 
10^  M"', respectively. The Kb values are close to border between classical intercalation 
and non-classical intercalation that indicates the binding mode may be electrostatic, 
probably with covalent preference in bimetallic complexes. The electrochemical 
behaviour of the complexes [Ci2H2iN406Co]5H20, [Ci2H23N407CoCu]Cl25H20, 
[Ci2H23N407CoNi]Cl25H20 and [Ci2H23N407CoMn]Cl25H20 were studied in H2O and 
displays a quasireversible Co'VCo', Cu'VCu', Ni"/Ni' and Mn"/Mn' redox couples. The 
voltammetric studies of the complexes in absence and presence of CT DNA exhibited a 
shift in the formal potential E° and ratio of anodic to cathodic peak currents Ipa/Ipc, 
indicating binding of the complexes to CT DNA.The viscosity of CT DNA decreases 
with increasing concentration of the complex, suggesting that complexes 
[Ci2H23N407CoCu]Cl25H20, [Ci2H23N407CoNi]Cl25H20 and 
[Ci2H23N407CoMn]Cl25H20 bind to CT DNA by electrostatic association with covalent 
preference. 
The homodinuclear [Ci6H3oNg05Sn2Cl4], heterotetranuclear [C)6H38Ng09Sn2Cu2Cl8] and 
[Ci6H38N809Sn2Mn2Cl8] macrocyclic complexes were synthesized and characterized by 
elemental analysis, IR, ' H , ^^C and 2D NMR correlation spectroscopy, UV/vis, EPR and 
molar conductance measurements. The interaction studies of [Ci6H3oN805Sn2Cl4], 
[Ci6H38N809Sn2Cu2Cl8] and [Ci6H38N809Sn2Mn2Cl8] with CT DNA were carried out by 
UV/vis titration, fluorescence, cyclic voltammetry and viscosity measurements. The 
complexes exhibited hyperchromism with blue shift of 1-4 nm. The intrinsic binding 
constant Kb for the complexes [Ci6H3oN80sSn2Cl4], [Ci6H38Ng09Sn2eu2Cl8] and 
[Ci6H3gN809Sn2Mn2Cl8] were determined to be 4.0 x lO" M ' , 6.0 x lO'' M"' and 4.1 x lO'' 
M ' , respectively. The K* values along with the Stem-Volmer constant K revealed that 
the complex [Ci6H38N809Sn2Cu2Cl8] binds more avidly to CT DNA in comparison to 
[Ci6H3oN80sSn2Cl4] and [Ci6H38N809Sn2Mn2Cl8]. These results were further 
authenticated by carrying out interaction studies of [CieHsoNgOsSnjCU], 
[Ci6H38N809Sn2Cu2Cl8] and [Ci6H38N809Sn2Mn2Cl8] with supercoiled pBR322 DNA 
employing gel electrophoresis, noticeably complex [Ci6H3gN809Sn2Cu2Cl8] exhibited 
effective DNA binding and cleavage in comparison to [CieHsoNsOsSniCU] and 
[Ci6H38N809Sn2Mn2Cl8]. 
To overcome the dose resistance, toxicity of the drugs, a model study based on 
electrochemotherapy (ECT) was carried out and the results were compared in absence 
and presence of the applied potential. On application of direct potential to the complexes 
[Ci6H3oN805Sn2Cl4], [Ci6H38N809Sn2Cu2Cl8] and [C,6H38N809Sn2Mn2Cl8], multifold 
increase in the magnitude of intrinsic binding constant Kb values were observed which 
suggests that the chemotherapeutic activity of the drug in presence of direct potential 
enhanced their easier permeability across the cell membrane and enabled the complexes 
to bind to a specific target DNA at lower concentration of drugs. The electrochemical 
VI 
behavior of complexes [Ci6H38Ng09Sn2Cu2Cl8] and [Ci6H38N809Sn2Mn2Cl8] were 
studied in H2O which displayed a quasireversible Cu'VCu' and Mn"/ Mn' redox couples. 
The shifts in electrochemical parameters ascertain the binding of [Ci6H38N809Sn2Cu2Cl8] 
and [Ci6H38N809Sn2Mn2Cl8] with CT DNA. The decrease in viscosity of CT DNA with 
increasing concentration of [Ci6H3oN805Sn2Cl4], [Ci6H3gN809Sn2Cu2Cl8] and 
[Ci6H38N809Sn2Mn2Cl8] fixrther support the binding of macrocyclic complexes with CT 
DNA. The complexes [CieHsoNgOsSnaCU] and [Ci6H3gN809Sn2Mn2Cl8l exhibit different 
DNA binding modes which were ascertained by UV/vis, fluorescence spectroscopy and 
viscosity measurements. The complexes [Ci6H3oN805Sn2Cl4] and 
[Ci6H3gN809Sn2Mn2Cl8] bind to CT DNA through electrostatic interaction, while 
[Ci6H38N809Sn2Cu2Cl8] complex binds to CT DNA through covalent in addition to the 
electrostatic interaction. The results of in vitro binding studies have been corroborated 
with molecular modeling. 
A new series of the glycosylated metal complexes [D-GlcCu(Pz)2], [D-GlcNi(Pz)2], [D-
GlcCo(Pz)2], [D-GlcFe(Pz)2]Cl, [D-GlcCu(lm)2], [D-GlcNi(Im)2] and [D-GlcFe(Im)2]Cl 
were synthesized and characterized by elemental analysis, molar conductance 
measurements and spectroscopic methods. The interaction of [D-GlcCu(Pz)2], [D-
GlcNi(Pz)2], [D-GlcCo(Pz)2], [D-GlcFe(Pz)2]Cl, [D-GlcCu(Im)2], [D-GlcNi(Im)2] and 
[D-GlcFe(lm)2]Cl with CT DNA have been carried out using absorption, emission, 
electrochemical and viscometeric methods. The intrinsic binding constant Kb of [D-
GlcCu(Pz)2], [D-GlcNi(Pz)2], [D-GlcCo(Pz)2], [D-GlcFe(Pz)2]Cl, [D-GlcCu(Im)2], [D-
vu 
GlcNi(lm)2] and [D-GlcFe(Im)2]Cl were deteraiined as 13.4 x 10^  U\ 4.5 x 10^  M"', 2.1 
X 10^  M'', 4.03 X 10^  M"', 9.4 x 10^  M"', 3.14 x 10^  M"' and 3.3 x 10* M'', respectively 
suggestive of strong binding of complexes with CT DNA, furthermore higher value of Kb 
for [D-GlcCu(Pz)2] and [D-GlcCu(Im)2] implies that these complexes interact more 
strongly with CT DNA in comparison to other complexes. The quenching constant K 
obtained from emission spectral methods were 1.33, 0.55, 0.33, 0.5, 0.48, 0.44 and 0.4, 
respectively. The hyperchromism observed in the ligand based transitions of complexes 
[D-GlcCu(Pz)2], [D-GlcNi(Pz)2], [D-GlcCo(Pz)2], [D-GlcFe(Pz)2]Cl, [D-GlcCu(lm)2], 
[D-GlcNi(Im)2] and [D-GlcFe(Im)2]Cl on binding to CT DNA suggest a covalent mode 
of binding, which involves the most favored coordination of guanine N7 of DNA to form 
MN3O2 chromophore. Complex [D-GlcCu(Pz)2], hydrotically cleave supercoiled pBR322 
DNA in Tris-HCl buffer in absence of an activating agent. The enhanced cleavage of 
pBR322 DNA was observed in presence of ascorbic acid as a reducing agent, [D-
GlcCu(Pz)2], also displays efficient photonuclease activity through double strand DNA 
breaks when irradiated with 365 nm light through mechanistic pathway involving 
hydroxyl radicals. In addition to the above binding studies, an in vitro "binding model 
study" of complex [D-GlcCu(Pz)2], with protein HSA, L-tyrptophan and their mixtures 
with CT DNA was carried out, which shows that [D-GlcCu(Pz)2] exhibited higher 
binding ability towards CT DNA in comparison to other biomolecules. 
In another set of experiments, new 3,4:9,10-Dibenzo-2,ll-dihydroxy-l,12-bispiperazine 
5,8-dioxododecane metal complexes [C24H36N4O6CU] and [C24H32N404Zn] were 
VIU 
synthesized and characterized by elemental analysis, IR, EPR, NMR, UV/vis, mass 
spectroscopy and molar conductance measurements. The complexes are non ionic in 
nature and possess octahedral geometry aroimd Cu^ '^ lZn^ "*' central metal ions. The binding 
studies of [C24H36N4O6CU] and [C24H32N404Zn] with CT DNA were investigated by 
UV/vis, fluorescence; cyclic voltammetry and viscosity measurements. The calculated 
binding constant Kb for [C24H36N4O6CU] and [C24H32N404Zn] obtained from UV/vis 
absorption smdies were 7.6 x 10^  M"', 8.08 x 10^  M"', respectively. The intrinsic binding 
constants were also estimated to be 7.0 x 10'* M'' and 7.53 xlO^ M"' for [C24H36N4O6CU] 
and [C24H32N404Zn], respectively by using emission titrations. These experimental 
results suggest that complexes are groove binders and interact to CT DNA with different 
affinities. Both the complexes in absence and presence of CT DNA show quasireversible 
wave corresponding to Cu'V Cu' and Zn'VZn' redox couple. The Changes in E1/2, AE, 
Ipa/Ipc ascertain the interaction of [C24H36N4O6CU] and [C24H32N404Zn] with CT DNA. 
Further, increase in viscosity of CT DNA with increasing concentration of complexes 
was observed. In vitro, antimicrobial activity against fimgi A. brassicicola, A. niger and 
bacteria E. coli, P. aeruginosa of complexes were carried out, which indicate that 
complex [C24H32N404Zn] is more active against both fungal and bacterial strains as 
shown by % inhibition data. 
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CHAPTER I 
Introduction 
Introduction 
Medicinal Inorganic chemistry - an area of research in bioinorganic chemistry emerging 
from interface of inorganic chemistry and biology is fast growing discipline of 
pharmaceutical science, which includes design and synthesis of metal-based drugs, metal 
containing diagnostic agents and metal sequestering or mobilizing agents [1-6]. This field 
has gained momentum only after the discovery of antitumour compound cisplatin [cis-
diamminedichloroplatinum (II)] [7]. To date this archetypical inorganic antitumour drug 
remains one of the most effective chemotherapeutic agent against solid malignancies 
especially testicular cancer. However, the clinical use of cisplatin against this tumour and 
others is severely limited by side effects (neuro, hepato, nephrotoxicity) in addition to 
inherent or acquired resistance of this drug to various phenotypes of cancers [8]. This has 
led to the development of other second generation alternative platinum drugs viz. 
carboplatin, oxaliplatin and JM216 [9], (Figure!), which are in wider clinical use for the 
(a) 
H,N, ,C1 
H3N ci 
(c) 
X. 
Figure 1. Platinum (II) complexes in clinical use, (a) cisplatin, a second generation 
alternative (b) carboplatin (c) oxaliplatin and (d) JM2I6. 
treatment of ovarian, lung and other types of cancers elucidating thereby, their cellular 
responses at the molecular level to alleviate the limitations of cisplatin [10]. Alternative 
strategies based on different metals and aimed at different targets were also developed. 
Amongst them non-platinum metal therapeutics include ruthenium complexes and 1st row 
transition metal complexes [11-14]. A variety of metal complexes were designed which 
interact specifically with classical target DNA. In classical chemotherapy, metal-based 
drugs target cellular DNA directly according to the cisplatin paradigm to generate lesions 
or interact with heterocyclic DNA bases via N7 positions of purines located in the major 
groove of double helix DNA, which ultimately trigger cell death [15-20]. Ruthenium (III) 
complexes interact with their biological targets DNA and proteins in particular, 
transferrin and albumin, with marked preference for surface imidazole groups and exhibit 
high in vitro and in vivo anticancer activities [21]. NAMI- A and KP1019, (Figure 2) the 
most prominent ruthenium based anticancer drugs have shown different modes of action 
and specifically aim at non-classical targets such as gene products and cellular 
transduction pathways [22-24]. NAMI-A and KP1019 were converted to more active Ru 
(II) species facilitating the coordination of ruthenium functionality to relevant 
biomolecules [25]. There is extensive research data available on chemical properties of 
NAMI-A and effects of NAMI-A on cellular level [26-35], but its exact mechanism of 
action still remains obscure. 
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Figure 2. Structures ofNAMI-A (left) and KP1019 (right). 
The development of vanadium complexes in 1985 for the treatment of diabetes has been a 
breakthrough in medicinal inorganic chemistry [36]. Vanadium based antidiabetic drug 
[(Bis maltolato) 0x0vanadium (IV)], BMOV was first complex that demonstrated 
superior activity over inorganic vanadium sources (VOSO4 or NaVOs) through both in 
vivo and in vitro assays of biological effectiveness [37-39]. This strategy of developing 
metal based pharmaceutical agents for the treatment of chronic diseases utilizing 
chelation or complexation by appropriate chelating agent can encounter challenges of 
drug design such as limiting the toxicity, pharmacokinetic uptake and low cost. 
Budotitane, which was the first non-platinum transition metal 
anticancer agent to be tested in clinical trials, (Figure 3) is quite effective against a 
number of ascites tumours and induced colorectal tumours in animals [40]. Clinical trials 
indicate that it was fairly well tolerated by patients with the dose limiting side effects 
being cardiac arrhythmia [41]. 
HjC— '^ O 
(f O OC2H5 
Figure 3. Structure of Budotitane. 
Metal complexes of vanadium exhibit anticancer activity by inhibiting enzymes involved 
in DNA metabolism. Vanadyl sulfate and sodium ortho vanadate inhibit the growth of 
proliferative tumour cells but have little effect on non-proliferative cells. The cytotoxicity 
was enhanced when H2O2 was added [42]. Activity against the L1210 murine leukemia 
cell line has been observed for the peroxo compounds (NH4)4[0(0(02)2V)2], 
M3[0(02)2(C204)V] (M = K ,^ NH4'' and NH4[0(02)(malato)V]. A vanadium (III) 
complex of cystein has also shown significant antitumour activity in mice [43-44]. 
Cobalt complexes have received less attention in comparison to other transition metal 
complexes [45-48]. Cobalt containing complexes offer an exciting possibility for oral 
delivery of a wide variety of peptide based drugs-most efficient chemotherapeutics. 
Currently, these peptide-based drugs are given intravenously because of digestive 
degradation and poor absorption. They covalently bind to the cobalt containing 
coenzymes vitamin B12 and are readily transported from the digestive to the circulatory 
via vitamin B12 transport system [49]. 
Metal-based antitumour drugs are mainly delivered to the body as prodrug (an inactive 
form, which is metabolized in vivo to the active species) and reach their target with prior 
activation by substitution or electron transfer induced transformations (Figure 4) [50]. 
The selective active/reduction of hypoxic-sensitive prodrugs in the reductive 
microenvironment of hypoxic tumours is a consequence of an insufficient formation of 
new blood vessels in rapidly growing tumours. This results in poor blood supply and is 
concomitant with a lower oxygen level hypoxia compared to normal tissues [50]. 
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Figure 4. Proposed simplified activation-by-reduction mechanisms fi}r Ru(III) (a), Pt(IV) 
(b) and Co(III)-based (c) hypoxias elective prodrugs. Reduction in the hypoxic tumour 
tissue (i) is followed by activation of the drug [aquation to the active aqua-species (a and 
b) or liberation of the cytotoxin (c)] (ii) and reaction with the target(s) (Hi). 
Co(in) is a deactivating carrier system for highly cytotoxic organic drugs. These can be 
released from the metal center upon reduction to Co(II) and exert their activity in 
hypoxic tissue. Ware et al [51] have prepared Co(III) complexes containing nitrogen 
mustard ligands with a aim to deactivate the highly potent but unselective free nitrogen 
mustard ligand by coordination via the nitrogen lone pair. Bis (3-methyl-2,4-pentane-
dionato)(N,N-(bis(2-chloroethyl)ethylenediammine)cobalt)-perchlorate(Figure5) exhibits 
20-fold increased cytotoxicity against hypoxic compared to normal cells [52]. The cobalt 
(III) complexes are ideal hypoxia selective drugs and the activity of these drugs largely 
depends on their environment and coordination geometry, which determines their redox 
properties. 
Figure 5. Structures of Bis (3-methyl-2, 4-pentane-dionato) (N, N- (bis (2-chloroethyl) 
ethylenediammine )cobalt)-perchlorate. 
Copper - a bioessential element plays a key role in biological processes, [53] and its 
complexes are preferred molecules for cancer inhibition [54-56]. Due to the plasticity and 
participation of copper as an integral part of the active site of metalloproteins familiarize 
its coordination with the human body's fiinctions [57-59]. It has been demonstrated that 
copper accumulates in tumours due to the selective permeability of cancer cell 
membranes to copper compounds [60]. Besides this, copper complexes offer biologically 
accessible redox potentials with +1 and +2 oxidation states. The tuning and prediction of 
redox potentials under consideration of net charge and biologically environment by 
structure modification provides a rational strategy for the development of tumour 
selective bioreductive drugs. 
V. C. da Silveira et al reported the cytotoxic effect of imine-copper complexes towards 
tumour cells (Figure 6). These complexes were able to transport copper through the cell, 
trigger oxidative stress inside the cell, and induce cell death, targeting mainly the 
organelles mitochondria and nuclei [61]. Their mechanism of action involves not only 
redox activity, with consequent generation of reactive oxygen species, but also specific 
interaction with membranes and organelles as delocalized lipophilic cations. 
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Figure 6. Structure of imine-copper complexes. 
A number of copper complexes have been screened for anticancer activity and some of 
them were found active both in vivo and in vitro. An antitumour copper salicylaldoxime 
(CuSAL) complex (Figure 7) induces topoisomerase (II) to form single strand nicks in 
DNA and poisoned its activity, which is a potential cellular target for a number of 
anticancer drugs [62]. 
OH 
OH 
Figure 7. Structure ofCuSAL. 
A new mononuclear copper (II) complex [Cu(HPClNOL)(Cl)]Cl.MeOH of tripodal N3O 
ligand where HPCINOL = [l-(bis-pyridine-2-ylmethyl-amino)-3-chloropropan-2-ol] was 
prepared and its in vitro antitumour activity towards human myeloid leukemia cell line 
has been checked. This complex promotes the death of THP-1 a human leukemia cells in 
vitro, inducing cell death by apoptosis (programmed cell death) [63], which were further 
confirmed by fluorescence microscopy, cell morphology and DNA degradation 
experiments. 
Zinc is the most abundant trace intracellular element and plays an important role in both 
genetic stability and function [64]. Mechanistically, Zinc has a significant impact on 
DNA as a component of chromatin structure, DNA replication and transcription and 
DNA repair [65]. Zinc (II) complexes of p-isopropylbenzaldehyde and methyl 2-pyridyl 
ketone thiosemicarbazones show potent cytotoxic activity and induction of apoptosis in 
cells resistant to cisplatin [66]. Mechanistic details of cellular uptake of zinc complexes 
of bis (thiosemicarbazone) (Figure 8) have been recently reported by Dilworth and 
coworkers [67]. Optical imaging allows for minor structural changes to be assessed at the 
cellular level, greatly aiding in the design of new and improved antitumour agents. 
Figure 8. Structure ofZn (II) bis(thiosemicarbazone) complex. 
B. Spingler et al have reported the zinc complex of 15-fluoro-1,4,7,10,13-
pentaazacyclohexadecan-14,16-dione (15-fluoro Cumac) and copper complexes of (15-
fluoro Cumac) and 15-fluoro-15-methyl-1,4,7,10,13-pentaazacyclohexadecan-14,16-
dione (15-fluoro-15-methyl Cumac) (Figure 9). The ligand binds to metal center by triple 
coordination of secondary amine in zinc complex. The interaction of the complex with 
poly d(GC) was studied by emission spectroscopic methods, which exhibited change 
exclusively in the positive band of the spectrum while the negative band remained 
unaffected. These results indicate that the zinc complex binds to B-DNA but does not 
promote the transition fi-om B to Z-DNA [68]. 
M = Zn, R,= F, R2 = H 
M = Cu, R,= F, R2 = H 
M = Cu, Ri= F, R2 = Me 
Figure 9. Structure of zinc and copper complexes of (15-fluoro Cumac) and (15-fluoro-
15-methyl Cumac). 
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Stable, inert, water soluble, versatile structures, spectroscopically and electrochemically 
active metal centers are the unique signatures of transition metal complexes, which make 
them sensitive diagnostic agents [69]. Additionally, transition metal complexes exhibit 
significant modulation effects, which can tune the mode of binding and their reactivity 
towards biomolecules. A vast number of ligands can be readily 'plugged' in and out of a 
wide variety of metal centers. This unique attribute of metal complexes provides system 
that utilizes strength of both synthetic organic chemistry and transition metal complexes. 
The choice of metal ion is the most important factor in the design of metal-based 
pharmaceutical, nevertheless ligand design cannot be overlooked as it can be altered to 
tune the delivery of the metal ion into the biological system. Thus, the refinement of 
biological properties of metal complexes by well-tailored multifiinctional ligands offer 
exciting possibilities and can play an integral role in muting the potential toxicity of 
metallodrug to have a positive impact in the areas of diagnosis and therapy. 
Ligand modification in geometry size, hydrophobicity, planarity and the charge and 
hydrogen bonding ability of the complexes may lead to spectacular changes in binding 
modes, location and affinity provide the chance to explore various valuable 
conformations or site specific DNA probes and potential chemotherapeutic agents [70]. 
Ligands can ensure protection of tissues fi'om toxic metal ion or in a contrasting strategy, 
enhance uptake of pharmacological beneficial metal ion [71]. Addition of subsitiuents 
like carbohydrate-appended ligands provide molecular recognition at the target site and 
also improve solubility of the drug candidate. Substituents that either binds preferentially 
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to membrane receptors glycosyl moieties/ amino acids or mimic naturally occurring 
hormones (e.g. sematostatin-like oligopeptides) [72] and assist rendering ligand with 
designed target specificity to reduce toxicity and reach maximum efficacy. 
Metal complexes of amino acids are involved in exchange and transport mechanism of 
trace metal ions in himian body. Such systems provide models of protein-DNA and 
peptide derived antitumour agent-DNA interaction. Various side groups of amino acid 
were found to have a potential to recognize the specific base sequence through hydrogen 
bond formation with the nucleic bases in DNA [73-74]. 
Sequence selective DNA binding of metal complexes containing series of amino acids (a 
short peptide chain) as ligands act as nucleic acid probes and antitumour drugs [75-78]. 
The copper or nickel metallo-complexes (Figure 10) act as DNA-interactive agents as 
they consist same functionalities employed by proteins or peptide derived natural 
products for DNA and RNA recognition [79]. These metal complexes exhibit redox 
reactivity, and cleave nucleic acids oxidatively in similar mechanism proposed for 
bleomycin, which is clinically employed as antitumour agents [80]. 
^ N ^ H 
Ni(II) Lys-Gly-His H Ni(II)Gly-Gly-His 
Figure 10. Nickel complexes ofaminoacids with different peptide side chains. 
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A rationally designed metal complex prepared from a trivalent cobalt ion and a 
tefradentate ligand (Figure 11) capable of binding natural amino acids with high and 
predictable regio- and stereospecificity appeared in Nature [81]. 
(a) (b) 
^ ' HOOC NH2 H3C CH3 
N N 
"-^^ Oil 
Figure 11. Structure of (a) tetradentate ligand (b) its Co (III) complex. 
Mixed ligand ternary complexes of nucleic acid bases and nucleotides such as thymine, 
cytidine, 2- thiouracil and amino acids viz. L-alanine, L-phenylalanine and L-tryptophan 
(Figure 12) were prepared and characterized by micro chemical, thermal analysis, molar 
conductance, infrared and electronic spectral measurements. The substituted nucleosides, 
(uracils) act as chemical mutagens and inhibitors in the synthesis of nucleic acids and 
proteins and hence may be used as carcinostatic agents. The nucleoside acts as a 
monodentate ligand involving only N3 in metal coordination whereas the amino acids act 
as bidentate ligands through carboxylate oxygen and amino nitrogen [82-83]. 
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Figure 12. Structure of few ternary complexes of thymine, cytidine and different 
aminoacids. 
Transition metal complexes of macrocyclic ligands are found to be very versatile 
complexes due to their potential medicinal application [84], cancer diagnosis and 
treatment of tumours [85]. The preference for the macrocyclic complexes over other 
ligand metal system is motivated by their exceptional features [86] viz. ease of synthesis, 
relatively small size, excellent kinetic and thermodynamic stability of their metal 
complexes and biocompatibility in living system. Direct synthesis of macrocycles often 
results in very low yield of the desired product so, many synthetic routes of macrocyclic 
ligands involve the use of the metal ion template to orient the reacting groups of linear 
substrate in the desired conformation for the ring to close [87]. Macrocyclic bicyclic 
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compounds of transition metal [88] and /or lanthanide cations could offer ways to provide 
kinetic stabilities for chemical nucleases. D. R. Chand et al [89] have synthesized Eu(III) 
salts of macrobicyclic complexes and exhibit hydrolytic activity against plasmid DNA 
(Figure 13). These complexes can essentially either block the phosphate of substrate (i.e 
DNA), with negative effects on europium catalytic power or perhaps it act as cofactor in 
hydrolysis. 
(^ N 
O. 
'^^s;p^ in 
Figure 13. Structure of different macrobicyclic compounds. 
Bimetallic CuCu, CuCo, CuNi, CuZn, and CuMn complexes were reported by K. R. 
Rupesh et al [90]. The structures of these complexes have been proposed on the basis of 
FAB mass, elemental analysis, UV/vis, IR and EPR studies. All these complexes show 
significant DNA cleavage activities. Binding studies with CT DNA of these complexes 
show that the presence of aliphatic ligands possess additional binding effects including 
electrostatic, hydrogen bonding and van der Waals interaction. Among the synthesized 
complexes, bimetallic CuCu macrocyclic complexes exhibited stronger DNA cleavage 
properties and could serve as artificial chemical nuclease and chemotherapeutic agents 
(Figure 14). 
15 
(PF6)4 
Figurel4. Structure of bimetallic Copper-Copper bimetallic macrocyclic complex. 
Y. G. Fang et al have synthesized a series of multinuclear macrocyclic complexes of Co 
(II) Zn (II) and Cu (II) (Figure 15). The interaction between the complexes and plasmid 
DNA was studied. The agarose gel electrophoresis results reveal that these complexes are 
potential catalysts for the artificial cleavage of DNA under physiological conditions [91]. 
HN.7CF3COOH 
R=CH2CH(CH3)2 Co2+ 
R=CH2CH Zn2+ 
2+ Cu 
Figure 15. Structure of multinuclear marocyclic complexes ofCo(II), Zn(II) and Cu(II). 
The complexes [C2H5Sn(TAMLOC5H5N] and [C2H5Sn(TAMr)C5H5N] where TAML = 
tetraazamacrocyclic ligand (Figure 16) were synthesized and characterized by IR, 'H , 
'^C, "^Sn NMR and X-ray crystal data. These complexes displayed effective antitumour 
activity [92]. 
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Figure 16. Proposed structure of the complexes X - 1, 2, 3 or 4, R = CHS/C2H5. 
Carbohydrates and their derivatives are the most abundant class of biomolecules known 
to have a large variety of biological functions such as storage transport and transmission 
of genetic information, enzymatic reactions and regulation of the metabolism [93-95]. 
Carbohydrates are capable of inducing a protective antibody response and this 
immunological reaction is a major contributor to the survival of the organism during 
infection [96]. Due to the manifold donor sites of nearly equivalent oxygen atoms and 
due to equilibria between several isomers, carbohydrates are in general, very versatile, 
"chameleon" like ligands [97]. Thus abundance of electronegative functional groups and 
a well-defined stereochemistry make carbohydrates potentially interesting ligands for 
binding of metal ions in natural systems [98-99]. The interaction of transition metal -
carbohydrate complexes with DNA is significantly important, as many natural agents are 
capable of modifying nucleic acids only in the presence of metal ion and oxygen [100]. 
Y. Chen et al [101] have reported synthesis, characterization and cytotoxicity of novel 
carbohydrate linked cisplatin analogue, cis - dichloro [2, B-D-glucopyranosidyl propane-
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1,3 - diamine] platinum (Figure 17). The in vitro antitumour activity of this carbohydrate 
based complex shows that it is active as cisplatin against human cancer cells. A series of 
platinum terpyridine complexes containing a glycosylated acetylide unit were reported 
[102]. One of the derivative was found to be significantly more cytotoxic than cisplatin. 
The glycosylated arylacetylide of complex was a key structural motif in governing the 
observed cytotoxicity. 
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Figure 17. (a) A carbohydrate cisplatin analogue (b) and a platinum terpyridine complex 
containing a glycosylated acetylide unit. 
Copper (II), zinc (II) and cobalt (II) complexes of N-D-glucosamine ft- napthylaldehyde 
and glycine (Figure 18) were synthesized by J. Shen et al [103]. Their interaction with 
DNA and anticancer activity was studied by surface-enhanced Raman spectra (SERS) 
combined with fluorescence spectra in presence of the ethidium bromide. 
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Figure 18. Structure of complexes of N-D-glucosamine fi- napthylaldehyde and glycine. 
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The fluorescence spectra of these complexes exhibited decrease in fluorescence intensity 
on addition of DNA in presence of EthBr. However, the decrease of fluorescence 
intensity was less than 50% revealing that all the complexes did not show intercalating 
ability with DNA, which was attributed to the coordination of amine group of glycine to 
the complexes, which has further reduced their anticancer activity. 
EthBr, a planar aromatic heterocyclic dye, with strong affinity for double stranded DNA 
is a fluorescence probe with high sensitivity and selectivity. The fluorescence of this 
compound is very weak itself and the enhancement of fluorescence occurs when special 
intercalation with DNA takes place. 
EthBr(weak-fluorescent)+DNA(non fluorescent) •»—^ EthBr- DNA (strong fluorescent). 
While coexisting drug agent, M, can act on DNA in a similar way competing with EthBr 
to combine DNA and depressing the enhanced fluorescence. 
M (non fluorescent) + DNA (non fluorescent) - M-DNA (non -fluorescent) 
The novel tetranuclear copper (II) complexes with a-D-glucose-1-phosphate [Cu4 (/i-OH) 
(a-D-Glc-IP)2 (L)4 (H2O)] (N03)3 (L= bipyridine,l,10-phenathroline) were prepared and 
characterized by X-ray crystallography methods [104]. These complexes could provide 
useful information in elucidation of phosphate dependant bioprocess and in the 
development of biommetic reactions. 
The introduction of substituents into carbohydrate skeleton may influence solubility and 
catalytic activity of complexes, even if the substituent is not directly coordinated to metal 
[105]. For the first time, carbohydrate derived chiral hydrazides as ligands for metal ion 
complexation were synthesized [106]. The mononuclear structure proposed for the 
complex of 1,2,3,4-tetra-O-methyl-a-D-glucopyranuronic acid salicylidene hydrazide 
(Figure 19) was characterized by NMR, IR and mass spectroscopy. 
Figure 19. Structure of complex of 1,2,3,4-tetra-O- methyl-a-D-glucopyranuronic acid 
salicylidene hydrazide. 
Metal ion complexation of Li^ , Na ,^ K"^ , Mg*, Ca ,^ Ba^ "^ , Pb^"*^  etc. with 4,6-0-
benzylidene-N-(o-carboxyphenyl)-P-D-glucopyranosylamine (Figure 20) were 
synthesized and isolated as solid products and characterized by analytical means as well 
as spectral technique viz. 'H, '^C NMR, FTIR and FAB mass spectrometry [107]. The 
complexation of N-glycosylamine with different metal ions revealed binding of the 
carboxylates, the glycosylic-NH and in a few cases, the saccharide-OH groups. Even 
after binding to metal ions, the anomeric configuration of saccharide was unaltered and 
remains in the P form. Complexation of the saccharides with metal ions are generally 
hampered by some problems such as easy anomerization, conformational changes and 
configurational inversion in the presence of metal ions, weak acidic nature of saccharide -
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-OH groups etc. These were overcome by selective blocking as well as by C-l-N 
glycosylation. 
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.•2+ -^7 2+ Figure 20. Structural representation for the binding of (a) Li'^, Na^^ (b) Mg^^, Ca ^ (c) 
Pb^^ to glucosamine moieties. 
G. Cerchiaro et al with an aim of verifying different carbohydrate anomers coordinated to 
copper (II) ions. Some copper (II) complexes with D-glucose (Glc), D-fructose (Fru) and 
D- galactose (Gal) were prepared and investigated by spectroscopic techniques [108]. 
The regioselective directing power of organometallic moieties towards the reactivity of 
sugar substrate were extensively studied by N. Bertazzi et al [109] to verify the 
modification of the biological activity when coordinated to sugar (Figure 21). Among the 
acidic carbohydrate derivatives, D-galactouronic acid (H2GalA) is a molecule of 
biological importance. It is present in plants as pectin, (polygalactouronic acid) which is 
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the main component of the cell wall as well as in some exopolysaccharides (present in 
plant roots) where it acts as a chelating agent towards metal ions [110]. Derivatives of 
pectin have been recently tested as potential anticancer drugs. 
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Figure 21. Equilibrium in D2O solution of a,fi-Me2SnGalpA, (GalpA^'=D-galacturonate^' 
pyranosidic form). 
A solution study on the coordinative ability of galactaric acid (GalAH2), D-glucosamine 
(GlcN) and D-glucosaminic acid (GlcNAH) (Figure 22) towards Fe^^ ion was studied by 
E. Ferrari and M. Saladini. Galactaric acid behaves as a chelating ligand through 
carboxylic and alpha hydroxylic oxygen in the protonated or dissociated form depending 
on pH value. Introduction of anchoring group into a sugar molecule as a primary 
coordination site promotes the coordination and deprotonation of the alcoholic hydroxylic 
groups of the carbohydrate moiety. Two complex species [Fe2GalA(OH)4] and Na [Fe 
Gal AH-2].2H20 were isolated in the solid state and characterized by IR spectroscopy. 
UV-Spectroscopic study provides useful information to identify complex species 
formation and their stability constants were determined by means of potentiometric 
measurements [111]. 
fHBSiS 
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Figure 22. Structure (a) galactaric acid (GalH}), D-glucosamine (GlcN) and D-
i+ glucosaminic acid (GlcNAH )(b) Fe^''- (GlcNAH) complex. 
A successful modification of D-glucose into corresponding Schiff base compounds 
through partial protection and glycosyl amination, followed by condensation with 
substituted salicylaldehydes was reported by A. K. Sah et al [112]. Such modifications 
performed on D-glucose not only help in increasing the solubility of the products in non-
aqueous solvents, but also restricts the anomerisation of saccharide moiety in solution. 
Metal ion. binding to ONO core developed, results in six and five membered chelates 
(Figure 23). MuUiple chemical modificafion of D-glucose to Schiff bases are considered 
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as active site directed reversible inhibitors of glycosides and some of these compounds 
have been proposed as oral anti-diabetic agents [113]. 
Figure 23. D-glucose derived Schiffbase with metal ion binding ONO core. 
The complexes of type [CuL'jCb, [CuL^]^^ and [CuL '^'"^Y^ where l}= 3,10-bis (2-
hydroxy ethyl)-l, 3,5,8,10- hexaazacyclotetradecane; L^=2,6,9,13-( tetraparacyclophane); 
L= N, V-dialkyl-l,10-phenanthroline-2,9-dimethanamine, R= methyl (L^), n-propyl (L^), 
isopropyl (L^), sec-butylCL'*), tert-butyl (L^) groups (Figure 24) interacted with DNA by 
different modes and shows DNA cleavage activities. The functional groups on the side 
chains and different substituents play a key role in deciding the mode and extent of 
binding of these copper complexes to DNA. 
H r ^ H 
\ / \ / 
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[CULY^ [CuL '^^ '] [CuL'lCb 
Figure 24. Chemical structures of the macrocyclic copper (II) complexes. 
24 
Interaction of metal complexes with DNA employs extensive spectroscopic studies using 
different structural modifications to evaluate the mode and extent of binding; and 
mechanism of binding event. Absorption and fluorescence spectroscopic studies, cyclic 
voltammetry, viscosity measurements and gel electrophoresis were used to study the 
interaction and cleavage activities of these complexes with DNA [114-116]. On addition 
of CT DNA, all complexes except [CUL'JC^ show decrease in molar absorptivity 
(hypochromism) of LMCT absorption bands (Figure 25). 
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Figure 25. Absorption spectra of (a) fCul'jCh (b) [CuL^f^ (c) [CuL^'f^ in the absence 
(—) and presence (-—) of increasing amounts ofCTDNA. 
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The complex [CuL']Cl2 exhibits an increase in absorptivity (hyperchromism) with no 
shift. These observations suggest copper complexes of L and L ligand bind to DNA 
through partial intercalation by providing an aromatic moiety present in ligand frame 
work to overlap with stacking base pairs of DNA helix. On the other hand, complex 
[CuL'jCb does not possess aromatic ring to facilitate intercalation rather it possesses NH 
and OH groups, which facilitate hydrogen bonding with base pairs of DNA. Competitive 
ethidium bromide binding study was employed to understand the mode of DNA 
interaction of [CuL']Cl2, [CuL ]^^ "^  and [CuL* ]^^ complexes. The addition of complexes to 
DNA causes appreciable reduction in emission intensity indicating that the complex 
competes with EthBr in binding to CT DNA (Figure 26). 
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Figure 26. Emission spectra of EthBr bound to DNA in the absence and presence of the 
(a) fCuL'jCh (b) [CuL^fUc) [CuL^'f\ 
Cyclic voltammetry is the most effective and versatile technique available for the 
mechanistic study of redox systems [117]. Complexes [CUL']C12 and [CuL^]^^ show 
irreversible and fairly reversible/ quasireversible one electron redox process (Figure 27). 
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On the addition of CT DNA, the decrease in peak potentials and peak currents were 
observed. The decrease in respective electrochemical parameters is due to slow diffusion 
of an equilibriimi mixture of free and DNA bound complexes to the electrode surface. 
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Figure 27. Cyclic voltammogram of (a) [CuL JCh in the absence (outer line) and in 
presence (inner line) of CT DNA (b) [CuL^ f^ in absence f—j and in presence (—) of 
DNA 
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Viscosity measurements were also carried out to understand the binding mode of the 
complexes [CuL'jCb , [CuL^JClj and [CuL '^'"^ '^ ] (Figure 28). In presence of [CuL'jCb, 
there is no obvious effect on relative viscosity of CT DNA. This change in viscosity may 
be explained by a binding mode, which produced bends or kinks in DNA. Where as 
complexes of ligand L^  and L '^"^ ^ had a reverse effect on the relative viscosity of CT 
DNA. With addition [CuL^] and [Cu L '^'"^ '^ ], the relative viscosity of CT DNA is 
increased. Since increase is far less than that observed for an intercalators such as EthBr 
and therefore, these results suggest that the complexes [CuL^]^^ and [Cu L '^"^ ]^ interact 
with DNA via partial intercalation between DNA base pairs. 
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Figure 28. Effect of increasing amounts of (a) [Cul'jCh (b) [CuL^f^ (c) [CuL '^'" '^'] on 
the relative specific viscosity ofCTDNA, l/R=[Metal complex]/[DNA]. 
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The characterization of DNA recognition by transition metal complexes has been 
supported by nuclease activity associated with redox activity or photo activated metal 
complexes [118-119]. DNA cleavage was controlled by relaxation of supercoiled circular 
form of pBR322 DNA into the nicked and linear form. When a circular plasmid DNA is 
subjected to agarose gel electrophoresis, the fastest migration will be observed for 
supercoiled form (Form I). If one strand is cleaved, the supercoils will relax to produce a 
slower moving open circular form (Form!!). If both strands are cleaved, a linear form 
(Form III) will be generated that migrates in between. Complexes [CuL ]^'^ * and [CuL '^ '^^] 
induced an effective nuclease activity under identical conditions using different reducing 
agents. 
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Present work 
The design and development of metal complexes, particularly those aimed to target 
nucleic acid in a site specific manner or to mimic the function of enzymes that participate 
in nucleic acid strand cleavage can lead to safer and more rational approaches to novel 
therapeutic agents for cancer, viral disease and tools for molecular biology. These 
complexes offer opportunity to explore the effects of central metal atom, the ligand and 
the coordination geometries on the binding event. By varying the ligands, it is possible to 
modify the mode of interaction of the complexes with nucleic acids and facilitate 
individual application. The application of metal complexes has permitted the target of 
specific DNA site by matching the shape, symmetry and functionality of metal 
complexes to that of the DNA target. 
A biologically significant amino acid alanine, which acts as bidentate ligand has been 
tethered to ammonia and formaldehyde in the presence of metal chlorides (Co(III), Ni 
(II), Cu(II) and Mn(II) chlorides) to achieve new bimetallic complexes. The binding of 
bimetallic complexes with CT DNA has been studied by UV/vis, cyclic voltammetry and 
viscosity measurements. The results suggest that complexes bind to CT DNA 
electrostatically with covalent preference. 
Macrocycles are of interest owing to their importance in biological system and their 
utility as novel probes of nucleic acid structure. To study the influence of heterometallic 
system on DNA binding, new heterometallic macrocyclic complexes were synthesized. 
The DNA binding studies viz. absorption titration, fluorescence spectral studies, cyclic 
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voltammetry, viscosity measurements and agarose gel electrophoresis have been 
performed. 
Carbohydrates are the preferred molecules due their polyhydroxy and stereospecific 
nature, excellent coordinating ability, water solubility, low toxicity and weak 
immunogenicity. Metal complexes of D-glucose and other biologically important 
heterocyclic compounds pyrazole/imidazole can be fruitful in elucidating the mechanistic 
pathway of metal based drugs at molecular level. Therefore, we have synthesized a series 
of glycosylated metal complexes containing pyrazole/imidazole as secondary ligands. We 
have investigated their DNA binding capabilities by employing several spectroscopic 
(UV/vis absorption and fluorescence spectroscopy), cyclic voltammetry and viscosity 
measurements. The cleavage of supercoiled pBR322 DNA by [D-GlcCu(Pz)2] in absence, 
presence of activating agent (ascorbic acid) and under illuminated conditions at 365 nm 
(12W) monochromatic light source was observed using gel electrophoresis. In addition, a 
comparative binding studies of [D-GlcCu(Pz)2] with different biomolecules (HSA, L-
tryptophan) and their mixtures with CT DNA was carried out to recognize the most 
favoured biomolecule for which it shows highest affinity. 
Another set of metal complexes were synthesized by reaction of 3,4: 9,10-Dibenzo-2, 11-
dihydroxy-l,12-bispiperazine-5,8-dioxododecane with Cu(II) and Zn(Il) chlorides. The 
CT DNA binding studies of these complexes were carried out by electronic absorption, 
fluorescence titrations and cyclic voltammetric measurements. The antimicrobial activity 
was also carried out against various bacterial and ftingal strains. 
CHAPTER II 
Experimental 
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CHAPTER II 
EXPERIMENTAL METHODS 
The following techniques were employed 
1. Characterization techniques 
1.1 Infrared spectroscopy 
1.2 Ultra-violet and visible spectroscopy 
1.3 Nuclear magnetic resonance spectroscopy 
1.4 Electron paramagnetic resonance spectroscopy 
1.5 Mass spectroscopy 
1.6 Molar conductance measurements 
2. DNA binding studies 
2.1 Cyclic voltammetry 
2.2 Absorption spectral studies 
2.3 Fluorescence spectral studies 
2.4 Gel electrophoresis 
2.5 Viscometry studies 
1. Characterization techniques 
1.1 Infrared spectroscopy 
The infrared spectroscopy is a useful technique to characterize a compound. It results 
from transition between vibrational and rotational energy levels. IR region of the 
electromagnetic spectrum covers a wide range of wavelength from 200 to 4000 cm"'. It 
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has been found that in IR absorption, some of the vibrational frequencies are associated 
with specific groups of atoms and remain same irrespective of the molecules in which the 
group is present. These are called characteristic frequencies [120] and their constancy 
results from the constancy of bond force constants from molecule to molecule. The 
important observation that the"lR spectrum of a complex molecule consists of 
characteristic group frequencies makes IR spectroscopy, unique and powerful tool in 
structural analysis. 
1.2 Ultraviolet and visible spectroscopy 
When a molecule absorbs radiation, its energy is increased. This increased energy is 
equal to the energy of the incident photon expressed by the relation 
E = hv 
E =hc/>. 
where h is Planck's constant, v is the frequency, X is the wavelength of the radiation and 
c is the velocity of light. Most of the compounds absorb light in the spectral region 
between 200 and 800 nm resulting in the excitation of electrons of the molecules from 
ground state to higher electronic states. In transition metals, all the five'd' orbitals viz. 
dxy, dyz, dxz, dz^  and dx^ .y^  are degenerate. However, in coordination compounds due to the 
presence of ligands, this degeneracy is destroyed and d orbitals split into two groups tzg 
(dxy, dyz and dxz) and Cg (dz^  and dx^ .y^ ) in an octahedral complex and t and e in a 
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tetrahedral complex. The set of t2g orbitals goes below the original level of degenerate 
orbitals in octahedral complexes and the case is reversed in tetrahedral complexes (Figure 
29a,b). 
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Figure 29 (a) Splitting of the d energy levels in an octahedral complex. 
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Figure 29 (b) Ligand field splitting of a tetrahedral complex, 'g' subscript is omitted in 
Tj symmetry. 
At energy higher than the ligand field absorption bands, we commonly observe one or 
more very intense bands that go off scale unless log e is plotted. These are the charge 
34 
transfer bands, corresponding to electron transfer processes that might be either ligand -^ 
metal (L —> M) or metal -^ ligand (M ^ L). M —>^ L transitions occur for metal ion 
complexes that have filled, or nearly filled, t2g orbitals with ligands that have low lying 
empty orbitals. These empty orbitals are ligand K* orbitals in complexes such as those of 
pyridine, bipyridine, 1,10-phenanthroline, CN", CO and NO. Figure 30 shows overlap of 
a t2g metal orbital and K* of CO. 
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Figure 30. Metal carbon double bonding. 
The L —• M charge-transfer (C-T) spectra have been studied more thoroughly. The 
intense bands are for Laporte-allowed transitions commonly of the p (ligand) —> d (metal) 
type. The ionization energy for the ligand (or its ease of oxidation) as well as the 
oxidation state and electronic configuration of the metal (or its ease of reduction) 
determines the energy of the transition. No net oxidation-reduction usually occurs, 
because of the short lifetime of the excited state [121]. 
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13 Nuclear magnetic resonance spectroscopy 
The nuclei of certain isotopes possess a mechanical spin or angular momentum. The 
NMR spectroscopy is concerned with nuclei having nuclear spin quantum number 
I = 1/2, example of which include 'H, '^C, ^'P, "'Sn and '^F. 
For a nucleus with I = 1/2, there are two values for the nuclear spin angular momentum 
quantum number mi = ±1/2 which are degenerate in the absence of a magnetic field. 
However, in the presence of the magnetic field, this degeneracy is destroyed such that the 
positive value of mi corresponds to the lower energy state and negative value to higher 
energy state separated by AE. 
In an NMR experiment, one applies strong homogeneous magnetic field causing the 
nuclei to presses. Radiation of energy comparable to AE is then imposed with radio 
frequency transmitter equal to precision or Larmor frequency and the two are said to be 
in resonance. The energy can be transferred from the source to the sample. The NMR 
signal is obtained when a nucleus is excited firom low energy to high energy state. 
1.4 Electron paramagnetic resonance spectroscopy 
EPR spectroscopy [122] is the branch of absorption spectroscopy in which radiation 
having firequency in the microwave region is absorbed by energy levels of electrons with 
unpaired spins. The magnetic energy splitting is done by applying a static magnetic field. 
For an electron of spin S = 1/2, the spin angular momentum quantum number will have 
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values of nis = ±1/2. In absence of magnetic field, the two values of nis i.e. +1/2 and -1/2 
will give rise to a doubly degenerate spin energy state. If a magnetic field is applied, this 
degeneracy is lifted and leads to the non-degenerate energy levels. The low energy level 
will have the spin magnetic moment aligned with the field and correspond to the quantum 
number ms = -1/2. On ttie other hand, tiie high energy state wiU have the spin magnetic 
moment opposed to the field and correspond to the quantum number ms = +1/2. 
U Mass spectroscopy 
At electron beam energy of about 9 to 15 electron volts, depending on the molecule 
involved, a molecular ion is formed by interaction with the beam electrons. Recognition 
of the parent ion (actually a radical ion) is of great importance because it gives the 
molecular weight of the sample [123]. At this point, the molecular weight is an exact 
numerical molecular weight not the approximation obtained by the all other molecular 
weight procedures. Mass spectra is usually obtamed at an electron beam energy of 70 
electron volts and under these conditions numerous firagment ions (including the parent 
ions) versus their relative concentrations constitutes the mass spectrum of the samples. 
The Augmentations occur on the basis of mass/charge (m/z). The largest peak in the 
spectrum is called base peak and assigned a value of 100%. The other peaks are reported 
as percentage of the base peak. 
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1.6 Conductance measurements 
The conductivity measurement is one of the simplest and easily available techniques used 
to study the nature of the complexes. It gives direct information regarding whether a 
given compound is ionic or covalent. For this purpose, the measurement of molar 
conductance (Am), which is related to the conductance value in the following manner is 
made. 
cell constant x conductance 
Am = 
concentration of solute expressed in mol cm'" 
Conventionally, solutions of IxlO'^  M strength are used for the conductance 
measurements. Molar conductance values of different types of electrolytes in a few 
solvents are given as, 1:1 electrolyte has a value of 80-115 ohm'' cm^ mol'' in MeOH, 
65-90 ohm'' cm^ mol'' in DMF, 78-80, 50-70 ohm'' cm^ mol"' DMSO and 35-45 ohm*' 
cm^ mol'' in EtOH [124-125]. Similarly a solution of 2:1 electrolyte has a value of 160-
220 ohm'' cm^ mol'' in MeOH, 130-170 ohm'' cm^ mol*' in DMF and 70-90 ohm"' cm^ 
mol"' in EtOH. 
2. DNA binding studies 
Calf thymus DNA was procured from Sigma Chemical Company and tris base was 
obtained from E. Merck. All the experiments involving interaction of the complexes with 
CT DNA were conducted in buffer containing tris (0.01 M) adjusted to pH 7.2 with 
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hydrochloric acid. The CT DNA was dissolved in tris-HCl buffer and was dialyzed 
against the same buffer overnight. Solutions of CT DNA gave ratios of UV absorbance at 
260 and 280 nm above 1.8, indicating that the DNA was sufficiently free of protein [126]. 
DNA concentration per nucleotide was determined by absorption spectroscopy using the 
molar absorption coefficient 6600 dm"' mol"' cm"' at 260 nm [127]. The stock solution 
was stored at 4°C. 
2.1 Cyclic voltammetry 
Cyclic voltammetry involves the measurement of current-voltage curves under diffusion 
controlled, mass transfer conditions at a stationary electrode, utilizing symmetrical 
triangular scan rates ranging from a few millivolts per second to hundred volts per 
second. The triangle returns at the same speed and permits the display of a complete 
polarogram with cathodic (reduction) and anodic (oxidation) waveforms one above the 
other. Two seconds or less is required to record a complete polarogram [128]. 
Consider the reaction 
O + ne • R (i) 
Assuming semi-infinite linear diffusion and a solution containing initially only species O. 
With the electron held at a potential Ei where no electrode reaction occurs. The potential 
is swept linearly at v v/sec so that the potential at any time is 
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E(t) = Ei-vt 
or Epcak = E°-0.0285 
The rate of electron transfer is so rapid at the electrode surface that species O and R 
immediately adjust to the ratio according to the Nemst equation, which is as follows., 
Co (0,t) = Co* - [nFACnDo)''']-' f I(7t)(t-x)-"' dx (ii) 
I = nFACo*(nDoa)''^  x (o t) (iii) 
Redox (electron-transfer) reactions of metal complexes can be investigated by cyclic 
voltammetry. An electrode is immersed in a solution of the complex and voltage is swept 
while current flow is monitored. No current flows until oxidation or reduction occurs. 
After the voltage is swept over a set range in one direction, the direction is reversed and 
swept back to the original potential. The cycle may be repeated as often as desired. 
Figure 31 shows the cyclic voltammograms (CV) for a reversible one-electron redox 
reaction such as, 
CpFe(CO)LMe • CpFe(CO)LMe* + e' 
Sweeping the potential in an increasing direction oxidize the complex as the anodic 
current la flows; reversible reduction of CpFe(CO)LMe'^  generates cathodic current Ic on 
the reverse sweep. The magnitude of the current is proportional to the concentration of 
the species being oxidized or reduced. 
The measured parameters of interest on these cyclic voltammograms are Ipa/Ipc the ratio 
of peak currents, Epa - Epc the separation of peak potentials and the formal electrode 
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potential E°. For a Nemstian wave with stable product, the ratio Ipa/Ipc = 1 regardless of 
scan rate, E° and diffusion coefficient, when Ipa is measured from the decayihg current as 
a base line. The difference between Epa and Epe (AEp) is a useful diagnostic test of a 
Nemstian reaction. Although AEp is slightly a function of E°, it is always close to 
2.3RT/nF. 
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The technique yields information about reaction reversibilities and also offers a rapid 
means of analysis for suitable systems. The method is particularly valuable to study 
interaction of metal ions to DNA as it provides a useful compliment to other methods of 
investigation, such as UV/vis spectroscopy. Cyclic voltammetric studies were 
accomplished on a CH Instrument Electrochemical analyzer using a three-electrode 
configuration comprised of a Pt wire as the auxiliary electrode, a platinum micro-cylinder 
as the working electrode and Ag/AgCl as the reference electrode. Electrochemical 
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measurements were made under nitrogen atmosphere. All electrochemical data were 
collected at 298 K and are uncorrected for junction potentials. 
2.2 Absorption spectral studies 
In a closed constant volume system, the rate of a chemical reaction is defined as the rate 
of change of the concentration of any of the reactants and products with time. The 
concentration can be expressed in any units of quantity per unit volume e.g. moles per 
liter, moles per cubic centimeter. The rate will be defined as positive quantity regardless 
of the component whose concentration change is measured. 
The rate of a chemical reaction is not measured directly instead the concentration of one 
of the reactants or products is determined as a fimction of time. A common procedure for 
determining the reaction order is to compare the experimental results with integrated rate 
equations for reactions of different orders. For a first order rate equation, integrating by 
separate variables using integration limits such that at t = 0, c = CQ and at t = t, c = c. 
[129]. 
-dc/dt = kc 
or ln(Co/c) = kt 
The intrinsic binding constant Kb of the complex to CT DNA was determined from 
equation (1), through a plot of [DNA]/ 8a-8f vs [DNA], where [DNA] represents the 
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concentration of DNA, and 8a, Sf, and 8b the apparent extinction coefficient (Aobs /[M]), 
the extinction coefficient for free metal complex (M), and the extinction coefficient for 
the free metal complex (M) in the fully boimd form, respectively. In plots of [DNA]/ea-ef 
vs. [DNA], Kb is given by the ratio of slope to intercept [130-131]. These absorption 
spectral studies were performed on USB 2000 Ocean Optics and UV-1700 PharmaSpec 
UV/vis spectrophotometers (Shimadzu). 
[DNA] / |8a-8fl = [DNA]/lSa-ed + l /Kbl8a-8f l (1) 
2.3 Fluorescence spectral studies 
When molecules that have absorbed light are in a higher electronic state, they must lose 
their excess energy to return back to the ground state. If the excited molecule returns to 
the ground state by emitting light, it exhibits fluorescence and spectrum thus obtained is 
called emission spectrum. This phenomenon is generally seen at moderate temperature in 
liquid solution. The emission spectrum is obtained by setting the excitation 
monochromator at the maximum excitation wavelength and scanning with emission 
monochromator. Often an excitation spectrum is first made in order to confirm the 
identity of the substance and to select the optimum excitation wavelength. Further 
experiments were carried out to gain support for the mode of binding of complexes with 
CT DNA. Non-fluorescent or weakly fluorescent compounds can often be reacted with 
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strong fluorophores enabling them to be determined quantitatively. On this basis 
molecular fluorophore EthBr was used which emits fluorescence in presence of CT DNA 
due to its strong intercalation. Quenching of the fluorescence of EthBr bound to DNA 
were measured with increasing amount of metal complexes as a second molecule and 
Stem-Volmer quenching constant K was obtained from the following equation 2 [132]. 
Io / I= l+Kr (2) 
where r is the ratio of total concentration of complex to that of DNA and lo and I are the 
fluorescence intensities of EthBr in the absence and presence of complex. Binding 
constant K of the metal complexes was also determined from equations 3 and 4 
(Scatchard's equations) by emission titration [133-134]. 
CF = C T ( I / I O - P ) ( 1 - P ) (3) 
r/c = K(n-r) (4) 
CF (concentration of metal complex), CT (concentration of metal complex added), I and 
lo are fluorescence intensities in presence and absence of CT DNA, respectively. P is the 
ratio of the observed fluorescence quantum yield of the boimd metal complex to that of 
the free metal complex. The value P was obtained as the intercept by extrapolating from a 
plot of I/Io vs 1/ [DNA], r denotes ratio of CB (=CT-CF) to the DNA concentration and c, 
is the free metal complex concentration and "n" is the binding site number. Emission 
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intensity measurements were carried out using Hitachi F-2500 spectrofluorometer at 
room temperature. 
2.4 Gel electrophoresis 
Gel electrophoresis is a technique widely used for separation and analysis of charged 
biomolecules like nucleic acids [135-136]. Any charged biomolecule migrates when 
placed in an electric field. The ratio of migration of a molecule depends on its net charge, 
size, shape and the applied current. This can be represented as follows 
V = E.q/f 
Where V = velocity of migration of the molecule, E = electric field in volts/cm, q = net 
charge on the molecule, f = frictional coefficient which is function of mass and shape of 
molecule. The movement of a charged molecule in an electric field is often expressed in 
terms of electrophoretic mobility (n), which is defined as the velocity per unit of electric 
field. 
^ = V/E = E . q / f E 
For molecules with similar conformation, "f " varies with size but not with shape. Thus 
electrophoretic mobility (n) of a molecule is directly proportional to the charge density 
(charge/mass ratio). Molecules with different charge/mass ratio migrate under the electric 
field at different rates and hence get separated. This is the basic principal for all the 
electrophoretic techniques. Depending upon the nature of support medium, 
electrophoresis is of different types such as paper, starch, polyacrylamide and agarose gel 
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electrophoresis. We have opted agarose gel electrophoresis, because agarose gels are 
more porous as compared to polyacrylamide gels and are, therefore, used to fractionate 
large macromolecules such as DNA that cannot be readily penetrate into and move 
through other types of supporting materials. Agarose is a linear polymer of D-galactose 
and 3,6-anhydro-L-galactose. When an electric field is applied across agarose gel, DNA 
molecules that are negatively charged at neutral pH, migrates towards oppositely charged 
electrode at rates determined by their molecular size and conformation. DNA molecules 
of the same size but with different conformation travel at different rates. The order of 
migration velocity in the increasing order of various forms of DNA is: supercoiled DNA 
> linear double strand DNA > open circular DNA. 
2.5 Viscometry studies 
The hydrodynamic changes are the consequence of the change in length of the molecule, 
the diminished bending between layers and the diminished length-specific mass. 
Viscosity measurements were carried out using Ostwald's viscometer at 29 ± 0.01 °C. 
Flow time was measured with a digital stopwatch. Each sample was measured three times 
and an average flow time was calculated. Data were presented as (ti/rio) versus binding 
ratio ([M]/[DNA]), [137-138] where r| is a viscosity of DNA in the presence of complex 
and Tio is the viscosity of DNA alone. Viscosity values were calculated from the 
observed flow time of DNA containing solution (t >100s) corrected for the flow time of 
buffer alone (to), T| = t- to. 
CHAPTER III 
Novel bimetallic complexes of copper, nickel and manganese 
derived from Co"' complex and their interaction studies with 
calf thymus DNA 
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CHAPTER III 
Experimental 
NiCl2.6H20, CUCI2.2H2O, MnCl2.4H20 (Merck) and C0SO4.7H2O (BDH) were utilized 
as received. Calf thymus DNA was purchased from Sigma chemical Co. All reagent 
grade compounds were used without further purification. Carlo Erba Analyzer Model 
1108 was used for microanalysis. Interspec 2020 Fourier-transform (FTIR) spectrometer 
was used for recording IR spectra in Nujol mull. UV/vis spectra were recorded on USB 
Ocean Optics 2000 spectrometer. Data were reported in >wmax/nm- The NMR spectra were 
obtained on a Bruker DRX-300 spectrometer, respectively. Chemical shifts were reported 
on 5 scale in parts per million (ppm). EPR spectrum of copper (II) complex was recorded 
on Varian E 112 spectrometer at the X-band frequency (9.1GHz) at LNT. Cyclic 
voltammetry measurements were recorded on CH instrument electrochemical analyzer. 
All voltaiimietric experiments were performed in single compartmental cell of volume 
10-30 ml. The supporting electrolyte was 0.4 M KCl in distilled water. Solutions were 
deoxygenated by purging N2 gas for 15 minutes prior to measurements, during 
measurements a stream of N2 was passed over the solution. Molar conductances were 
measured at room temperature on Digisim electronic conductivity bridge. 
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Synthesis of [(4,6,8-Triazaundecandioato)-6-N,N -methano-(P-alaninato)]-cobalt 
(III) pentahydrate (Ci2H2iN406Co]5H20 
This complex was synthesized according to the procedure described earlier [139]. 
Synthesis of [aqua(4,6,8-Triazaundecandioato)-6-N,N -methano-(P-aIaninato)l-
cobalt (III) copper (II) chloride pentahydrate [C12H23N4O7C0CUICI25H2O 
To an aqueous solution of [C12H21N4O6C0] 5H2O (2.50 g, 5.36 mmol) dissolved in 20 ml 
H2O was added methanolic solution of CUCI2.2H2O (0.918 g, 5.36 mmol) dissolved in 50 
ml MeOH in 1:1 ratio. The resulting solution was stirred ca. 4 hours. Slow evaporation of 
the solution yielded green colored solid complex, which was thoroughly washed with 
EtOH and dried in vacuo over fused CaC^. 
OH2 
^" '° + r r i HjO/MeOH ^^^X /Co 
.CUCI2 ^ T ^ . N / 1 
- -NH " 
CI25H2O 
•N I ^ N . 
\ 
y 
N 
Scheme 1. Propsed structure ofcomplex[C]2H23N407CoCu]Cl25H20. 
Synthesis of [aqua(4,6,8-Triazaundecandioato)-6-N,N -methano-(p-alaninato)]-
cobalt (III) nickel ai) chloride pentahydrate [C,2H23N407CoNi]Cl25H20 
To an aqueous solution of [C12H21N4O6C0] 5H2O (0.94 g, 2.02 mmol) dissolved in 20 ml 
H2O was added methanolic solution of NiCl2.6H20 (0.48 g, 2.02 mmol) dissolved in 50 
TiUi^iS 
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ml MeOH in 1:1 ratio. The solution was stirred ca. 4 hours. Later, slow evaporation of the 
mixture yielded blue colored product which was thoroughly washed with ethanol and 
then dried in vacuo over fused CaCb. 
OH, 
O o 
AooA 
0~ 
-0 
• ^ . ^ / ^ o -
^O 0 ^ 
SHjO 
H •N 'N: 
NH H 
+ NiClj H,0/MeOH 
O. 
•N 
CI25H2O 
N-' 
y N 
NH H 
y N 
Scheme 2. Propsed structure of complex[Ci2H2iN407CoNi]Cl25H20. 
Synthesis of [aqua (4,6,8-Triazaundecandioato)-6-N,N-methano-(P-alaninato)]-
cobalt (III) manganese (II) chloride pentahydrate [Ci2H23N407CoMn]Cl2 5H2O 
To an aqueous solution of [C12H21N4O6C0] 5H2O (0.94 g, 2.02 mmol) in 20 ml H2O was 
added methanolic solution of MnCl4.4H20 (0.40 g, 2.02 mmol) in 50 ml MeOH in 1:1 
ratio. The solution was stirred for ca. 4 hours. Slow evaporation yielded blue product, 
which was thoroughly washed with ethanol and then dried in vacuo over fused CaCb. 
OH2 
O 
^O O 
-00/ 
o A, Mn I / \ ' 
5H2O 
+ MnCl2 
H,0/MeOH O, 
O O 
H-N 
CI25H2O 
~N: 
KJ H 
Scheme 3. Propsed structure ofcomplex[Ci2H23N40TCoMn]Cl25H20. 
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Results and discussion 
The important properties and physical data of the complexes are given in Table 1. All the 
complexes are highly water soluble and insoluble in all organic solvents. Complexes 
[Ci2H23N407CoCu]Cl25H20, [Ci2H23N407CoNi]Cl25H20 and [C,2H23N407CoMn] 
Cl25H20,'are hygroscopic and are ionic in nature. The analytical data of the complexes 
conform to structures proposed in scheme 1-3. 
IR spectra 
Free amino acids exhibit two absorption bands corresponding to v(C=0) and v(C-O), 
symmetric and asymmetric vibration of carboxylate group at 1610 cm"' and 1440 cm"', 
respectively (Table 2). The IR spectrum of the complex [Ci2H2iN406Co]5H20 exhibits 
band at 1671 cm"' and 1380 cm"', which indicate that the carboxylate group of aminoacid 
was coordinated to the cobalt metal ion. A medium intensity band at 3300 cm'' was 
attributed to N-H stretching vibration which is lower in comparison to v(NH2) suggesting 
the participation of NH group in complexation [140]. In the complexes 
[Ci2H23N407CoCu]Cl25H20, [C,2H23N407CoNi]Cl25H20 and 
[Ci2H23N407CoMn]Cl25H20, bands were observed at 1633, 1647 and 1647 cm"' which 
were attributed to v(C=0) and at 1320-1340 cm"' due to v(C-O) vibrations respectively, 
[141-142] indicating the coordination of second metal ion to carboxylate group. 
However, a band due to N-H stretching vibration at 3300 cm"' remains unaltered in the 
bimetallic complexes [Ci2H23N407CoCu]Cl25H20, [C,2H23N407CoNi]Cl25H20 and 
[Ci2H23N407CoMn]Cl25H20. Other medium intensity bands appear at 1300-1400 cm"'. 
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1499 and 2352 cm"' which were assigned to v(C-C), v(C-N) and v(C-H) stretching 
vibrations, respectively [143-144]. A broad absorption band at 800-900 cm"' ascribed to 
coordinated water molecule was observed in the complexes [Ci2H23N407CoCu]Cl25H20, 
[Ci2H23N407CoNi]Cl25H20and [Ci2H23N407CoMn]Cl25H20 [145]. The far IR spectrum 
of monometallic complex [Ci2H2iN406Co]5H20 reveal bands due to v(Co-O) and v(Co-
N) stretching vibrations at 501 cm'' and 580 cm'', respectively. In the bimetallic 
complexes bands due to v(M-O) stretching vibrations [M=Cu, Ni, Mn] were observed in 
the range of 420- 432 cm"'. 
EPR spectra 
The X-band EPR spectrum of [Ci2H23N407CoCu]Cl25H20 was acquired at liquid 
nitrogen temperature (LNT) under the magnetic field strength of 3000 ± 1000 guass using 
TCNE as field marker. The geometry of complexes in solution was confirmed by running 
the spectrum in H2O. The solution EPR spectra of complex [Ci2H23N407CoCu]Cl25H20 
exhibited only a single broad isotropic signal centered at giso= 2.04. The value was in 
good agreement with unpaired electron mainly located in dz orbital. This pattern is 
typical for complex with square pyramidal environment [146]. 
NMR spectra 
'H, '^C and 2D NMR spectra of complex [Ci2H23N407CoNi]Cl25H20 were carried out in 
DMSO-dfi in order to deduce the formulation of the complexes. In 'H NMR spectrum of 
complex [Ci2H23N407CoNi]Cl25H20, signals due to fi-ee carboxylic (COOH) and amine 
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(NHa) groups at 12.0-10.0 and 5.3-5.4 ppm, respectively were absent and signal due to 
(NH) protons appear at 4.54 ppm (Figure 32) [147], indicating the coordination of 
aminoacid to second metal atom via carboxylate group. Other resonances appear at 2.39-
2.50, and 3.38 ppm due to CH2, CH2N and NHCH2 protons respectively [148-149] 
(Table3). The 'H N M R data is further confirmed by 2D NMR data (Table 3) and depicted 
in Figure 33. '^ C NMR spectrum of the complex [Ci2H23N407CoNi] CI25H2O exhibits -
CH2, CH2-NH, -NCH2 and C=0 carbon resonance signals at 39.0, 40.2, 119 and 170.0 
ppm, respectively (Table 4), which further authenticate the proposed structure of the 
complex [150-152]. 
iti i a 
DP* 10 6 
Figure 32. 'HNMR spectrum of[C,2H23N407CoNijCh5H20. 
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Figure 33. 2D COSYNMR spectrum [Ci2H23N407CoNiJ CI25H2O. 
Electronic spectra 
The electronic spectra of complexes [Ci2H2iN406Co]5H20, [C12H23N4O7C0CU] 
CI25H2O, [C,2H23N407CoNi]Cl25H20 and [Ci2H23N407CoMn]Cl25H20 were recorded in 
aqueous solutions. The monometallic complex [Ci2H2iN406Co]5H20 displays a band at 
520-530 nm, exhibiting octahedral geometry of cobalt metal ion [147]. The bimetallic 
complex [Ci2H23N407CoCu]Cl25H20 reveals a broad d-d band at 730-850 nm, which was 
assigned tentatively to dz^-> dx^_ y^  and dxy,dyz-^  dx^_ y^  transitions suggesting square 
pyramidal environment around copper (II) metal ion [153]. This was further authenticated 
by the EPR spectral data. The UV/vis spectrum of complex [Ci2H23N407CoNi]Cl25H20 
exhibits a broad band at 650 nm corresponding to ^Bi(F) -^ •^ A2,^ E (P) transition, which 
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was consistent with square pyramidal geometry of nickel [154]. In the electronic 
spectrum of complex [Ci2H23N407CoMn]Cl25H20, no band was observed in the visible 
region due to inactive transition of Mn(II) metal ion, as each orbital is singly occupied 
and spin inversion is forbidden. Peaks of spin inversion were low enough to be detected 
in visible range. Furthermore, presence of bands at 520-530 nm in all bimetallic 
complexes indicate that Co(III) retained its octahedral geometry. Intense charge transfer 
bands (TC- %*) (LMCT) bands were observed in the region of 250-300 nm in all 
complexes. 
Interaction studies with DNA 
The interaction of monometallic complex [Ci2H2iN406Co]5H20 and bimetallic 
complexes [Ci2H23N407CoCu]Cl25H20, [Cj2H23N407CoNi]Cl25H20, 
[Ci2H23N407CoMn]Cl25H20 with CT DNA were investigated using UV/vis absorption 
titrations. The fixed amount of complexes (0.17 x 10'^  M) were titrated with the 
increasing amount of CT DNA (0.17- 0.3 x 10"^  M). The interaction of CT DNA was 
investigated by monitoring the changes in intraligand (IL) bands (Figure 34-36). On 
addition of CT DNA both monometallic [Ci2H2iN406Co]5H20 and bimetallic complexes 
[Ci2H23N407CoCu]Cl25H20, [Ci2H23N407CoNi]Cl25H20, [C,2H23N407CoMn]Cl25H20 
exhibited hyperchromism with a bathochromic shift of 2-5 nm in IL bands. The 
hyperchromic effect implies structural damage of CT DNA helix and suggests interaction 
of complexes to DNA by electrostatic or covalent mode of binding, while hypochromic 
effects are due intercalation of complexes vnih DNA [155-156]. 
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Figure 34. Absorption spectral traces of complex [C12H21N4O6C0] 5H2O in Tris HCl 
buffer upon addition of CTDNA. Inset; Plots offDNAJ / Sa- e/ versus [DNA] for the 
titration of CT DNA with complexes (•), experimental data points; full lines, linear 
fitting data. 
300 400 
Waveiength (nm) 
Figure 35. Absorption spectral traces of complex [C12H23N4O7C0CU] CI25H2O in Tris 
HCl buffer upon addition of CT DNA.Inset; Plots of [DNA] / e^- £/ versus [DNA] for 
the titration ofCTDNA with complexes(u), experimental data points; full lines, linear 
fitting data. 
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To compare quantitatively the affinity of complexes toWSffroCT DNA, the intrinsic 
binding constant Kb for these complexes were calculated using equation 1, the intrinsic 
binding constant of monometallic complex [Ci2H2iN4Co]5H20 was found to be 1.2 x lO"' 
M'', while the Kb values for bimetallic complexes [C2iH23N4CoCu]Cl25H20, 
[C2iH23N4CoNi]Cl25H20, [C2iH23N4CoMn]Cl25H20 were 1.4 x 10^  M"', 2.2 x 10^  M"', 
respectively. We observed that the Kb value for the bimetallic complex 
[C2iH23N4CoCu]Cl25H20 is slightly higher in comparison to monometallic complex 
[Ci2H2iN4Co]5H20. This was due to reason that copper metal ion do not exhibit a 
significant hydrolytic enzyme activity, as it is not a natural cofactor of phosphodiesterase 
enzyme which plays a key role in DNA hydrolysis [157]. There is a two fold increase in 
the Kb values of bimetallic complexes [C2iH23N4CoNi]Cl25H20, and 
[C2iH23N4CoMn]Cl25H20 suggesting that the binding mode may be electrostatic with a 
covalent preference due to the presence of second metal ion. Since the Kb values are 
smaller than classical intercalators such as EthBr whose binding constant Kb is of the 
order of 10^-10^ M"' [56], therefore electrostatic mode of interaction with CT DNA is 
interpreted. 
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Figure 36. Absorption spectral traces of complex [Ci2H23N407CoNi]Cl25H20 (upper) 
and [Ci2H23N407CoMn] CI25H2O (below) in Tris HCl buffer upon addition of CTDNA. 
Inset; Plots offDNAJ /Sa- £/ versus [DMA] for the titration ofCT DNA with complexes 
(k.),(u) experimental data points; full lines, linear fitting data. 
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Electrochemistry 
Electrochemical methods are widely used to study the interaction of CT DNA with metal 
chelates. Based on shift of formal potentials in the cyclic voltammograms, the interaction 
mode of complexes with DNA can be mferred [158]. The electrochemical behavior of 
complexes [C,2H2iN406Co]5H20, [Ci2H23N407CoCu]Cl25H20, [C,2H23N407CoNi]Cl2 
5H2O and [Ci2H23N407CoMn]Cl25H20 and their interaction with CT DNA were carried 
out by cyclic voltammetry in the potential range between 1.4 to -1.2 at the scan rate of 0.3 
Vs"'. Cyclic voltammograms of complexes [Ci2H2iN406Co]5H20, 
[Ci2H23N407CoCu]Cl25H20, [Ci2H23N407CoNi]Cl25H20 and [C,2H23N407CoMn] 
CI25H2O in aqueous solution initiated at 0.6 V revealed an quasireversible reduction 
wave at ca 0.4 V, which is due to an electron transfer process of Co'" + e~-^ Co". In 
complex [Ci2H2iN406Co]5H20, a second well defined quasireversible redox couple was 
observed at -0.4 V corresponding to simple one electron redox couple Co"/Co', which 
was followed by another one electron quasireversible wave attributed to redox couple of 
Co'VCo'". For Co'VCo' couple, the difference between anodic and cathodic peak potential 
AEp and formal potential Em were 0.14V and -0.39V. The ratio of anodic and cathodic 
peak current was 0.447 implying a quasireversible electron transfer process. The formal 
electrode potential E1/2, AEp and ratio of anodic and cathodic peak currents Ipa /Ipc values 
for Co"/Co"'redox couple were 0.963V, 0.56V and 0.105 respectively [159]. At different 
scan rates, the voltammogram does not show any major change. On addition of CT DNA, 
there is a considerable shift in E\n as well as ^Ep was observed for Co"/Co' and Co"/ 
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Jii Co couples at constant parameters. The ratio for peak currents Ipa/Ipc were 0.501, 0.594 
for these two redox couples. Significant shift in formal potential Em, AEp and Ipa Ape 
ratio implies that complex [Ci2H2iN406Co]5H20 binds to calf thymus DNA (Figure 37). 
-/ Figure 37. Cyclic voltammogram at a scan rate 0.3 Vs' in H2O (a) [C12H21N4O6C0] 
5H2O (b) C,2H2iN406Co]5H20 in presence ofCTDNA. 
The cyclic voltammograms of the bimetallic complexes [C)2H23N407CoCu]Cl25H20, 
[Ci2H23N407CoNi]Cl25H20 and [Ci2H23N407CoMn]Cl25H20 reveal two redox couples, 
one of which is attributed to single electron transfer process of Cu" / Cu', Ni"/Ni', Mn" / 
Mn' [160-161]. These redox couples have been merged with Co'VCo' and appear in the 
form of a single redox wave in the voltammograms of [Ci2H23N407CoCu]Cl25H20, 
[Ci2H23N407CoNi]Cl25H20 and [Ci2H23N407CoMn]Cl25H20. In the cyclic 
voltammogram of complex [Ci2H23N407CoCu]Cl25H20, AEp. E1/2 and peak current ratio 
values due to redox couple Cu" / Cu' were 0.17V, -0.38V, 0.22, respectively and it also 
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exhibited a second quasirrversible redox couple due an electron transfer process Co" / 
Co'" for which AEp , E\n and Ipg/Ipc values are 0.05V, -0.98V and 0.10, respectively 
(Figure 38). 
1 2 
1.0 
o.« 
0.6 
0.1. 
az 
0 
-0 .2 
-0 .4 
- 0 . 6 
-0 .8 
-1.0 
-
-
J 
A / /A . i fX=^ y^ ^"-^ ""^ _^^J 
/\^___^ 
^^—^-^==..^='====-^~^^^ 
1 1 [ 1 1 I . J 1 . 1 1 
I t 1.2 1.0 a s 0 6 0.1 0 2 0 
Polent io l /V 
-0.2 -0 .4 -0 .6 - 0 8 -IX) 
,-/ Figure 38. Cyclic voltammogram at a scan rate 0.3 Vs' in H2O (a) 
fC,2H23N407CoCuJCh5H20 (b) [C,2H23N407CoCu] Ch 5H2O in presence ofCTDNA. 
While in case of complex [Ci2H23N407CoNi]Cl25H20, the observed values for respective 
peak potentials and peak currents due to redox couple Ni" / Ni were 0.138V, -0.39V and 
0.71, respectively. Another redox couple wave in complex [Ci2H23N407CoNi]Cl25H20 is 
attributed to Co" / Co"' couple which exhibits AEp, E1/2 and Ipa/Ipc values 0.12V, 0.95V 
and 0.964, respectively (Figure 39). 
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„- / Figure 39. Cyclic voltammogram at a scan rate 0.3 Vs' in H2O (a) [Ci2H23N407CoNiJ 
CI25H2O (b) [Ci2H23N407CoNiJ CI25H2O in presence ofCTDNA. 
Similarly in complex [Ci2H23N407CoMn]5H20Cl2 AEp, Em and voltammeteric current 
ratio values assigned to redox couples Mn" / Mn' and Co" / Co'" were -0.12V, -0,39V, 
0.53 and 0.14V, 0.87V and 0.25 respectively. On addition of CT DNA, bimetallic 
complexes undergo considerable changes in AEp, E1/2 values due to both redox couples 
M " / M ' (where M = Cu, Ni, Mn) and Co" / Co"'. The ratio of peak currents after the 
addition of CT DNA were 0.52, 0.81 and 0.47 for M " / M ' and 0.10, 0.95, 0.27 for Co" / 
Co"' couples in the bimetallic complexes [Ci2H23N407CoCu]Cl2H20, [Ci2H23N407CoNi] 
CI25H2O and [Ci2H23N407CoMn]Cl25H20, respectively (Figure 40). The voltammetric 
peak current ratio were less than the ratio of peak currents in absence of CT DNA clearly 
suggesting the strong binding of bimetallic complexes to CT DNA. 
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Figure 40. Cyclic voltammogram at a scan rate 0.3Vs'' in H2O (a) [Ci2H23N40TCoMn] 
ChSHiO (b) [C,2H23N407CoMn] Ch 5H2O in presence ofCTDNA 
Viscosity studies 
Hydrodynamic measurements like viscosity that is sensitive to length changes is regarded 
as least ambiguous and most critical test of a binding metal complex in solution in 
absence of crystallographic data [162]. A classical intercalation model results in 
lengthening the DNA helix as base pairs are separated to accommodate the binding metal 
complex, leading to increase in DNA viscosity. In contrast, partial, non-classical 
intercalation of complexes produces kinks in the DNA, thus reduce its effective length 
and concomitantly its viscosity. As a means of further clarifying the binding of the 
complexes [Ci2H2iN406Co]5H20, [Ci2H23N407CoCu]Cl25H20, [Ci2H23N407CoNi] 
CI25H2O and [Ci2H23N407CoMn]Cl25H20, viscosity measurements were carried out on 
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CT DNA by varying the concentration of added complexes at 29 ± 0.1 °C. Values of T^ /rio 
were plotted against [complex]/[DNA] in absence and presence of complexes 
[Ci2H2iN406Co]5H20, [Ci2H23N407CoCu]Cl25H20, [Ci2H23N407CoNi]Cl25H20 and 
[Ci2H23N407CoMn]Cl25H20. All the complexes show decrease in relative viscosity of 
DNA solutions depicted in Figure 41. These complexes bind to DNA by electrostatic 
interaction, probably with covalent preference. 
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Figure 41. Effects of increasing amount of complexes [Ci2H2iN406Co]5H20 (a), 
[Ci2H23N407CoCu]Cl25H20 (b). [C,2H23N407C0Ni]Cl25H20 (C), [C,2H23N407CoMn] 
CI25H2O (d) on the relative viscosity ofCTDNA at 29 ±O.J °C. [DNA] = J x l(r\ 1/R 
=[complex]/[DNA]. 
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CHAPTER IV 
Synthesis of new heterometallic macromolecules: Their 
DNA-binding, cleavage activity and in vitro model 
electrochemotherapy study 
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CHAPTER IV 
Experimental 
Triethylenetetramine, Diethyloxalate (Fluka), Tris base (Merck), SnCl4.5H20 (Loba 
Chemei), CUCI2.2H2O (Qualigens), MnCl2.4H20 (sd.fine), 6X loading dye (Fermental 
Life Science) and supercoiled plasmid pBR322 DNA (Genei) were utilized as received. 
Calf thymus DNA was purchased from Sigma Chemical Company and was stored at 4 
°C. All reagent grade compounds were used without further purification. Interspec 2020 
FTIR spectrometer was used for recording IR spectra of KBr pellets in the range of 400-
4000 cm'^ Electronic spectra were recorded on UV-1700 PharmaSpec Uv-vis 
spectrophotometer (Shimadzu). Data were reported in Xmax/nm. Emission spectra were 
determined with a Hitachi F-2500 fluorescence spectrophotometer. Microanalyses of the 
complexes were obtained on a Carlo Erba Analyzer Model 1108. 'H, '•'C and 2D NMR 
spectra were recorded on a Bruker DRX-300 spectrometer. Chemical shifts were reported 
in 5 scale (ppm). EPR spectrum of copper (II) complex was recorded on Varian E 112 
spectrometer at the X-band frequency (9.1GHz) at liquid nitrogen temperature (LNT) 
using tetracyanoethylene (TCNE) as field marker. Cyclic voltammetry was carried out at 
CH instrument electrochemical analyzer. All voltammetric experiments were performed 
in single compartmental cell of volume 10-15 ml containing a three-electrode system 
comprised of a Pt-disk working electrode, Pt-wire as auxiliary electrode and an Ag/AgCl 
electrode as reference electrode. The supporting elecfrolyte was 0.4 M KNO3 in milli-Q 
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water. Deaerated solutions were used by purging N2 gas for 15 minutes prior to 
measurements. Molar conductance was measured at room temperature on Digisun 
electronic conductivity bridge. Interaction of complexes with calf thymus (CT DNA) was 
performed in 0.01 M buffer (pH 7.2). The plasmid pBR322 DNA cleavage assay of water 
soluble [CieHaoNgOsSnaCU], [Ci6H38N809Sn2Cu2Cl8] and [CuHsgNgOQSnjMnaClg] 
complexes were carried out using the method described by [163]. The 1000 nM stock 
solutions these complexes were prepared in nuclease free water. The covalently closed 
circular (>90%) plasmid pBR322DNA (~300ng) in a final volimie of 50 i^M were treated 
with varying concentration of complexes [Ci6H3oN805Sn2Cl4], [Ci6H38N809Sn2Cu2Cl8] 
and [Ci6H38N809Sn2Mn2Cl8]. Agarose gel electrophoresis was performed at 300 mA for 
2 h and stained with ethidium bromide (0.5mg/ml) for 30 minutes. The gels were 
documented and analyzed by UVP gel. 
Synthesis of Macrocycle l,4,7,10,13,16,19,22-octaaza-2^,14,15-tetraoxo 
cyclohexadecane [Ci6H32N804]MAC 
The expanded polyazamacrocycle [Ci6H32N804]MAC was prepared by adopting the 
procedure reported earlier [164]. 
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Synthesis of l,4,7,10,13,16,19,22-Octaaza-2,3,14,15-tetraoxocyclohexadecanetin (IV) 
chloride ICi6H3oN805Sn2CL,] 
To a solution of [C16H32N8O4] (0.4 g, 1 mmol) in 10 ml methanol was added a solution 
of SnCl4.5H20 (0.702 g, 2 mmol) in 10 ml methanol dropwise with stirring at room 
temperature. A white precipitate formed was filtered off, washed with ethanol and further 
dried in vacuo. 
Synthesis of the l,4,7,10,13,16,19,22-octaaza-2,3|14,lS-tetraoxocyclohexadecanetin 
(IV)Cu(II)chloride [CeHssNgOpSnzCuzCls] 
To a solution of [Ci6H3oN805Sn2Cl4] (0.793 g, 1 mmol) in 10 ml of methanol was added 
CUCI2.2H2O (0.342 g, 2 mmol) in 5 ml of methanol dropwise. The resulting solution was 
stirred for 1 hour, a green colored precipitate formed was filtered and thoroughly washed 
with methanol and dried in vacuo. 
Synthesis of the l,4,7,10,13,16,19,22-octaaza-2^,14,15-tetraoxocyclohexadecane tin 
(IV)Mn(II)chloride [Ci6H38N809Sn2Mn2Cl8] 
The complex [Ci6H38N809Sn2Mn2Cl8] was synthesized according to the procedure 
described for [C,6H38N809Sn2Cu2Cl8] with MnCl2.4H20 (0.396 g, 2 mmol). The brown 
colored product obtained was washed with methanol and dried in vacuo. 
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Scheme 4a. Proposed structure of [C16H32N8O4JMAC, [Ci6H3oN805Sn2Cl4], 
[CsHssNsOgSniCuiClsJ and [CieHssNsOgSmMmChJ. 
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[Cf^soNsOsSniCU] fCi6H38N809Sn2Cu2Cl8j [C,6Hs8N809Sn2Mn2Cl8] 
Scheme 4b. Cylindrical bonded three dimensional model of complexes 
[C,6H3oN80,Sn2Cl4], [C,6Hs8N80gSn2Cu2Cl8] and [C,6H38N809Sn2Mn2Cl8. Color 
scheme: Sn'^dark green; Cu" dark gray; Mn" Brown; N dark blue; O red; C gray; 
Results and discussion 
The synthetic scheme of the complexes [Ci6H3oN805Sn2Cl4], [Ci6H38N809Sn2Cu2Cl8] 
and [Ci6H38N809Sn2Mn2Cl8] has been exhibited in scheme 4a and three dimensional 
model with cylindrical bonds depicted in scheme 4b. The important properties and 
physical data of the complexes are given in Table 5. [Ci6H32N804]MAC is soluble in 
H2O and MeOH, while [Ci6H3oN805Sn2Cl4], [Ci6H38N809Sn2Cu2Cl8] and 
[Ci6H38N809Sn2Mn2Cl8] are soluble in H2O. The molar conductance measurements in 
H2O show that [Ci6H3oN805Sn2Cl4], [C,6H38N809Sn2Cu2Cl8] and 
[Ci6H38N809Sn2Mn2Cl8] are non-ionic in nature. 
IR spectra 
The IR spectrum of free macrocycle [Ci6H32N804]MAC display v(NH) bands at 3260 and 
3128cm' due to free NH and inter or intra NH hydrogen bonds, respectively [165]. A 
medium intensity band at 1653 cm"' was assigned to v(C=0) vibrations [166]. The 
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absorption bands observed at 2940 and 2882 cm"' were attributed to v(CH2) vibration 
modes [167] and characteristic stretching bands due to v(C-C), v(C-N) appeared at 1362 
cm"' and 1453 cm"', respectively [168,165]. In the complex [Ci6H3oN805Sn2Cl4] 
absorption band due to free NH undergoes a shift of 20 cm"', indicating the involvement 
of NH. The disappearance of NH band at 3128 cm"' due to dissociation of amide protons, 
ftirther confirms the formation of complex [CisHsoNsOsSnaCU] [164,169]. In the IR 
spectra of [Ci6H38N809Sn2Cu2Cl8] and [Ci6H38N809Sn2Mn2Cl8], no major change was 
observed in IR frequencies of macrocyclic framework, except bands due to v(C=0) were 
shifted to 1631 and 1630 cm"'. This observation implies the coordination of the second 
metal ion Cu^ "^ /Mn^ * occurs through carbonyl groups of macrocycle. The broad medium 
intensity band at 3458, 3442 cm"' were ascribed to coordinated water molecules in 
complexes [Ci6H38N809Sn2Cu2Cl8] and [Ci6H38N809Sn2Mn2Cl8], respectively. 
Furthermore, far IR spectra of [Ci6H3oN805Sn2Cl4], [Ci6H38N809Sn2Cu2Cl8] and 
[Ci6H38N809Sn2Mn2Cl8] revealed absorption bands due to v(Sn-N), v(Cu-O) and v(Mn-
0) at ~ 465cm'', 435cm"' and 431cm"', respectively [170-171] (Table 6). 
EPR spectra 
The geometry of macrocyclic complex [Ci6H38N809Sn2Cu2Cl8] in aqueous solution was 
investigated by recording X-band spectrum at LNT, using tetracyanoethylene as a field 
marker (g = 2.0027). The epr spectrum displayed an isotropic signal centered at giso=2.11, 
confirming the octahedral environment of Cu (II) metal ion [172]. 
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NMR spectra 
The H, C and 2D Cosy NMR were carried out in D2O to confirm the basic skeleton of 
[C|6H32N804]MAC and [CieHaoNgOsSnzCU] (Table 7, 8). The 'H NMR spectrum of 
[Ci6H32N804]MAC revealed methyl and NH, protons of NHCH2CH2NH, 
CONHCH2CH2NH, CONHCH2CH2NH at 6 3.65, 3.63, 3.37 and 4.67 ppm, respectively 
[173,147]. The 'H NMR spectrum of [Ci6H3oN805Sn2Cl4] (Figure 42) exhibited 
characteristic resonances at S 3.46, 3.64 and 3.49 ppm assigned to NCH2, NHCH2CH2NH 
and NHCH2 protons [173-175]. A singlet observed at 4.81 was assigned to NH protons. 
The NMR data was further confirmed by 2D NMR and is depicted in Figure 43. 
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Figure 42. 'HNMR spectrum of the complex [Ci6HioN80iSn2Cl4]. 
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Figure 43. 2£) COSYNMR spectrum of the complex [CieHjoNsO58172014]. 
The '^ C NMR spectrum of [Ci6H32N804]MAC showed signals at 38.15, 43.40 161.17 
ppm attributed to CONHCH2, CH2NH and C=0 carbon atoms, respectively [166,176-
177]. The '^ C spectra of [Ci6H3oN805Sn2Cl4] exhibited carbon resonances due to CH2, 
CH2N and C=0 at 41.93,46.11 and 160.13 ppm, respectively [176-178]. Thus above data 
supports the proposed structure of the [Ci6H32N804]MAC and complex 
[CfiHsoNgOsSnzCU]. 
Electronic absorption spectra 
The electronic absorption spectra of [Ci6H3oN805Sn2Cl4], [Ci6H38N809Sn2Cu2Cl8] and 
[Ci6H38N809Sn2Mn2Cl8] in aqueous solution were carried in the range of 200-1100 nm. 
74 
to provide further insights about geometry around the metal ions. The electronic spectrum 
of [Ci6H3oN805Sn2Cl4] revealed a high energy band at 211 nm attributed to intraligand 
7t- K* charge transfer bands. Complex [Ci6H38N809Sn2Cu2Cl8] displayed two well 
resolved bands at 219 nm, 350 nm assigned to charge transfer (TI- %*) and ligand metal 
charge transfer bands (LMCT) bands, respectively. A low energy broad band at 604 nm 
was attributed to ligand field B^ig—•^ B2g transition, suggesting the octahedral geometry 
around Cu" metal ion [179]. On the other hand, complex [Ci6H38N809Sn2Mn2Cl8] 
exhibited a high energy charge transfer bands (IL) at 214 nm and 278 nm and band 
observed at 406 nm which was assigned to metal to charge transfer (MLCT) transitions, 
respectively [180]. 
DNA binding studies 
The interaction of [Ci6H3oN805Sn2Cl4], [Ci6H38N809Sn2Cu2Cl8] and 
[Ci6H38N809Sn2Mn2Cl8] with CT DNA was monitored by UV/vis spectroscopy. Figure 
44(a-c) displays the spectra in absence and presence of CT DNA, keeping the 
concentration of complexes (6.67x10'^ M) fixed. On increasing the concentration of CT 
DNA (6.67-33.0 x 10 M), there is an increase in the absorption intensity of 
[Ci6H3oN805Sn2Cl4], [Ci6H38N809Sn2Cu2Cl8] and [Ci6H38N809Sn2Mn2Cl8] indicative of 
hyperchromism. The percent hyperchromism observed for [C(6H3oN805Sn2Cl4], 
[Ci6H38N809Sn2Cu2Cl8] and [Ci6H38N809Sn2Mn2Cl8] were 25%, 30% and 23%, 
respectively. "Hyperchromic effect" suggests that there is structural damage to DNA 
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helix as a consequence of strong binding of complexes to CT DNA [156]. Furthermore, 
the mode of binding is either electrostatic or covaient while intercalation was ruled out 
completely which is a characteristic feature of "Hyporchromic effect". Since complex 
[Ci6H3oN805Sn2Cl4] has two Sn metal atoms (homodinuclear metal center), it should 
display different binding mode (electrostatic) showing preferential selectivity to 
phosphate backbone of DNA helix [181]. The complex [Ci6H38N809Sn2Cu2Cl8] and 
[Ci6H38N809Sn2Mn2Cl8] contain heterodinuclear Sn2Cu2 & Sn2Mn2 metal cores (one 
transition and non -transition metal ions); Cu^ "^  prefers to bind via covaient linkage to N7 
of DNA [182] and Sn, a hard lewis acid binds to the negatively charged -P=0 backbone 
of DNA double helix. Our results suggest that complex [Ci6H38N809Sn2Cu2Cl8] binds to 
DNA more strongly in contrast to [Ci6H3oN805Sn2Cl4] and [Ci6H38N809Sn2Mn2Cl8]. The 
complexes [Ci6H3oN805Sn2Cl4] and [Ci6H38N809Sn2Mn2Cl8] shows same affinity. This 
has been quantified by intrinsic binding constants Kb of complex [Ci6H3oN805Sn2Cl4], 
[Ci6H38N809Sn2Cu2Cl8] and [Ci6H38N809Sn2Mn2Cl8] using equation 1 by monitoring 
changes in absorbance in IL bands at 259nm with increasing concentration of CT DNA. 
The Kb values obtained for [Ci6H3oN805Sn2Cl4], [Ci6H38N809Sn2Cu2Cl8] and 
[Ci6H38N809Sn2Mn2Cl8] were 4.0 x lO" M"', 6x10'* M"' and 4.1 x lO'' M"', respectively. 
As expected, the Kb value for [Ci6H38N809Sn2Cu2Cl8] was highest while Kb value for 
[Ci6H38N809Sn2Mn2Cl8] was of same magnitude as in case complex [Ci6H3oN805Sn2Cl4]. 
This is an exceptional feature of bimetallic complexes where insertion of second metal 
ion enhances the binding affinity to DNA bases. It is well-established that Cu^ "^  prefers 
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covalent coordination linkage to N7 of guanine nucleobase of DNA, while Mn^ "^  shows 
preference for 02, in a similar manner to Sn metal ions [182], which displays strong 
preferential binding to phosphate of DNA helix. Therefore [Ci6H3oN805Sn2Cl4] and 
[Ci6H38N809Sn2Mn2Cl8] behave in the same manner showing affinity towards either 
oxygen of phosphate or oxygen of cytosine in the GC base pair combination of DNA. 
K , - 4 i i l O ' M ' 
Wavelength (nm) 
Figure 44a. Absorption spectral traces of [CieHsoNsOiSniCU] in Tris HCl buffer upon 
addition ofCTDNA. Inset; Plots of [DNA] / Sa - sjversus [DNA] for the titration ofCT 
DNA with complexe (m), experimental data points; full lines, linear fitting data. 
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NVavelength ( n m ) 
Figure 44b. Absorption spectral traces of [Ci6H38N809Sn2Cu2Cls] in Tris HCl buffer 
upon addition of CT DNA. Inset; Plots offDNAJ / Sa- s/ versus [DNAJfor the titration 
ofCTDNA with complexes (A), experimental data points; full lines, linear fitting data. 
W'ave leneth (i:im) 
Figure 44c. Absorption spectral traces of [Ci6H3sN80gSn2Mn2Cl8] in Tris HCl buffer 
upon addition of CT DNA. Inset; Plots of [DNA] / Sa- sj versus [DNA] for the titration 
ofCTDNA with complexes (*), experimental data points; full lines, linear fitting data. 
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Effect of direct potential on metal complex - CT DNA interactions 
The model studies based on electroporation were performed, which creates a direct 
passage through the membrane barrier of drugs in particular to gain easier access to 
cytosol [183]. Electroporation is rapidly developing field and several studies on the 
clinical use of electroporation for drug delivery to tumors are showing encouraging 
results. It has been established that electrochemotherapy is an efficient, safe and 
inexpensive option of treatment that can be offered to cancer patients with variety of 
tumours [184]. In this study, effect of direct potential on interaction of CT DNA with 
complexes [Ci6H3oN805Sn2Cl4], [Ci6H38N809Sn2Cu2Cl8] and [Ci6H38N809Sn2Mn2Cl8] 
were observed. The platinum wire at a distance of 1 cm was used to apply the potential 
(0-2.5 V) across the aqueous solution in of [Ci6H3oN805Sn2Cl4], [Ci6H38N809Sn2Cu2Cl8] 
and [Ci6H38N809Sn2Mn2Cl8] in 3 ml cuvette keeping the total volume fixed. The 
absorbance was monitored at different potentials by titrating [Ci6H3oN805Sn2Cl4], 
[Ci6H38N809Sn2Cu2Cl8] and [Ci6H38N809Sn2Mn2Cl8] at 259 nm with varying 
concentration of CT DNA. Complex [Ci6H3oN805Sn2Cl4] displays maximum 
hyperchromism, when a potential of 1.5 V was applied across solution as displayed in 
Figure 45a. The intrinsic binding constant Kb value was determined in presence of the 
applied potential and it was observed to be seven times of higher magnitude than the Kb 
value observed in absence of the applied potential. 
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Figure 45a. Effect of direct potential on absorbance o/[Ci6H3oN805Sn2Cl4] in Tris HCl 
buffer upon addition ofCTDNA. 
Complexes [Ci6H38N809Sn2Cu2Cl8] and [Ci6H38N809Sn2Mn2Cl8] also exhibit 
enhancement in hyperchromism at 259 nm while the applied voltage is 1.0 V, exhibited 
in Figure 45 (b,c). 
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Figure 45b. Effect of direct potential on absorbance of [Ci6H38N80^n2Cu2Cl8] in Tris 
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Figure 45c. Effect of direct potential on Absorption of [Ci6H3sN809Sn2Mn2Cls] in Tris 
HCl buffer upon addition ofCTDNA. 
The magnitude of Kb value has increased of the order of five and three times, in contrast 
to their Kb values, (Figure 45d) which were determined in absence of the potential. 
These experiments reveal that electric potential could induce effective DNA damage by 
increasing the permeability into the cells which may augment the number of DNA breaks 
[185-186]. The cells or tissues which are exposed to direct current for a brief period of 
time induce transmembrane changes that are due to dielectric breakdown of membrane of 
once a certain threshold is surpassed and thereby therapeutic effects of drugs are 
enhanced. As a consequence, lower dosage of drugs can be administered, therefore 
limiting the toxicity of drug [187]. 
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Figure 45d. Comparative intrinsic binding constant Kb values of fC]6HsoN805Sn2Cl4j, 
fCi6H3sNsO()Sn2Cu2Cl8j and [Ci6HssN80gSn2Mn2Cl8] in absence and presence of direct 
potential. 
Molecular Modeling 
Molecular modeling method is an attractive scaffold to explore the interactive relation 
between complex geometries and the binding site available at the molecular target DNA 
[188]. Different structural properties lead to different binding modes; infact, one of the 
most important factors governing the binding mode is the molecular shape. Literature 
reveals that van der Waals interaction play a major role in selecting intercalation site 
while DNA binding controlled by electrostatic attraction, is governed mainly by 
dispersive forces [189]. In this study, experimental results reveal electrostatic binding of 
complexes [Ci6H3oN805Sn2Cl4], [Ci6H3gN809Sn2Mn2Cl8] and covalent binding of 
[Ci6H38N809Sn2Cu2Cl8] to CT DNA. The computational molecular modeling studies 
were carried out by using ChemDraw Ultra 8.0. It was estimated that the distance 
between tin atoms in complex [Ci6H3oNg05Sn2Cl4], was ca 7A° similar to the distance 
82 
between the adjacent phosphoroiis atoms of phosphodiester backbone (6A°) [190] as 
exhibited in Figure 46a. This suggests that the tin site in complex [Ci6H3oN80sSn2Cl4], 
cooperatively interact with the two phosphodiester backbone groups in DNA strand as 
proposed in Figure 46b. This was in accordance to some earlier reports on electrostatic 
interaction of tin complexes to DNA helix where the most likely site of metalation has 
been found to be vicinal phosphodiester groups [181]. Complex [Ci6H38N809Sn2Cu2Cl8] 
has structural similarity to tCi6H3oN805Sn2Cl4] except that second metal ion Cu^ * has 
been incorporated in the ligand framework which contributes significantly to the selective 
recognition of base pairs viz. N7 of the guanine in addition to the electrostatic attractive 
forces between Sn'^ and phosphate group of DNA helix (Figure 46c). On the contrary, 
complex [Ci6H38N809Sn2Mn2Cl8] displays same effect as [Ci6H3oN805Sn2Cl4] because 
Mn^ "^  (Figure 46d), prefer to bind with almost same affinity as Sn'^ metal ion to the 
oxygen of phosphate backbone of DNA helix, further authenticating the plausible 
explanation suggested in the UV/vis and electrochemotherapy studies. 
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Figure 46a. Schematic drawings, of DNA fragment with A-G-C-T bases and their 
respective three dimensional molecular models of DNA fragment with A-G-C-T base 
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Figure 46b. Schematic drawings, showing interaction of fCi6H3oNsOsSn2Cl4j with DNA 
fragment with A-G-C-T bases and respective three dimensional molecular model showing 
[C/6H3oNsOsSn2Cl4j electrostatically bound to DNA. 
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Figure 46c. Schematic drawings, showing interaction of [Ci6H3sN80gSn2Cu2Cl8] with 
DNA fragment with A-G-C-T bases and respective three dimensional molecular model 
showing fCi6H3sN80gSn2Cu2ClsJ covalently bound to DNA. 
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Figure 46d. Schematic drawings, showing interaction of [Ci6H3sN80gSn2Mnfils] with 
DNA fragment with A-G-C-T bases and respective three dimensional molecular model 
[Ci6HssNs09Sn2Mn^ls] electrstatically bound to DNA. 
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Electrochemical study 
The electrochemical responses recorded in Immol solution of [Ci6H38N809Sn2Cu2Cl8] 
and [Ci6H38N809Sn2Mn2Cl8] in 0.4 M KNO3 exhibits reduction peaks at -0.598V and 
-0.429V, respectively. In a subsequent anodic scan, the anodic peaks appear at -0.179V 
and -0.249V. The voltammetric responses remain unchanged at different scan rates, 
which features that initial complexes are regenerated during the potential cycle. These 
results were attributed to one electron transfer, corresponding to quasireversible Cu'VCu' 
and Mn"/Mn' redox couples of [Ci6H38N809Sn2Cu2Cl8] and [Ci6H38N809Sn2Mn2Cl8] 
The anodic to cathodic current ratios for these couples were consistently less than unity in 
cyclic voltammograms at a restricted potential range (-1.2 - 3.0, 2.4V). This 
electrochemical information can be correlated with previously reported data [191-193]. 
The difference between voltammeteric responses of [Ci6H38N809Sn2Cu2Cl8] and 
[Ci6H38N809Sn2Mn2Cl8] in the absence and presence of CT DNA are depicted in Figure 
47-48. The significant shift in peak potentials and current ratios of 
[Ci6H38N809Sn2Cu2Cl8l and [Ci6H38N809Sn2Mn2Cl8] was observed upon addition of CT 
DNA. The summary of voltammetric results for [Ci6H38N809Sn2Cu2Cl8] and 
[Ci6H38N809Sn2Mn2Cl8] in absence and presence of CT DNA has been given in Table 9. 
The shift in respective electrochemical parameters occurs due to slow diffusion of 
equilibrium mixture of the fi'ee and DNA bound complexes to electrode surface [116]. 
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-/ Figure 47. Cyclic voltammogram at a scan rate 0.3 Vs'' in H2O (a) 
[Ci6H38N809Sn2Cu2Cl8] in absence ofCT DNA (b) [Ci6H38N80gSn2Cu2Cl8] in presence 
ofCTDNA. 
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Figure 48. Cyclic voltammogram at a scan rate 0.3 Vs'' in H2O (a) 
[Ci6H38N809Sn2Mn2Cl8j in absence ofCTDNA (b) [C,6H38N80gSn2Mn2Cl8] in presence 
ofCTDNA. 
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Fluorescence studies 
The complexes [CieHsoNgOsSnzCU], [Ci6H38N809Sn2Cu2Cl8] and 
[Ci6H38N809Sn2Mn2Cl8] do not display any luminescence either in H2O or in presence of 
CT DN A, therefore competitive binding studies weie canied out vising ethidium biomide 
(EthBr) as fluorescent probe which is most sensitive fluorescence probe that can bind 
DNA [194]. Fixed amount of DNA (0.2 x 10"^  M) was titrated with increasing amount of 
metal complexes [Ci6H3oN805Sn2Cl4], [Ci6H38N809Sn2Cu2Cl8] and 
[Ci6H38N809Sn2Mn2Cl8] (0.2-1.0 x 10"^ M) Figure 49(a-c). Titration of CT DNA lead an 
appreciable reduction in emission intensity upon addition of [Ci6H3oN805Sn2Cl4], 
[Ci6H38N809Sn2Cu2Cl8] and [Ci6H38N809Sn2Mn2Cl8] to CT DNA pretreated with EthBr 
fluorophore resulting in decrease in binding of EthBr to CT DNA. The enhanced 
fluorescence intensity of EthBr-DNA tends to decrease after interacting with metal 
complexes [195]. 
The quenching efficiency calculated by Stem-Volmer quenching constant K obtained 
from equation 2 and was found to 0.06,0.12 and 0.07, respectively. The larger K value of 
the complex [Ci6H38Ng09Sn2Cu2Clg] in comparison to [Ci6H3oN805Sn2Cl4] and 
[Ci6H38N809Sn2Cu2Cl8] reveals that [Ci6H38N809Sn2Cu2Cl8] binds more strongly to CT 
DNA. This indicates that complexes bound to helix exterior or free in solution are more 
accessible to quencher while those to interior of helix are less accessible [48,196]. These 
results are also consistent with absorption spectral studies. 
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Figure 49a. Emission spectra of [Ci6H3oNs03Sn2Cl4] in the presence ofCTDNA in Tris-
HCl buffer. Inset: Plots of !„/1 versus [M]/[DNAJ, [M]= [Ci6H3oN803Sn2Cl4]. 
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Figure 49b. Emission spectra of [Ci6H38Ns09Sn2Cu2Cl^ in the presence ofCTDNA in 
Tris-HCl buffer. Inset: Plots of lo/1 versus fM]/[DNA], [M]= [C,6H38N80gSn2Cu2Cl8]. 
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Figure 49c. Emission spectra of [Ci6H38N809Sn2Mn2Cl8] in the presence ofCTDNA in 
Tris-HCl buffer. Inset: Plots of !„/1 versus [MJ/fDNA], [M]= [C,6H38N809Sn2Mn2Cl8]. 
DNA cleaving studies 
The effect on integrity and electrophoretic mobility of supercoiled (SC) pBR322 DNA by 
complexes [Ci6H3oN805Sn2Cl4], [Ci6H3«N809Sn2Cu2Cl8] and [Ci6H38N809Sn2Mn2Cl8] 
were investigated by using gel electrophoresis. The consequence of the (SC) pBR322 
DNA cleavage in absence of any reductant leads to the relaxation of supercoiled circular 
form into nicked circular (Form II) and linear (Form III) [197]. To determine the DNA 
cleavage ability of complexes [Ci6H3oN805Sn2Cl4], [Ci6H38N809Sn2Cu2Cl8] and 
[Ci6H38Ng09Sn2Mn2Cl8], (SC) pBR322DNA (300ng) was incubated with increasing 
concentration of [Ci6H3oN805Sn2Cl4], [Ci6H38N809Sn2Cu2Cl8] and 
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[Ci6H38N809Sn2Mn2Cl8] in Tris-HCl buffer at pH 7.2 (Figure 50a-c) for 1 hour without 
addition of a reductant. The reaction mixture was subjected to gel electrophoresis and 
DNA cleavage was observed. The complex [Ci6H3oN805Sn2Cl4] shows discernible DNA 
cleavage with increase in concentration, more intensified nicked (Form 11) and linear 
(Form III) was observed. The mobility of each form decreased with increase in the 
concentration of [Ci6H3oN805Sn2Cl4]. A significant conversion of SC coiled pBR322 
DNA to Form II and Form III was observed with increase in concentration of 
[Ci6H38N809Sn2Cu2Cl8]. Further, at higher concentration, electrophoretic results of 
[Ci6H38N809Sn2Cu2Cl8] revealed the adduct formation due to high amount of bound 
DNA, which retards the mobility of pBR322 DNA. Similarly, complex 
[Ci6H38N809Sn2Mn2Cl8] showed different forms of pBR322DNA with different 
intensities. On increasing the concentration of [Ci6H38N809Sn2Mn2Cl8], more intensified 
Form III was observed, while as Form II starts disappearing. Therefore electrophoretic 
experiments reveal that complex [Ci6H38Ng09Sn2Cu2Cl8] shows higher binding and 
cleaving ability of pBR322 DNA in comparison to [Ci6H3oNg05Sn2Cl4] and 
[Ci6H38N809Sn2Mn2Cl8]. 
Fontill 
Form III 
Form I 
Figure 50a. Cleavage of supercoiled plasmid pBR322 DNA (300ng) by 
[Ci6H3oN805Sn2Cl4j; lane 1: DNA; lane 2: JOfxM [Ci6H3oNs05Sn2Cl4j+ DNA; lane 3: 
20fiM [C,6H3oN805Sn2Cl4] + DNA; lane 4: 30fxM [CieHioNgOiSnTCU] + DNA; lane 5: 
40fiM [CieHioNgOsSnzCUl + DNA; lane 6: SOfxM [CicHioNaOiSniCU] + DNA; lane 7: 
dOMMfCieHsoNsOsSniCl^J + DNA; lane 8: lOfiM [C,6H3oN805Sn2Cl4] + DNA. 
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Figure 50b. Cleavage of supercoiled plasmid pBR222 DNA (SOOng) by 
[Ci6Hs8N809Sn2Cu2Cl8] lane 1: DNA, lane 2: lOfiM [Ci6H38N809Sn2Cu2Cl8] + DNA; 
lane 3: 20fiM [C,6H38N809Sn2Cu2Cl8j + DNA; lane 4: SOfxM [C,6Hi8N809Sn2Cu2Cl8] + 
DNA; lane 5: 40fiM [C,6H38N80gSn2Cu2Cl8] + DNA; lane 6: SOfxM 
[Ci6H38N809Sn2Cu2Cl8j+ DNA; lane 7: 60nM[C,6H38N809Sn2Cu2Cl8] + DNA. 
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Figure 50c. Cleavage of supercoiled pBR322 DNA (SOOng) by fCi6H38N809Sn2Mn2Cl8j 
lane 1: DNA; lane 2: lOfiM [C,6H38N80^n2Mn2Cl8] + DNA; lane 3: 20fxM 
[C}6H38Na09Sn2Mn2Cl8] + DNA; lane 4: SOfiM [Ci6H38N809Sn2Mn2Cl8j + DNA; lane 5: 
40MM [C,6H38N809Sn2Mn2Cl8] + DNA; lane 6: 50fxM [Ci6H38N809Sn2Mn2Cl8]+DNA; 
lane 7: dO/uM [C,6H38N809Sn2Mn2Cl8j + DNA; lane 8: 70f^M [C,6H38N80gSn2Mn2Cl8] + 
DNA. 
Viscosity Measurements 
The viscosity measurements are useful technique for exploring the binding mode of 
complexes with CT DNA. This method is considered as least ambiguous and most critical 
test of binding in solution in absence of crystallographic data [198]. A classical 
intercalator causes a significant increase in the viscosity of DNA solution due to increase 
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in separation in overall DNA contour length [134]. A partial / or non-classical 
intercalation of metal complexes would reduce the DNA viscosity [199]. The effect of 
complexes [CjeHsoNgOsSniCU], [Ci6H38N809Sn2Cu2Cl8] and [Ci6H38N809Sn2Mn2Cl8] on 
the viscosity of CT DNA is shown in Figure 51. The plots show relative viscosity 
decreases with increase in concentration of complexes, the decrease in relative viscosity 
of DNA may be explained by a binding mode which produced bends or kinks in the DNA 
and thus reduced its effective length and concomitantly its viscosity, therefore binding 
reduces the number of independently moving DNA molecules in solution and hence lead 
to decrease in viscosity [114]. 
1.01 
0.02 0.04 0.06 0.08 
1/R 
Figure 51. Effect of increasing amount of [Ci6H3oN^5Sn2Cl4](m), 
[Ci6H3sN809Sn2Cu2Cl8j(») and [C,6H38N809Sn2Mn2Cls](A) on relative viscosity ofCT-
DNAat29±0.rC[DNA]= IxlCT^M, 1/R = [complex] / [DNA]. 
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CHAPTER V 
Metal based next generation cancer drug formulation, 
synthesis, characterization and their in vitro DNA 
interaction studies. 
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CHAPTER V 
Experimental 
D-glucose, Tris base (Merck), CUCI2.2H2O (Qualigens), NiCli.eHiO, C0CI2.6H2O, 
FeCla, pyrazole, imidazole, (Fluka), 6X loading dye (Fermental Life Science) and super 
coiled pBR322 plasmid DNA (Genei) were utilized as received. Disodium salt calf 
thymus DNA (CT DNA), Human serum albumin (HSA) and L-tryptophan were 
purchased from Sigma Chemical Company and stored at 4 "C. All reagent grade 
compounds were used without fiirther purification. Interspec 2020 FTIR spectrometer 
was used for recording IR spectra of KBr pellets in the range of 400- 4000 cm''. 
Electronic spectra were recorded on UV-1700 PharmaSpec Uv- vis spectrophotometer 
(Shimadzu). Data were reported in A,max/nm. Emission spectra were determined with a 
Hitachi F-2500 fluorescence spectrophotometer. Microanalyses of the complexes were 
obtained on a Carlo Erba Analyzer Model 1108. 'H, '^C and 2D NMR spectra were 
recorded on a Bruker DRX-300 spectrometer. Chemical shifts were reported in 5 scale 
(ppm). EPR spectrum of copper (II) complex was recorded on Varian E 112 spectrometer 
at the X-band frequency (9.1GHz) at liquid nitrogen temperature (LNT) using 
tetracyanoethylene (TCNE) as field marker. Cyclic voltammetry was carried out at CH 
instrument electrochemical analyzer. All voltammetric experiments were performed in 
single compartmental cell of volume 10-15 ml containing a three-electrode system 
comprised of a Pt-disk working electrode, Pt-wire as auxiliary electrode and an Ag/AgCl 
electrode as reference electrode. The supporting electrolyte was 0.4 M KNO3 in milli-Q 
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water. Deaerated solutions were used by purging N2 gas for 15 minutes prior to 
measurements. Molar conductance was measured at room temperature on Digisun 
electronic conductivity bridge. Interaction of complexes with CT DNA was performed in 
0.01 M buffer (pH 7.2). The cleavage of supercoiled pBR322 DNA in absence of 
activating agents was observed using gel electrophoresis. In reactions using supercoiled 
pBR322 plasmid DNA 300 ng in Tris-HCl buffer at pH 7.4 was treated with complex [D-
GlcCu(Pz)2] (0.05-0.2 mmol). The samples were incubated for 2 hours at 37° C. A 
loading buffer containing 25% bromophenol blue, 0.25% xylene cyanol, 30% glycerol 
was added and electrophoresis was carried out at 60 V for 2 hours in Tris-HCl buffer 
using 1% agarose gel containing 1.0 ^g/ml ethidium bromide. To identify the reactive 
oxygen species involved in cleavage reactions, the radical scavenger like 5 % DMSO was 
introduced. 
The DNA cleavage with added reductant was monitored as in case of cleavage 
experiment without added reductant using agrose gel electrophoresis. Reactions using 
supercoiled pBR322 plasmid DNA in Tris-HCl buffer at pH 7.4 was treated with 
complex [D-GlcCu(Pz)2] (0.025 - 0.1 mmol) and ascorbic acid (0.01 mmol), which was 
diluted to a total volume of 0.05 mmol. The samples were incubated for 1 hour at 37°C. 
Similarly in photocleavage studies, reaction mixture was carried out under illuminated 
conditions at 365 nm (12W) monochromatic light source. TTie samples were incubated 
for 1 hour at 37°C and analyzed for photocleaved products using gel electrophoresis as 
discussed above. Reaction using supercoiled pBR322 plasmid DNA in Tris-HCl was 
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treated with complex [D-GlcCu(Pz)2] (0.05 - 0.2 mmol). All the gels were viewed by 
UVP gel doc system and photographed. 
Synthesis of D - Glucose - bis pyrazolyl copper (II) [D-GlcCu(Pz)2] 
[C12H24N4O9CU] 
To a solution of D-glucose (1.80 g, 10 mmol) in 10 ml H2O was added CUCI2.2H2O (1.71 
g, 10 mmol) in 10 ml methanol, a green colored solution obtained was stirred for 2 hours 
at room temperature. A solution of pyrazole (1.36 g, 20 mmol) in 10 ml methanol was 
added slowly to the reaction mixture, a fluorescent green colored precipitate formed was 
filtered and washed thoroughly with methanol and dried in vacuo. 
Synthesis of D - Glucose - bis pyrazolyl nickel (II) [D-GIcNi(Pz)2] 
lCi2H32N40,3Ni] 
The complex [D-GlcNi(Pz)2] was synthesized with NiCl2.6H20 (2.37 g, 10 mmol) by a 
similar method as described for [D-GlcCu(Pz)2]. The blue green colored product obtained 
was filtered, washed with methanol and dried in vacuo. 
Synthesis of D - Glucose - bis pyrazolyl cobalt (II) [D-GIcCo(Pz)2] 
lC,2H26N40ioCo] 
The complex [D-GlcCo(Pz)2] was synthesized with C0CI2.6H2O (2.37 g, 10 mmol) by a 
similar method as described for [D-GlcCu(Pz)2]. The pink colored precipitate obtained 
was filtered, washed with methanol and dried in vacuo. 
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Synthesis of D - Glucose - bis pyrazolyl ferric (III) chloride [D-GlcFe(Pz)2]Cl 
lCi2H2oN407FelCI 
To a solution of D-glucose (1.80 g, 10 mmol) in 10 ml H2O was added FeCb (1.62 g, 10 
mmol) in methanol. To this in situ generated complex, a solution of pyrazole (1.36 g, 20 
mmol) in 10 ml methanol was added slowly. A brown solution formed was further stirred 
for 6 hoiirs and a 20 ml toluene was added to remove water by azeotropic distillation. The 
reaction mixture was kept at room temperature to obtain a brown colored solid, washed 
with methanol and dried in vacuo. 
Synthesis of D - Glucose - bis imidazolyl copper (II) [D-GlcCu(Im)2l 
[C,3H22N407CU] 
The complex [D-GlcCu(Im)2] was synthesized with imidazole (1.36 g, 20 mmol) by a 
similar method as described for [D-GlcCu(Pz)2]. A green colored product obtained was 
filtered, washed with methanol and dried in vacuo. 
Synthesis of D - Glucose - bis imidazolyl nickel (II) [D-GIcNi(Im)2] 
(C,2H32N40,3Ni] 
The complex [D-GlcNi(Im)2] was synthesized with nickel chloride NiCl2.6H20 (2.37 g, 
10 mmol) and imidazole (1.36 g, 20 mmol) by a sunilar procedure as described for 
[D-GlcFe(Pz)2]. 
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Synthesis of D - Glucose - bis imidazolyl ferric (III) chloride [D-GlcFe(Im)2]Cl 
IC12H20N4O7 FeCl] 
The complex [D-GlcFe(Im)2]Cl was synthesized with FeCb (1.62 g, 10 mmol) by a 
similar procedure as described for [D-GlcNi(Im)2]. The brown colored solid was washed 
with methanol and dried with in vacuo. 
OHjO/MeOH 
2) stirr 
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M = Cu,Ni,Co,re,X=Cl 
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N-N Y 
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Scheme 5a. Propsed structure of complexes [D-GlcCu(Pz)2], [D-GlcNi(Pz)2], [D-
GlcCo(Pz)2]. [D-GlcFe(Pz)2]a. [D-GlcCu(Im)2]. [D-GlcNi(Im)2] and 
[D-GlcFe(Im)2]Cl 
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[D-GlcCu(Pz)2] [D-GlcNi(Pz)2] [D-GlcCo(Pz)2] 
[D-GlcFe(Pz)2]Cl [D-GlcCu(Im)2] [D-GlcNi(Im)2] 
[D-GlcFe(Im)2]Cl 
Scheme 5b Cylindrical bonded three dimensional model of complexes [D-GlcCu(Pz)2], 
[D-GlcNi(Pz)2], [D-GlcCo(Pz)2], [D-GlcFe(Pz)2]Cl, [D-GlcCu(lm)2], [D-GlcNi(Im)2] 
and [D-GlcFe(Im)2]Cl Color scheme Cu" dark gray, Ni" dark gray, Co" blue, Fe" 
Brown, N dark blue, O red, C gray. 
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Results and discussion 
Glycosylated metal complexes [D-GlcCu(Pz)2], [D-GlcNi(Pz)2], [D-GlcCo(Pz)2], [D-
GlcFe(Pz)2]Cl, [D-GlcCu(Im)2], [D-GlcNiam)2] and [D-GlcFe(Im)2]Cl were synthesized 
by the reaction of in situ generated metal complexes of D-glucose, and pyrazole/ 
imidazole. The complexes [D-GlcCu(Pz)2], [D-GlcNi(Pz)2], [D-GlcCo(Pz)2], [D-
GlcFe(Pz)2]Cl, [D-GlcCu(hn)2], [D-GlcNi(Im)2] and [D-GlcFe(Im)2]Cl were 
characterized by various analytical and spectroscopic methods. The coordination 
geometry around metal ion in [D-GlcCu(Pz)2], [D-GlcNi(Pz)2], [D-GlcCo(Pz)2], [D-
GlcFe(Pz)2]Cl, [D-GlcCu(hn)2], [D-GlcNi(Im)2] and [D-GlcFe(Im)2]Cl is square 
pyramidal. Spectroscopic studies and analytical data supported proposed structure 
(scheme 5a) and three dimensional models with cylindrical bonds are depicted in scheme 
5b. All the complexes are soluble in H2O, DMSO and DMF. The molar conductance 
measurements in H2O shows that [D-GlcCu(Pz)2], [D-GlcNi(Pz)2], [D-GlcCo(Pz)2], [D-
GIcCu(Im)2] and [D-GlcNi(Im)2] were non-ionic while [D-GlcFe(Pz)2]Cl, 
[D-GlcFe(Im)2]Cl were ionic in nature. The binding studies with CT DNA were 
performed by using various techniques. The important properties and physical data of the 
complexes are given in Table 10. 
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IR Spectra 
The IR spectra of complexes [D-GlcCu(Pz)2], [D-GlcNi(Pz)2], [D-GlcCo(Pz)2], [D-
GlcFe(Pz)2]a, [D-GlcCu(Im)2], [D-GlcNi(Im)2] and [D-GIcFe(Im)2]Cl exhibited 
characteristic broad bands of metal bound saccharide moieties in comparision to 
corresponding simple metal ion adducts, which generally display sharp signals [200] 
(Table 11). The broad and intense band observed in the range 3300-3416 cm'' were 
assigned to v(O-H) and indicate the breakage of hydrogen bonding [200]. The secondary 
interaction of free hydroxyl groups with metal ions in these complexes was indicated by 
the shape position and width of the bands. The v(O-H) of H2O also appear in this region 
but was overlapped with the v(O-H) bands [201]. The IR spectra of [D-GlcCu(Pz)2], [D-
GlcNi(Pz)2], [D-GlcCo(Pz)2], [D-GlcFe(Pz)2]Cl, [D-GlcCu(Im)2], [D-GlcNi(Im)2] and 
[D-GlcFe(Im)2]Cl are shown-in Figure 52. The bands observed at 2851-2991cm'' were 
assigned to v(C-H) stretching vibrations [202]. The characteristic bands observed at 1618-
1653, 1318-1437 and 1000-1100 cm"' were attributed to 6(H0H), v(C-C), v(C-O) and 
v(C-H), respectively [203]. Additionally, bands at ca. 1512-1538 cm"' observed in the IR 
spectra of [D-GlcCu(Pz)2], [D-GlcNi(Pz)2], [D-GlcCo(Pz)2], [D-GlcFe(Pz)2]Cl, [D-
GlcCu(Im)2], [D-GlcNi(Im)2] and [D-GlcFe(Im)2]Cl which were attributed to v(C=N-
C=C) stretching vibration of pyrazole and imidazole [204-207]. The far IR spectra of 
these complexes exhibit absorption bands at ca. 626-553 and 493-417cm'' due to v(M-0) 
and v(M-N) vibrations, respectively (M = Cu, Ni, Co, Fe) which revealed the binding of 
saccharide and secondary ligand to the metal ion. 
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Figure 52. IR spectra of complexes (i)[D-GlcCu(Pz)2], (ii)[D-GlcNi(Pz)zJ, (m)[D-
GlcCo(Pz)J, (W)[D-GlcFe(Pz)2]Cl, (v)[D-GlcCu(Im)2]. (vi)[D-GlcNi(Im)2j and (vii)[D-
GlcFe(Im)2]Cl 
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EPR spectra 
The X-band EPR spectra of [D-GlcCu(Pz)2] and [D-GIcCu(Im)2] were recorded at liquid 
nitrogen temperature (LNT) in solid state using tetracyanoethylene (g = 2.00277) as field 
marker. The EPR spectra of [D-GlcCu(Pz)2] and [D-GlcCu(Im)2] exhibited broad signal 
having 'g' isotropic values 2.09 and 2.09, 2.22, respectively, which are characteristic for 
square pyramidal environment. Similar spectra having 'g' isotropic values were reported 
earlier [208-209] for metal saccharide complexes of different metal ions. Such isotropic 
lines usually result due to intermolecular spin exchange, which broadens the spectral 
lines. This intermolecular spin exchange is caused by the strong spin coupling, which 
occurs during collision of paramagnetic centers. 
NMR Spectra 
'H and '^ C NMR spectra of complexes [D-GlcNi(Pz)2] and [D-GlcNi(Im)2] were 
recorded in D2O. Resonances arising from different saccharide protons generally overlap 
resulting in broadening of signals, and thereby individual resonances are difficult to 
identify. However, complexes [D-GlcNi(Pz)2] and [D-GlcNi(Im)2] revealed broad 
envelope with fine structure at 8 3.1 - 4.8 ppm attributed to strongly coupled skeletal 
proton signals of saccharides [210]. The signals at ~ 6.1-7,6 ppm in both [D-GlcNi(Pz)2] 
and [D-GlcNi(Im)2] were attributed to the aromatic protons of pyrazole and imidizole 
rings, respectively [204]. However resonances due NH of heterocyclic moiety was not 
observed in both the complexes indicating the formation of complex occurs through 
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dissociation of NH protons (Tablel2). Based on the coordination induced shifts A6 (CIS 
= Scompiex- Siigand) [D-GlcNi(Pz)2] and [D-GlcNi(Im)2] exhibited maximum shifts with C-3 
and C-4 carbon atoms A6 = 1.7 and 1.2 respectively, indicating the favorable interaction 
of C-3 and C-4 hydroxyls with the metal ions though, other carbon signals shifted to 
different extents due to the influence of metal ion binding [211]. The A5 values indicate 
that the metal ions bound to saccharide OH of C-3 and C-4 atoms, in comparison to 
saccharide O", which gave higher A6 values [201]. The complexes [D-GlcNi(Pz)2] and 
[D-GlcNi(Im)2] also revealed '^ C resonances at 95.79 and 126 ppm, respectively which 
were assigned to carbon skeltons of pyrazole and imidazole ligands [204] (Table 13). 
Electronic spectra 
The electronic spectra of freshly prepared aqueous solutions of [D-GlcCu(Pz)2], [D-
GlcNi(Pz)2], [D-GlcCo(Pz)2], [D-GlcFe(Pz)2]Cl, [D-GlcCu(Im)2], [D-GlcNi(Im)2] and 
[D-GlcFe(Im)2]Cl were carried out in the region 200-1 lOOnm. The UV/vis spectra of 
[D-GlcCu(Pz)2] and [D-GlcCu(Im)2], revealed prominent bands at 747 imi and 658 nm 
attributed to dxz, dyz-^  dx2.y2 ligand field transitions, respectively [212]. The strong bands 
in the UV region at 295, 246 and 220 nm were assigned to the ligand to metal charge 
transfer (LMCT) and intraligand (IL) charge transfer bands, respectively. These results 
are typical for square pyramidal geometry around Cu^ * metal ion [212-213]. The bands at 
747 and 658 nm thus confirmed the square pyramidal geometry of [D-GlcCu(Pz)2] and 
[D-GlcCu(Im)2] as deduced by EPR studies. 
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The electronic spectra of complexes [D-GlcNi(Pz)2] and [D-GlcNi(Im)2] displayed spin 
allowed transition at 644 and 638 nm assigned to ^Bi(F) - • ^A3E(P) transitions. These 
values were consistent with pentacoordinate geometry around Ni metal ion [154,214]. 
The spectra also exhibited LMCT transition at 385 and 300 nm in addition to XL band at 
220 run, respectively. 
The UV/vis spectrum of [D-GlcCo(Pz)2] exhibited a d-d band at 504 run and strong UV 
band at 220 run consistent with square pyramidal environment of Co^ ^ ion [215]. The 
complexes [D-GlcFe(Pz)2]Cl and [D-GlcFe(Im)2]Cl did not display any band in visible 
region, however, strong bands at 220 nm and a shoulder at 282 and 312 nm were 
attributed to intraligand and LMCT transitions, respectively. 
DNA binding studies 
The interaction of complexes [D-GlcCu(Pz)2], [D-GlcNi(Pz)2], [D-GlcCo(Pz)2], [D-
GlcFe(Pz)2]Cl, [D-GlcCu(Im)2], [D-GlcNi(Im)2] and [D-GIcFe(Im)2]Cl with CT DNA 
were carried out by titrating fixed amount of complexes (0.067 x 10"^ M) with increasing 
concentration of CT DNA (R = 0 - 4.97, R = [DNA]/[M], where M = [Metal complex]). 
The absorption spectra of complexes [D-GlcCu(Pz)2], P-GIcNi(Pz)2], P-GlcCo(Pz)2], 
[D-GlcFe(Pz)2]Cl, [D-GlcCu(Im)2], [D-GlcNi(Im)2] and [D-GlcFe(Im)2]Cl revealed 
hyperchromism at 260 nm with no blue or red shift, however slight red shift (1-2 nm) at 
210 nm was observed in the intraligand (IL) charge transfer bands. A similar 
hyperchromic effect has been observed for IL bands of trinuclear copper complexes on 
interaction with CT DNA [216]. The percent hyperchromism observed for [D-
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GlcCu(Pz)2], [D-GlcNi(Pz)2], [D-GlcCo(Pz)2], [D-GlcFe(Pz)2]Cl, [D-GlcCu(Im)2], [D-
GlcNi(Im)2] and [D-GlcFe(Im)2]Cl are given in table 14. Further the "hyperchromic 
effect" observed on the addition of CT DNA to complexes reflects the structural damage 
to the secondary structure of DNA duplex as a consequence of strong binding of the 
complexes [156]. This was attributed to the covalent binding of the complexes to the CT 
DNA via N7 of guanine nucleobase of DNA double helix. The presence of heterocyclic 
rings can facilitate partial intercalation by insertion of the complexes into the adjacent 
base pairs of DNA. The binding strength of [D-GlcCu(Pz)2], [D-GlcNi(Pz)2], [D-
GlcCo(Pz)2], [D-GlcFe(Pz)2]Cl, [D-GlcCu(hn)2], [D-GlcNi(Im)2] and [D-GlcFe(Im)2]Cl 
have been compared quantitavely by calculating Kb values using equation 1, monitoring 
the changes in IL bands with increasing concentration of CT DNA [Figure 53 (a-g)]. The 
Kb values of complexes are given in table 14. The Kb values of [D-GlcCu(Pz)2] and [D-
GlcCu(Im)2] show multifold increase in comparison to Kb values of [D-GlcNi(Pz)2], [D-
GlcCo(Pz)2], [D-GlcFe(Pz)2]Cl, [D-GlcNi(Im)2] and [D-GlcFe(Im)2]Cl complexes, which 
have been attributed to the strong affinity of copper complexes for sequence specific 
binding to N7 nucleobase of DNA [182]. Copper complexes are avid DNA binders in 
comparison to other transition metal complexes [216]. The Kb values of the complexes 
are smaller than classical intercalators ethidium bromide (where Kb values are in the order 
of 10^  M"') [157], therefore intercalating mode of binding of complexes to DNA was 
ruled out. 
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Figure 53a. Absorption spectral traces of [D-GlcCu(Pz)2] in Tris HCl buffer upon 
addition ofCTDNA. Inset; Plots of [DNA] / Ca - Sf versus [DNA] for the titration ofCT 
DNA with complexes, (m )experimental data points; full lines, linear fitting data. 
3.0 
2.0 
< 
1.0 . 
192.00 250.00 300.0 
Wavelength (lun) 
350.00 
Figure 53b. Absorption spectral traces of [D-GlcNi(Pz)2] in Tris HCl buffer upon 
addition ofCTDNA. Inset; Plots of [DNA] / Sa - S/versus [DNA] for the titration ofCT 
DNA with complexes, (^) experimental data points; full lines, linear fitting data. 
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Figure 53c. Absorption spectral traces of [D-GlcCo(Pz)2] in Tris HCl buffer upon 
addition ofCTDNA. Inset; Plots offDNAJ / Sa - Sf versus [DMA] for the titration ofCT 
DNA with complexes, (y) experimental data points; full lines, linear fitting data. 
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Figure 53d. Absorption spectral traces of [D-GlcFe(Pz)2]Cl in Tris HCl buffer upon 
addition ofCTDNA. Inset; Plots of [DNA] / Ba- Cf versus [DNA] for the titration ofCT 
DNA with complexes, (A) experimental data points; Jull lines, linear fitting data 
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Figure 53e. Absorption spectral traces of [D-GlcCu(Im)2] in Tris HCl buffer upon 
addition ofCTDNA. Inset; Plots offDNAJ/sa- Sf versus [DNAJfor the titration ofCT 
DNA with complexes, (*) experimental data points; full lines, linear fitting data. 
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Figure 53f. Absorption spectral traces of [D-GlcNi(Im)2j in Tris HCl buffer upon 
addition ofCTDNA. Inset; Plots of [DNAJ / Sa - ^versus [DNAJfor the titration ofCT 
DNA with complexes, (• )experimental data points; full lines, linear fitting data. 
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Figure 53g. Absorption spectral traces of [D-GlcFeflmJJCl in Tris HCl buffer upon 
addition ofCTDNA. Inset; Plots of[DNA] / Sa - e/versus [DNA] for the titration ofCT 
DNA with complexes, (') experimental data points; full lines, linear fitting data. 
Comparative binding studies 
In a drug delivery, cellular uptake processes, aquation and interaction of drugs with 
serum transport proteins and DNA, plays important role in its mode of action [217-218]. 
These processes have been monitored by different methods [219-222], which have 
emerged as an important tool in metallo-dnig discovery. We have utilized absorption 
spectral method to carry out an in vitro "binding model study" of [D-GlcCu(Pz)2]- a 
potential drug candidate with biomolecules (HSA, CT DNA and L-tryptophan). The 
absorption spectral titration, at a constant concentration of [D-GlcCu(Pz)2] (0.067 xlO" 
^M) was carried out with increasing concentration of biomolecules (CT DNA, HSA, L-
tryptophan) (R = 0 - 4.97, R = [Biomolecules]/ [D-GlcCu(Pz)2]) and their mixtures. The 
114 
spectral titration of [D-GlcCu(Pz)2] with HSA exhibited a hyperchromism at 201,277 nm 
with a red shift of 14 and 3 nm, respectively. On increasing the concentration of L-
tryptophan, the absorption spectrum of [D-GlcCu(Pz)2] displayed "hyperchromic effect" 
with no batho or hypsochromic shift. The intrinsic binding constant Kb calculated were 
3.16 X 10^  M"' and 4.33 x 10* M"' for HSA and L- tryptophan, respectively. 
The mixtures of HSA and CT DNA exhibited hyperchromism at 200 nm and 260-277nm 
with a bathochromic shift of 14 nm was observed at 260-277 nm. On mcreasing the 
equimolar ratio of HSA and CT DNA mixture, a sharp decrease in binding constant value 
(3.5 X 10'' M'') in comparison to that for CT DNA was observed. The absorption spectral 
titration of mixtures of L- tryptophan and CT DNA revealed hyperchromism at 218,260-
280 nm with no red shift. The Kb value (7.14 x 10^  M"') was almost half in magnitude in 
comparison to that for CT DNA. Similarly the absorption titration of mixtures of HSA, L-
tryptophan and CT DNA also featured hyperchromism at 200 and 260-280 nm with a red 
shift of 14 nm at 200 nm. The Kb value was 100 times lower in magnitude in comparison 
to that of CT DNA. The Kb values along with percent affinity towards these biomolecules 
and their mixtures are shown in Figure 54. Therefore a comparative binding study of 
[D-GlcCu(Pz)2] with Human serum albumin, L- tryptophan and their mixtures with CT 
DNA were carried out to recognize the most favored biomolecules for which it displayed 
highest binding ability, fiirther multifold decrease in binding ability of [D-GlcCu(Pz)2] 
with mixtures of these biomolecules was observed. The proposed distribution of 
[D-GlcCu(Pz)2] based on model study is given in Figure 55. On the basis of absorption 
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spectral data, it was observed that [D-GlcCu(Pz)2] shows highest affinity towards the 
main cellular target DNA. 
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Figure 54. Kb values along with percent affinity of[h~GilcCu(i?^Jtowards CT DNA; HSA; 
L- tryptophan, HSA+ CT DNA; L- tryptophan + CT DNA; HSA+L- tryptophan+ CT 
DNA. 
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Figure 55. Proposed distribution of [D-GlcCu(Pz)2] based on in vitro binding model 
study. 
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Cyclic voltammetry 
Cyclic voltammetry has been used to probe the interaction (electrostatic or intercalation) 
of metal complexes with CT DNA [223]. This technique has been successfully employed 
to discriminate the enantioselective interaction of metal-complexes with CT DNA [224]. 
The application of cyclic voltammetry to the study of interaction of redox-active metal 
complexes with DNA provides a useful complement to the spectral and viscometeric 
studies. The cyclic voltammetric responses of [D-GlcCu(Pz)2], [D-GlcNi(Pz)2], [D-
GlcCo(Pz)2], [D-GlcFe(Pz)2]Cl, [D-GlcCu(Im)2], [D-GlcNi(Im)2] and [D-GlcFe(lm)2]Cl 
in absence and presence of CT DNA are well defined and are depicted in Figure 56 (a-g). 
The cyclic voltammograms of [D-GlcCu(Pz)2], [D-GlcNi(Pz)2], [D-GlcCo(Pz)2], [D-
GlcFe(Pz)2]Cl, [D-GlcCu(Im)2], [D-GlcNi(Im)2] and [D-GlcFe(Im)2]Cl in the absence of 
CT DNA revealed a non- Nerstian but fairly reversible/quasireversible one electron redox 
process involving M"/M"'' couple [M = Cu, Ni, Co (n=2), M = Fe (n = 3)] as judged from 
peak potential separation of 0.081-0.386V (0.59V for a one electron transfer process). For 
all complexes, the peak current ratios Ipa/Ipe are far from unity (unity for chemically 
reversible redox system), suggesting a quasireversible electron transfer. At different scan 
rates (0.1-0.3 Vs''), the cyclic volatmmograms of [D-GlcCu(Pz)2], [D-GlcNi(Pz)2], [D-
GlcCo(Pz)2], [D-GlcFe(Pz)2]Cl, [D-GlcCu(Im)2], [D-GlcNi(Im)2] and [D-GlcFe(Im)2]Cl 
did not show any major change. On addition of CT DNA to all complexes, the peak 
potential separation AEp decreases. The Em values of DNA-bound complexes follow the 
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same order as that for free complexes. The net shift in Em can be used to estimate the 
ratio of equilibrium constants for M "* and M "^'^ ^ complexes to DNA using equation, 
Eb"'- Ef"' = 0.059 log (Vi)^ / K „^ 
Where Eb"', Ef" are the formal potentials of M "*^  / M ^ ""'^  couples in the free and boimd 
forms, respectively and A!^ n-i, Kn are corresponding binding constants for the binding of 
(n-1) and n species to DNA, respectively. The K^„-i/ / K n^ are binding constants for 
respective species to DNA. Interestingly K(„.i)' and K„^ values of complexes 
[D-GlcCu(Pz)2], [D-GlcNi(Pz)2], [D-GlcCo(Pz)2], [D-GlcFe(Pz)2]Cl, [D-GlcCu(Im)2], 
[D-GlcNi(Im)2] and [D-GlcFe(Im)2]Cl are near unity, which suggest that they are 
involved in DNA interaction favouring both oxidation states equally. A similar 
observation has been made S. Mahadaven et al [225-227]. Furthermore, the significant 
shift in the electrode potentials and peak current ratios on addition of CT DNA can be 
explained in terms of the diffusion of an equilibrium mixture of free and DNA bound 
metal complexes to the electrode surface [116] thus implying a strong binding of these 
complexes with CT DNA. A summary of the voltammetric results of complexes in 
absence and presence of CT DNA are given in table 15. 
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Figure 56a. Cyclic voltammogram at a 
scan rate 0.3 Vs' in H2O (a) [D-
GlcCu(Pz)2] in absence of CT DNA (b) 
[D-GlcCu(Pz)2] in presence ofCTDNA. 
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Figure 56b. Cyclic voltammogram at a scan 
rate 0.3 Vs-' in H2O (a) [D-GlcNi(Pz)2] in 
absence of CT DNA (b) [D-GlcCu(Pz)2] in 
presence ofCTDNA. 
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Figure 56c. Cyclic voltammogram at a 
scan rate 0.3 Vs'^ in H2O (a) [D-
GlcCo(Pz)2] in absence ofCTDNA (b) 
[D-GlcCo(Pz)2] in presence ofCTDNA. 
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F i g u r e 56d . CvcZ/c voltammogram at a 
scan rate 0.3 Vs' in H2O (a) [D-
GlcFe(Pz)2]Cl in absence of CT DNA 
(b) [D-GlcFe(Pz)2]Cl in presence of 
CTDNA. 
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Figure 56e. Cyclic voltammogram at a 
scan rate 0.3 Vs'' in H2O (a) [D-
GlcCu(Im)2] in absence of CT DNA (b) 
[D-GlcCu(Im)2] in presence ofCTDNA. 
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Figure 56f. Cyclic voltammogram at a 
scan rate 0.3 Vs' in H2O (a) [D-
GlcNi(Im)2] in absence ofCTDNA (b) [D-
GlcNi(Im) 2] in presence ofCTDNA. 
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Figure 56g. Cyclic voltammogram at a 
scan rate 0.3 Vs'' in H2O (a) [D-
GlcFe(Im)2jCl in absence of CT (b) [D-
GlcFe(Im)2]a in presence ofCTDNA. 
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Fluorescence spectral studies 
The interaction of complexes [D-GlcCu(Pz)2], [D-GlcNi(Pz)2], [D-GlcCo(Pz)2], [D-
GlcFe(Pz)2]Cl, [D-GlcCu(Im)2], [D-GlcNi(Im)2] and [D-GlcFe(Im)2]Cl with CT DNA 
was also investigated by changes in fluorescence characteristics of the complexes upon 
binding to the CT DNA. Competitive ethidium bromide (EthBr) binding study was 
undertaken to understand the mode of CT DNA interaction of [D-GlcCu(Pz)2], [D-
GlcNi(Pz)2], [D-GlcCo(Pz)2], [D-GlcFe(Pz)2]Cl, [D-GlcCu(Im)2], [D-GlcNi(Im)2] and 
[D-GlcFe(Im)2]Cl. The molecular fluorophore EthBr emits intense fluorescence in the 
presence of CT DNA due to its strong intercalation between the adjacent DNA base pairs. 
Addition of second molecule, which binds to DNA more strongly than EthBr, would 
quench the DNA-induced EthBr [228]. The extent of quenching of the fluorescence of 
EthBr bound to DNA would reflect the extent of DNA binding of second molecule. On 
addition of complexes [D-GlcCu(Pz)2], [D-GlcNi(Pz)2], [D-GlcCo(Pz)2], [D-
GlcFe(Pz)2]Cl, [D-GlcCu(Im)2], [D-GlcNi(Im)2] and P-GlcFe(Im)2]Cl (6.67 x 10"^ -33 x 
10"' M) to DNA pretreated with EthBr ([DNA]/[EthBr]=l), the decrease in emission 
intensity was observed Figure 57(a-g). The emission intensity in absence and presence of 
CT DNA of [D-GlcCu(Pz)2], [D-GlcNi(Pz)2], [D-GlcCo(Pz)2], [D-GlcFe(Pz)2]Cl, [D-
GlcCu(Im)2], [D-GlcNi(Im)2] and [D-GlcFe(Im)2]Cl are depicted in Figure 58(a-b). Two 
mechanisms were proposed to account for quenching of EthBr emission, the replacement 
of molecular fluorophore and/or electron transfer. The non replacement-based quenching 
has been suggested with DNA-mediated electron transfer from the excited ethidium 
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bromide to acceptor metal complexes. If all the complexes follow any one of the two 
mechanisms, then the extent of replacement of EthBr should be higher than the observed 
values. As there is no complete quenching of the EthBr- induced emission intensity, an 
intercalative mode of DNA-binding of [D-GlcCu(Pz)2], [D-GlcNi(Pz)2], [D-GlcCo(Pz)2], 
[D-GlcFe(Pz)2]Cl, [D-GlcCu(Im)2], [D-GlcNi(Im)2] and [D-GlcFe(Im)2]Cl was ruled out. 
Further the quenching extents "K" for [D-GlcCu(Pz)2], [D-GlcNi(Pz)2], [D-GlcCo(Pz)2], 
[D-GlcFe(Pz)2]Cl, [D-GIcCu(Im)2], [D-GlcNi(Im)2] and [D-GlcFe(Im)2]Cl have been 
estimated by using Stem-Volmer equation 2 and are given in table 14. The enhanced "K" 
values for complexes [D-GlcCu(Pz)2] and [D-GlcCu(Im)2] supports absorptional spectral 
studies. A possible mode of binding could be covalent binding of [D-GlcCu(Pz)2], [D-
GlcNi(Pz)2], [D-GlcCo(Pz)2], [D-GlcFe(Pz)2]Cl, [D-GlcCu(Im)2], [D-GlcNi(Im)2] and 
[D-GlcFe(Im)2]Cl with the nitrogen donors of purine, which might facilitate the uncoiling 
of double strand, thus decreasing the DNA-EthBr fluorescence intensity [90]. 
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Figure 57a. Emission spectra of 
[D-GlcCu(Pz)2] in the presence of 
DNA in Tris-HCl buffer. 
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Figure 57b. Emission spectra of 
[D-GlcNi(Pz)2]in the presence of DNA 
in Tris-HCl buffer. 
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550 600 650 
Wavelength (nm) 
Figure 57c. Emission spectra of [D-
GlcCo(Pz)2] in the presence ofCTDNA in 
Tris-HCl buffer. 
Wavelength (nm) 
Figure 57d. Emission spectra of [D-
GlcFe(Pz)2]Cl in the presence ofCT DNA 
in Tris-HCl buffer. 
' I I ' ' 
Wavelength (nm) 
Figure 57e. Emission spectra of [D-
GlcCu(Im)2], in the presence ofCTDNA 
in Tris-HCl buffer. 
Wavelength (nm) 
Figure 57f. Emission spectra of [D-
GlcNi(Im)2], in the presence of CT 
DNA in Tris-HCl buffer. 
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Figure 57g. Emission spectra of [D-
GlcFe(Im)2]Cl in the presence of CT 
DNA in Tris-HCl buffer. 
0.4 0.5 
[M]/[DNA] 
Figure 58a. Plots of yi versus [M]/[DNA], [M] = [D-GlcCu(Pz)2] (•), [D-GlcNi(Pz)2] 
(•), [D-GlcCo(Pz)J (A) and[D-GlcFe(Pz)2]Cl ( T ; . 
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Figure 58b. Plots ofljl versus [M]/[DNA], [M]= [D-GlcCu(Im)2] (m).[D-GlcNi(Im)2j 
(•) and [D-GlcFe(Im)2]Cl (T). 
DNA Cleavage studies 
The potential of metal complexes to act as nuclease mimic agents and enhance the 
cleavage of nucleic acids has attracted significant attention [229-231]. The role of metal 
complexes in DNA hydrolysis appears to include the positioning of both the substrate and 
of a coordinated water that act as an activated nucleophile [232]. The DNA cleavage 
ability of the complex [D-GlcCu(Pz)2]was assessed by incubating it with supercoiled 
(SC) pBR322DNA in Tris-HCl buffer for 2 hours without addition of a reductant. The 
reaction mixture was subjected to agarose gel electrophoresis and a concentration 
dependant DNA cleavage was observed Figure 59(a). With increase in concentration of 
the [D-GlcCu(Pz)2] more intense nicked (Form II) was observed, whereas no conversion 
to linear form (Form III) was shown by complex [D-GlcCu(Pz)2]. Form I and II of 
pBR322 DNA are visible on the gel indicating that the [D-GlcCu(Pz)2] are involved in 
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double strand DNA cleavage [233]. To ascertain whether any favorable reducing agent 
added to the reaction mixture could account for increased supercoiled pBR322DNA 
degradation by the [D-GlcCu(Pz)2], cleavage reaction were performed in aerobic 
conditions by using ascorbic acid to the reaction mixture containing supercoiled 
pBR322DNA in Tris-HCl buffer Figure 59(b). In the control experiment using ascorbic 
acid and in absence of a complex, no cleavage of pBR322 DNA was observed. On 
increasing the concentration, [D-GlcCu(Pz)2] produces complete conversion of SC (Form 
I) to NC (Form II) and LC (Form III). The increased nuclease activity of the [D-
GlcCu(Pz)2] was apparently caused by enhanced stabilization of Cu (I) species formed by 
reduction of [D-GlcCu(Pz)2] by ascorbic acid. This suggests a possible mechanism 
involving the generation of hydroxyl radicals OH from ascorbic acid, similar hydroxyl 
radicals promoted DNA damages have been reported [234], Furthermore when the 
hydroxyl radical scavenger DMSO was added to the reaction mixture of [D-GlcCu(Pz)2], 
the cleavage reaction was inhibited, revealing that a freely diffusible hydroxyl radical is 
the reactive oxygen species directly responsible for initiation of cleavage reaction. 
The DNA cleavage activity of [D-GlcCu(Pz)2] with increasing concentration were also 
carried out using SC pBR322DNA m Tris-HCl buffer and upon irradiation with UV light 
of 365 nm Figure 59(c) and involves double strand DNA cleavage to generate nicked 
form through single-strand breaks [233], revealing that the [D-GlcCu(Pz)2] is an active 
species. Addition of hydroxyl radical scavenger DMSO to the reaction mixture tends to 
inhibit the cleavage reaction, suggesting the involvement of hydroxyl radical, in the 
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photocleavage reactions. It was suggested that photoexcited complex would follow a 
mechanistic pathway involving one or two electron reduction of the oxygen molecule to 
generate hydroxyl radicals rather than conversion of oxygen molecule to singlet oxygen, 
which has been observed in the photodynamic therapy cycle [235]. 
Figure 59a. Gel electrophoresis diagram showing cleavage ofpBR322 supercoiled DNA 
(SOOng) by fD-GlcCu(Pz)2j; Lane I: DNA; Lane 2: 0.05 mmol [D-GlcCu(Pz)2j+ DNA; 
Lane 3: 0.10 mmol [D-GlcCu(Pz)2] + DNA; Lane 4: 0.15 mmol [D-GlcCu(Pz)2j+ DNA; 
Lane 5: 0. 20 mmol [D-GlcCu(Pz)2]+ DNA. 
•Ill 
Figure 59b. Gel electrophoresis diagram showing cleavage ofpBR322 supercoiled DNA 
(300ng) by [D-GlcCu(Pz)2] in presence of radical scavenger (5% DMSO) and ascorbic 
acidH2A (0.01 mmol); Lane 1: DNA + [D-GlcCu(Pz)2j+ DMSO; Lane 2: DNA; Lane 3; 
0.025 mmol [D-GlcCu(Pz)2] + H2A+ DNA; Lane 4: 0.05 mmol [D-GlcCu(Pz)2j+ H2A + 
DNA; Lane 5: 0.075 mmol [D-GlcCu(Pz)2] + //2^+ DNA; Lane 6: 0.10 mmol [D-
GlcCu(Pz)2j+ H2A + DNA+5% DMSO. 
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Figure 59c. Gel electrophoresis diagram showing cleavage ofpBR322 supercoiled DNA 
(300ng) by [D-GlcCu(Pz)2]using monochromatic radiation (365nm) for 5 min followed 
by incubation (Ih) Lane [D-GlcCu(Pz)2J: DNA; Lane 2: 0.05 mmol [D-GlcCu(Pz)2j+ 
DNA; Lane 3: 0.10 mmol [D-GlcCu(Pz)2j+ DNA; Lane 4: 0.15 mmol [D-GlcCu(Pz)2]+ 
DNA; Lane 5: 0. 20 mmol [D-GlcCu(Pz)2j + DNA. 
Viscosity Measurements 
To further explore the binding mode of glycosylated complexes [D-GlcCu(Pz)2], [D-
GlcNi(Pz)2], [D-GlcCo(Pz)2], [D-GIcFe(Pz)2]Cl, [D-GlcCu(Im)2], [D-GlcNi(Im)2] and 
P-GlcFe(Im)2]Cl to CT DNA, viscometeric studies were carried out by measuring the 
flow rate of CT DNA through a viscometer as a function of concentration of added 
complexes (1/R = [M] / [DNA], [M] = [D-GlcCu(Pz)2], [D-GlcNi(Pz)2], [D-GlcCo(Pz)2], 
[D-GlcFe(Pz)2]Cl, [D-GlcCu(Im)2], [D-GlcNi(Im)2] and [D-GlcFe(Im)2]Cl). The 
hydrodynamic changes are result of the changes in length of molecules, the diminished 
bending between layers and the diminished length-specific mass [236]. The decrease in 
relative viscosity observed for [D-GlcCu(Pz)2], [D-GlcNi(Pz)2], [D-GlcCo(Pz)2], [D-
GIcFe(Pz)2]Cl, [D-GlcCu(Im)2], [D-GlcNi(Im)2] and [D-GlcFe(Im)2]Cl suggest that the 
hydrophobic interaction between complexes with DNA surface, encouraged by strong 
covalent binding interaction, leads to bending (kinking) of the DNA chain [237]. The 
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relative specific viscosity of DNA with increasing the concentration [D-GlcCu(Pz)2], [D-
GlcNi(Pz)2], [D-GlcCo(Pz)2], [D-GlcFe(Pz)2]Cl, [D-GlcCu(Im)2], [D-GlcNi(Im)2] and 
[D-GlcFe(Im)2]Cl are shown in Figure 60 (a-b). 
. ^ 0 . 2 5 -
xn 
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CO 
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• 
0.15 
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Figure 60a. Effect of increasing amount of [D-GlcCu(Pz)2] (m),[D-GlcNi(Pz)2] (•), [D-
GlcCo(Pz)2] (k) and [D-GlcFe(Pz)2]Cl ff) on relative viscosity ofCTDNA at 29 ±0.1 
"C. [CTDNA] = / ;c la^M, 1/R = [complex] / [CT DNA]. 
0.42H 
•g 0.2 8 
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0.00 
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Figure 60b. Effect of increasing amount of[D-GlcCu(Im)2], ("J, [D-GlcNi(Im)2j (•) and 
[D-GlcFe(Im)2]Cl(A) on relative viscosity of CT DNA at 29 ±0.1 "C. [CTDNA] =lxl(r\ 
1/R= [complex]/[CTDNA]. 
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CHAPTER VI 
Synthesis of new piperazine derived Cu (II) /Zn (II) metal 
complexes, their DNA binding studies, electrochemistry and 
anti-microbial activity; validation for specific recognition of Zn 
(II) complex to DNA helix by interaction with thymine base 
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CHAPTER VI 
Experimental 
Salicyaldehyde (sd.fme), 1, 2-dibromoethane, Piperazine hexahydrate, Tris base (Merck), 
CUCI2.2H2O (Qualigens), ZnCb (Rankem) were utilized as received. Calf thymus DNA 
thymine and guanine was purchased from Sigma chemical Co. All reagent grade 
compounds were used without further purification. Interspec 2020 FTIR spectrometer 
was used for recording IR spectra of KBr pellets in the range of 400- 4000 cm''. 
Electronic spectra were recorded on UV-1700 PharmaSpec Uv-vis spectrophotometer 
(Shimadzu). Data were reported in X,max/nm. Emission spectra were determined with a 
Hitachi F-2500 fluorescence spectrophotometer. Microanalyses of the complexes were 
obtained on a Carlo Erba Analyzer Model 1108. 'H and '^ C NMR spectra were recorded 
on a Bruker DRX-300 spectrometer. Chemical shifts were reported in 5 scale (ppm). EPR 
spectrum of copper (II) complex was recorded on Varian E 112 spectrometer at the X-
band frequency (9.1GHz) at liquid nitrogen temperature (LNT) using tetracyanoethlene 
(TCNE) as field marker. Cyclic voltammetry was carried out at CH instrument 
electrochemical analyzer. All voltammeteric experiments were performed in single 
compartmental cell of volimie 10-15 ml containing a three-electrode system comprised of 
a Pt-disk working electrode, Pt-wire as auxiliary electrode, and an Ag/AgCl electrode as 
reference electrode. The supporting electrolyte was 0.4 M KNO3 in milli-Q water. 
Deairated solutions were used by purging N2 gas for 15 minutes prior to measurements. 
Molar conductances were measured at room temperature on Digisun electronic 
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conductivity bridge. Interaction of complexes with calf thymus DNA (CT DNA) was 
performed in O.OIM Tris-HCl buffer (pH 7.2). Viscosity measurements were carried out 
using Ostwald's viscometer at 29 ± 0.01 "C. 
Antifungal screening 
Complex [C24H36N4O6CU] and [C24H32N404Zn] were tested for their in vitro growth 
inhibition activity against pathogenic fungus viz. Alternaria brassicicola and Aspergillus 
niger cultured on potato dextrose agar (PDA) medium and incubated at 25 ± 2 °C for 72 
hours by using poison food technique [238]. The PDA medium was sterilized in the 
autoclave in 15 kg/cm^ at 121° C which keeps the medium to retain its normal 
temperature and the solution of complexes [C24H36N4O6CU] and [C24H32N404Zn] is 
added in the PDA medium in the different concentration. The concentration is made in 
the range of 10-50 x 10"^  M. The inhibition of fungal growth, expressed in percentage 
terms was determined on the growth in test plates compared to respective control plates 
(untreated), as given by Vincent equation [239]. 
Inhibition %=100(C-T)/C 
Where C = diameter of fungal growth on the control plate, T = diameter of fungal on the 
test plate. 
Antibacterial screening 
The solution of complexes (10-50 x 10"^  M) in DMSO was applied on a paper disc 
prepared from sterilized paper (3mm diameter) with the help of micropipette. The discs 
were left in an incubator for 30 hours at 37° C and then applied on the bacteria grown on 
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potato dextrose agar (PDA) plates. Minimal agar was used for growth of specific 
bacterial species. Agar (50g) was suspended in freshly distilled water (IL), allowed to 
soak for 15 min. and then boiled on water bath until the agar was completely dissolved. 
The mixture was autoclaved for 15 minutes at 120 °C and then poured into previously 
washed and sterilized petri dishes and stored at 40° C for inoculation. 
Synthesis of 3,4 : 9,10-Diben2o-l,12-diformyI-5,8-dioxododecane [de Hi404]Ll 
The ligand [Ci6 H14O4] LI was synthesized using the method reported previously [240] 
Syathesis of 3»4:9,lO-Dibenzo-2,ll-dihydroxy-l,l2-bispiperazitte-5,8-dioxododecaae 
[C24H34N4O4] L2 
The ligand [C24H34N404]L2 was prepared according to the method reported earlier with a 
modification [241], and is described as below: 
To a solution of [Ci6Hi404]Ll (0.27 gm, 1 mmol) in 20 ml benzene was added piperazine 
hexahydrate (0.388gm, 2.0nmiol) in a Dean-Stark apparatus. The reaction mixture was 
refluxed for 1 hour. A white colored solid obtained was filtered, washed with ice cold 
methanol and dried in vacuo. 
Synthesis of 3,4:9,10-Diben2o-2,ll-dihydroxy-l,12-bispiperazine5,8-dioxododecane-
copper (II) 
[C24H36N4O6CU] 
To a solution of [ C24H34N404]L2 (0.442 gm, 1 mmol) in 10 ml methanol was added a 
solution of CUCI2.2H2O (0.170 gm, 1 mmol) in 10 ml methanol dropwise, a green colored 
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precipitate obtained was stirred for 1 hour which was filtered, washed thoroughly with 
methanol and dried in vacuo. 
Synthesis of 3,4:9,10-Dibeiizo-2,1 l-dihydroxy-l,12-bispiperazine-5,8-dioxododecane 
zinc (II) 
[C24H32N404Zn] 
Complex [C24H32N404Zn] was synthesized with ZnCh (0.13 gm 1 mmol) by similar 
procedure as described for complex [C24H36N4O6CU]. A white colored product obtained 
was filtered, washed thoroughly with methanol and dried in vacuo. 
^ ^ - I P-? 
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OH HO 
0 Q 
H H 
CUCI2/ \ZnCI , 
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o - ' ^ ^ o ^ ^ . ^ ^ ^ ^ " ^ o .| 
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Scheme 6a. Proposed structure of [C24H34N4O4JL2, [C24H36N4O6CUJ and 
[C24H32N404Zn]. 
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Scheme 6b. Cylindrical bonded three dimensional model of complexes [C24H36N4O6CU] 
and [C24H32N404Zn]. Color scheme: Cu" dark gray; Zn" dark gray; N dark blue; O red; 
Cgray. 
Results and discussion 
The spectroscopic studies and analytical data supports proposed structure, scheme 6(a) 
and three dimensional models with cylindrical bonds are depicted in scheme 6(b). Ligand 
[C24H34N404]L2 is soluble in many organic solvents and the complexes [C24H36N4O6CU] 
and [C24H32N404Zn] are soluble in DMSO and DMF. The important properties and 
physical data of the ligand and complexes are given in table 16. Molar conductance 
measurements in DMSO show that complexes are non ionic in nature. 
IR spectra 
The IR spectrum of ligand [C16 Hi404]Ll shows a characteristic absorption band at 1684 
cm"' due to aldehydic v(C=0) stretching vibrations [242]. Other bands at 1530 cm"' and 
1270-1295 cm"' were associated with phenolic v(C-O) stretching and bending vibrations 
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[149]. The absorption bands due to v (CH2) appear at 2952-2875 cm"' [243]. In the IR 
spectrum of [C24H34N404]L2 the band due to v(C=0) was not observed. Asymmeteric 
and symmetric stretching vibrations of methylene group were observed at 2809 and 2941 
cm"', respectively [244]. The stretching vibration due to v (NH) and v (OH) appeared as a 
single band at 3412 cm"'. The C=C bond stretching absorption of aromatic ring was 
observed at 1594 and 1506 cm"' and vibration due to v(CO) of alcoholic group appeared 
at 1100 cm"'. The band due to OH deformation was observed at 1286 cm''. The 
absorption band observed at 1420 and 1160 cm"' was attributed to C-N asymmetric and 
symmetric stretching vibrations, respectively [245]. 
The IR spectra of complexes [C24H36N4O6CU] and [C24H32N404Zn] exhibited bands at 
2837, 2863 and 2958-2958, 2932-2979 cm"' assigned to asymmetric and symmetric 
vibrations of methylene groups. The bands observed at 3419 cm"' and 3417 cm"' were 
ascribed to coordinated v(NH) stretching vibrations [246]. The band which appeared at 
1100 cm"' in free ligand [C24H34N404]L2 due to v(C-OH) was shifted to 1139 cm"' and 
1133 cm"', respectively, after complexation confirming the coordination of metal ion 
through O atom of deprotonated OH group. Similarly the bands due to C-N asyiimietric 
and symmetric vibrations undergo positive shift of 28, 21 and 30 cm"', indicating the 
involvement of nitrogen atoms in the formation of complexes. The far IR spectra of 
[C24H36N4O6CU] and [C24H32N404Zn] reveal (M-0) and (M-N) stretching vibrations in 
the range 439- 499 and 513-515 cm"', respectively (Tablel7). 
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EPR spectra 
The solid state X band EPR spectrum of complex [C24H36N4O6CU] acquired at liquid 
nitrogen temperature (LNT) is anisotropic. The spectrum shows axial symmetry, with 
three hyperfme peaks in the parallel region derived from the coupling of copper nucleus 
and the unpaired electron. The EPR signals of complex [C24H36N4O6CU] exhibited gi = 
2.037 g||= 2.36 and A||= 170 G values. The fact that g|| > gJ- confirmed an octahedral 
geometry with a (dx2-y2)' as ground state in the complex [C24H36N4O6CU] [149,247]. 
NMR spectra 
'H and '^ C NMR spectra of ligand [C24H34N404]L2 and complex [C24H32N404Zn] were 
recorded in DMSO-de (Table 18,19). The 'H NMR of ligand [C24H34N404]L2 revealed 
characteristic signals at 7.10-7.70, 3.2-3.4 and 4.58 assigned to aromatic, OCH2 and OH 
protons [248-249]. The resonance at 2.37-2.49 and 5.7 ppm were ascribed to CH2-CH2 
and NH protons of piperazine ring [249-251]. However, in the complex [C24H32N404Zn], 
resonances due aromatic ring protons remained unaltered. A singlet at 5.75 ppm was 
assigned to NH protons [250-251]. Resonating signals due OCH2 and CH2CH2 were 
observed at 3.17- 3.40 ppm and 2.3-2.6 ppm, respectively [248,249,252]. The slight shift 
in NH and absence of OH protons, suggests that complexation of metal ion takes place 
through NH and deprotonation of OH groups. The 'H NMR spectra of [C24H34N404]L2 is 
depicted in Figure 61. The '•'C NMR spectrum of ligand [C24H34N404]L2 exhibited 
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various signals at 128.6-135.26,46.28-47.21, 76.64-77.27 and 66.93, for aromatic carbon 
(C=C), CH2, CHOH, OCH2 groups, respectively [253,251,249]. On the other hand 
resonances due to carbon skeleton of complex [C24H32N404Zn] remain almost 
unchanged. Therefore, the spectroscopic data support the proposed structure of the ligand 
[C24H34N404]L2 and complex [C24H32N404Zn]. 
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Figure 61. 'HNMR spectrum of the ligand [C24H34N404JL2 
Electronic spectra 
The electronic absorption spectra of [C24H36N4O6CU] and [C24H32N404Zn] were recorded 
in 200-1100 nm region at room temperature. The electronic spectrum of [C24H36N4O6CU] 
in DMSO displayed a high energy bands at 230, 306 nm corresponds to TC- n* and ligand 
metal charge transfer (LMCT) transitions, respectively. The low energy d-d band at 760 
nm was assigned to ^Big-*^ E2g transition suggesting an octahedral geometry around Cu" 
metal ion [254,247]. The absorption spectrum of complex [C24H32N404Zn] revealed 
bands at 259 nm and 318 nm due to intraligand and LMCT transitions, respectively. 
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DNA interaction studies 
The binding of complexes with CT DNA was ascertained by electronic absorption 
titrations. Any interaction between the complexes and DNA is expected to perturb the 
ligand centered transitions of complexes. The change in the n- it* transitions of 
[C24H36N4O6CU] and [C24H32N404Zn] were determined as function of added 
concentration of (0.067-0.33 x 10"^  M) of CT DNA and the typical absorption titration 
curves for [C24H36N4O6CU] and [C24H32N404Zn] are given in Figure 62(a,b). A 
hyperchromism of 23% and 29% for [C24H36N4O6CU] and [C24H32N404Zn] with a red 
shift of 7-8 nm was observed. The intrinsic binding constant Kb has been calculated from 
equation 1, to compare quantitatively the affinities of [C24H36N4O6CU] and 
[C24H32N404Zn] to CTDNA and were found to be 7.6 x 10^  M"' and 8.08 x 10^  M"', 
respectively. The complex [C24H32N404Zn] shows a multifold increase in Kb value in 
comparison to the Kb values of complex [C24H36N4O6CU], which were attributed to the 
strong affinity of zinc complexes for selective recognition of nucleobase of double strand 
CT DNA. Literature survey reveals that Zn (II) complexes in contrast to Cu (II) and 
Ni(II) break the hydrogen bonds of A-T base pairs of DNA helix, bind selectively to 
thymine, altering the local structure of the AT- regions of DNA [255]. These 
"hyperchromic" spectral changes observed are typical of complex bovmd to DNA 
grooves, leading to small perturbations [256]. The "hyperchromic effect" was due to the 
dissociation of ligand aggregates [257-259] or due to its external contact (surface 
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binding) with the duplex by engaging in hydrogen- bonding interactions between 
coordinated NH and OH with functional groups positioned on the edge of DNA bases. 
In order to gain support for selective binding of the zinc complexes to thymine base of 
DNA helix involving possibly N3 thymine coordination, the interaction of 
[C24H32N404Zn] with DNA bases thymine and guanine was investigated using electronic 
absorption spectral technique. Addition of thymine to complex [C24H32N404Zn] results in 
an increase in an absorbance (88% hyperchromism) in the intraligand bands with a blue 
red shift of 2 nm (Figure 63 a). The hyperchromicity implies that the interaction between 
complex [C24H32N404Zn] and the thymine is combination of coordination of Zn metal ion 
after ligand dissociation/ or reorganization [257-259] and hydrogen bonding with 02,04 
oxygen atoms of thymine [255]. However, on addition of guanine to the complex 
[C24H32N404Zn] exhibited relatively small hyperchromic changes (70%) in absorbance 
(Figure 63b). These spectral changes revealed that the complex [C24H32N404Zn] have 
stronger binding afiFmity towards thymine in comparison to guanine. The complexes 
show preference for thymine due to two effects. When thymine binds, hydrogen bonds 
are formed between the NH groups of ligand; Secondly, a significant stronger molecular 
orbital interaction has been identified in thymine in comparison to guanine. The presence 
of electron withdrawing two oxo groups at the C2 and C3 position of the thymine ring 
lower the energy of the lone-pair orbital at N3 of thymine base. Our results are consistent 
with earlier reports on preferential binding to N3 position of thymine in the zinc 
complexes [260-261,255]. 
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Figure 62a. Absorption spectral traces; of complex [C2iH36N40^u] in Tris HCl buffer 
upon addition of CTDNA. Inset; Plots offDNAJ/Sa- ^versus [DMA] for the titration 
of CTDNA with complexes (m), experimental data points; full lines, linear fitting data. 
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Figure 62b. Absorption spectral traces of complex lC2^3:^404Zn] in Tris HCl buffer 
upon addition of CTDNA. Inset; Plots offDNA] / Sa- ef versus [DNAJfor the titration of 
CTDNA with complexes (A), experimental data points; full lines, linear fitting data. 
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Figure 63a Absorption spectral 
traces of complex [C24H32N404Zn] 
in H2O upon addition of Thymine. 
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Figure 63b. Absorption spectral traces 
of complex [C24H32N404Zn] phosphate 
buffer upon addition of guanine. 
Electrochemical studies 
The redox behavior of complexes [C24H36N4O6CU] and [C24H32N404Zn] in the absence 
and presence of CTDNA were studied in DMSO/H2O 5:95 by means of cyclic 
voltammetry at room temperature within potential range of 2.0 to -1.2V. Cyclic 
voltammetry is one of the most important electroanalytical techniques employed for 
interaction of metal complexes with biomolecules due to the similarity between various 
redox chemical and biological processes [262]. The cyclic voltammogram of complex 
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[C24H36N4O6CU] exhibits a quasireversible redox wave corresponding to Cu'V Cu' with 
Epc and Epa values -0.590V and -0.195V, respectively at the scan rate of 0.3 Vs"'. The 
ratio of anodic to cathodic peak currents IpJ Ipc was 0.407. The formal electrode potential 
Ei/2, AEp (difference in cathodic Epc and anodic Epa peak potentials) were -0.393V and 
0.394V, respectively. The AEp value is larger than Nemstian value observed for a one 
electron transfer redox couple [128]. At constant parameters, the addition of CT DNA 
results the shift in Ei/2= -0.363V and AEp = 0.537V (Figure 64), respectively. The ratio of 
Ipa/ Ipc is 0.303 for CT DNA bound metal complex [C24H36N4O6CU]. The shift in 
potentials and decrease in current ratio suggest the binding of complex [C24H36N4O6CU] 
to CT DNA [128]. 
The cyclic voltammogram of complex [C24H32N404Zn] (DMSO/H2O; 5:95, 25°C ) at 
scan rate 0.3 Vs'' features a quasireversble redox wave Zn'VZn' [263] with Em, AEp and 
Ipa/ Ipc values -0.384V, 0.4954V and 0.383, respectively. Upon addition of CT DNA 
under the same recording conditions complex [C24H32N404Zn] experience a shift in Em 
(-0.355V), AEp (0.419V) and ratio of anodic to cathodic peak currents Ipa/ Ipc was 0.247 
(Figure 65). At different scan rates both the complexes do not show any major change. 
The larger decrease in potentials and current ratios of complex [C24H32N404Zn] suggest 
that the [C24H32N404Zn] binds to CT DNA more strongly in comparison to complex 
[C24H36N4O6CU]. 
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Figure 64. Cyclic voltammogram at a 
scan rate 0.3 Vs' in DMSO/H2O (a) 
complex [C24H36N4O6CUJ (b) Complex 
[C24H36N4O6CUJ in presence ofCTDNA. 
Fluorescence spectroscopic studies 
PotentialA^ 
Figure 65. Cyclic voltammogram at a 
scan rate 0.3 Vs'' in DMSO/H2O 
a)[C24H32N404Zn](b)[C24H32N404Zn] 
in presence ofCTDNA. 
The complexes [C24H36N4O6CU] and [C24H32N404Zn] exhibit luminescence either in 
DMSO or in presence of CTDNA. Hence, binding studies of both the complexes to CT 
DNA were carried out by fluorescence spectral titrations in absence of any fluorophore 
[134]. Fixed amount of complexes (0.067 x 10"* M) were treated with increasing amount 
of CT DNA (0.067 - 0.33 x lO'^ M). The results of emission titration of complexes 
[C24H36N4O6CU] and [C24H32N404Zn] with DNA are illustrated in Figure 66 (a-b). Upon 
addition of CT DNA the emission intensity decreased steadily. The binding constant 
estimated for complexes [C24H36N4O6CU] and [C24H32N404Zn] by Scatchard's equation 
(3,4) were 7.0 x 10'* M"' and 7.53 x lO' M"', respectively. The binding constant K values 
148 
suggest that the interaction of [C24H32N404Zn] with the CT-DNA was stronger in 
comparison to [C24H36N4O6CU]. These results are consistent with the findings obtained 
from UV/vis spectral studies. 
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Figure 66a. Emission spectra of complex [C24H36N4O6CUJ in the presence ofCTDNA in 
Tris-HCl buffer. Inset: Plots of I / h versus [CT DMA]. 
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Figure 66b. Emission spectra of complex [C24H32N404Zn] in the presence ofCTDNA in 
Tris-HCl buffer. Inset: Plotsof I/lo versus [CTDNAf 
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Viscosity Measurements 
Spectroscopic data are necessary, but not sufficient to support a binding mode. 
Hydrodynamic measurements, which are sensitive to length change, are regarded as the 
least ambiguous and most critical test of binding in solution [162]. A classical 
intercalative mode causes a significant increase in viscosity of DNA solution due to its 
increase in separation of base pairs at intercalation sites and increases in overall DNA 
length. In contrast, complexes those bind exclusively in the DNA grooves by partial 
and/or non classical intercalation, under same conditions, typically cause less positive or 
negative or no change in DNA solution viscosity. However partial non-classical 
intercalator causes a kink in the DNA helix and reduces the length and its viscosity. To 
further clarify the binding mode of the metal complexes, viscosity measurements were 
carried out on CT DNA by varying the concentration of the added complex. The increase 
in relative viscosity of CT DNA was due to formation of bridged structures leading to 
extension of DNA duplexes, as propsed by McMillin et al [264]. The binding may may 
involve therefore irmer sphere complex formation via phosphate oxygen. The adducts 
formed by bridging the duplexes are stabilized by hydrophobic interaction or columbic 
interaction as reported earlier in some copper complexes [226,265]. The plot of relative 
specific viscosities r\/T[o vs [1/R] is shown in Figure 67. 
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Figure 67. Effects of increasing amount of complexes [C24H36N406Cu]{m) and 
[C24H32N404Zn]{») relative viscosity ofCT-DNA at 29 ±0.1 "C. [CT DNAJ = Ix lOr^M, 
1/R = [complex] / [CT DNAJ. 
Biological activities 
The susceptibility of certain of strains fungi and bacteria towards complexes 
[C24H36N4O6CU] and [C24H32N404Zn] were screened by measuring the size of the 
inhibition diameter. The % inhibition data was calculated by using Vincent equation and 
depicted in Figure 68(a-b). In vitro antimicrobial activity against fungus (A. brassicicola, 
A. niger) and bacteria {E. coli, P. aeruginosa) were tested with increasing concentration 
(10-50 X 10"^  M) of [C24H36N4O6CU] and [C24H32N404Zn]. The results revealed that the 
complex [C24H32N404Zn] is more effective in comparison to complex [C24H36N4O6CU] 
for both fungal and bacterial strains. The increase in biological activity of complexes may 
be due to the effect of the metal ion on the cell metabolism. A possible mode of toxicity 
increases may be considered in the light of chelation theory [266-267]. Chelation 
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considerably reduces the polarity of the metal ion because of partial sharing of its positive 
charge with the donor groups and possible n - electron delocalization over whole chelate 
ring. Such chelation could enhance the lipophilic character of central metal ion atom 
which subsequently favours its permeation through lipid layers of cell membrane 
resulting in the interference with normal cell process [268-270], 
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Figure 68a. Antifungal activity of 
Complexes [C24H36N40^u] and 
[C24H32N404ZnJ (10-50 x ICT^ M) in 
terms of percent inhibition against 
A. brassicicola, A. niger. 
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Figure 68 b. Antibacterial activity 
of Complexes [C24H36N4O6CUJ and 
[C24H32N404Zn] (lO-SOxia^M) in 
terms of percent inhibition against 
E. coli, P. aeruginosa. 
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Conclusion 
The challenge for new drug discovery efforts is to identify a novel molecular component 
which surpasses toxicity limits, ensures non resistance and has cost efficiency 
expenditure and enable specific delivery of a drug candidate within the body. In this 
work, the complexes were synthesized with aim to develop potential robust metal -based 
chemotherapeutics. Structure and biological properties are important aspects for the 
design of suitable drug candidate and therefore using structure activity relationship 
(SAR), molecules are altered progressively guided by biological data so that desirability 
of drug candidate is enhanced and their limitation are overcome. The structural 
modification of ligands in presence of metal ions can tune and further provide a rational 
approach for the development of tumour selective drugs. The interaction of these 
complexes with DNA ascertains their potential to act as DNA inhibitors as DNA is the 
main molecular target of anticancer drugs. The in vitro biological assays have proved that 
complexes [Ci2H23N407CoCu]Cl25H20, [Ci2H23N407CoNi]Cl25H20 and 
[Ci2H23N407CoMn] CI25H2O are avid DNA binders. Complexes [Ci6H3oN805Sn2Cl4], 
[Ci6H38N809Sn2Cu2Cl8] and [Ci6H38Ng09Sn2Mn2Cl8] exhibited artificial nuclease 
activity as function of increased concentration, therefore can also be exploited as 
important metallonucleases. Electroporation is a unique way to address drug delivery and 
currently much interest has stemmed up in this technique for timiour inhibition. Based on 
these model studies, effect of direct potential on interaction of CT DNA with complexes 
157 
[Ci6H3oN805Sn2Cl4], [C,6H38N809Sn2Cu2Cl8] and [Ci6H38N809Sn2Mn2Cl8] revealed 
much higher binding constant, these findings are unique as they demonstrate that the 
presence of direct potential can induce transmembrane dielectric breakdown of 
membrane cells and thereby therapeutic effects of drugs can be enhanced. As a 
consequence, lower dosage can be administrated limiting the drug toxicity. 
In the forefront is the recent area of glycobiology, which offers a "sweet and safe" 
approach to chemotherapies, which has laid profound affect on new research directions in 
drug discovery. The use of glycosyl substituents for enhanced tissues target, improved 
solubility and reduced toxicity have attracted many researchers to explore the possibility 
of carbohydrate - based drug strategies. Therefore new glycosylated metal complexes 
[D-GlcCu(Pz)2], [D-GlcNi(Pz)2], [D-GlcCo(Pz)2], [D-GlcFe(Pz)2]Cl, [D-GlcCu(Im)2], 
[D-GlcNi(Im)2] and [D-GlcFe(Im)2]Cl were reported and thier interaction with CT DNA, 
were carried out by different spectroscopic and biochemiaci techniques. These findings 
have demonstrated that these complexes are strong DNA binders and therfore can be 
utilized as cancer chemotherapeutic agents. Additionaly artificail cleavage activity of the 
complex [D-GlcCu(Pz)2] with plasmid pBR322 DNA, as a function of increased 
concetration of [D-GlcCu(Pz)2] and in absence, presence of reducing agent demnstrated 
that these complexes are superior cleaving agents. Further in vitiro compartive "binding 
model study" of [D-GlcCu(Pz)2] with biomolecules (HSA and L-tryptophan) and thier 
mixture with CT DNA was carried out to recognize the most faovoured biomolecule. 
Molecular architecture containing heterocyclic piperazine system has arose interest 
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owing to many reasons, notably their biological properties as antitumour antibiotics, 
HTV-i replication inhibitors, as anti-inflammatory and antimicrobial activities. Tethering 
such biologically active moieties with aldehydic molecular framework has rendered 
multi-combination agents inherently more potent than either of parent component. This 
synthetic strategy is unique and currently in great demand owing to the use of such 
multicombination stents in any therapies viz. cancer, HIV, neurodegenerative diseases. 
Therefore we have synthesized copper and zinc complexes of 3,4: 9,10-Dibenzo-2,11-
dihydroxy-l,12-bispiperazine-5,8-dioxododecane. The CT DNA binding ability of these 
complexes was monitored by different spectroscopic techniques and also exhibited 
antimicrobial activity. These studies prove the usefulness of these complexes synthesized 
in this work as potential drug candidates with reduced toxicity and warrants for vigorous 
in vitiro I in vivo antitumour investigations. 
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